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Abstract 
Introduction: Acute chemotherapy toxicity is common and can have negative 
effects for the patient and health economy and hospitalisation can be 
necessitated.  
Aims: To identify the incidence of toxicity and admission, and predictors of 
toxicity occurrence, severity, hospitalisation and length of stay.  
Method: Data was obtained from a proactive telephone assessment of acute 
toxicity 24 hours after administration of a first cycle of chemotherapy to patients 
in a large UK NHS teaching hospital.  
Results: 1539 patients were studied and the overall incidence of toxicity was 
35.6% (530 patients). Disease site and number of chemotherapy agents given 
were shown to predict toxicity, with breast and upper gastrointestinal cancers 
having a higher likelihood of toxicity. Disease was predictive of toxicity grade, 
with urology, gynaecology and lung cancer patients experiencing higher grades 
of toxicity than other tumour sites. The rate of hospital admission due to toxicity 
was 13.1% (203 patients) and median length of stay 3 days (1-28). The risk of 
admission had some risk factors in common with toxicity. Disease and the 
number of drugs in the regimen affected the risk of admission, with 
gynaecology, head and neck and lung cancer patients and patients who 
received 3 drugs having a higher likelihood of admission. Predictors in the sub-
groups of breast, colorectal and lung cancer patients did not differ greatly from 
the whole population and the number of drugs was shown to be a predictor of 
nausea, vomiting and fatigue when explored as secondary outcomes.  
Conclusion: The research partly addressed the main aim and highlighted 
areas where further research is required.  
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 1 
1.0 Introduction  
In the United Kingdom in 2011, more than 331,000 cases of cancer were 
diagnosed (Cancer Research UK, 2014). This equates to 524 cases per 
100,000 people. Since the mid-1970s this incidence has increased by more 
than 23% in males and 43% in females. There are many treatment options 
available for cancer using different modalities (such as chemotherapy, 
radiotherapy, surgery and hormonal therapy) and many different technologies. 
The modality of interest is chemotherapy, defined as systemic 
pharmacotherapy for cancer indications.  
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1.1 Chemotherapy 
The term “chemotherapy” is defined by the NCI dictionary of cancer terms as: 
“Treatment that uses drugs to stop the growth of cancer cells, either by killing 
the cells or by stopping them from dividing. Chemotherapy may be given by 
mouth, injection, or infusion, or on the skin, depending on the type and stage of 
the cancer being treated. It may be given alone or with other treatments, such 
as surgery, radiation therapy, or biologic therapy.” (National Cancer Institute, 
2018) 
In clinical practice it includes cytotoxic chemotherapy as well as targeted 
therapies including monoclonal antibodies and other biologic agents. Most 
anticancer agents act on cell division and thus interfere with cell replication and 
cancer proliferation (Neal and Hoskin, 2009). This is by a variety of 
mechanisms. Many drugs interfere with DNA replication or repair, others 
directly act on mitosis whereas others reduce tumour vasculature. Targeted 
agents often work on cell signalling pathways. Immunotherapies use a variety 
of mechanisms that induce destruction of cancer cells by the immune system 
(National Cancer Institute, 2018). All agents are associated with some degree 
of toxicity, as is any drug.  The term systemic anticancer therapy (SACT) is 
regularly used in practice to include chemotherapy and targeted therapies for 
cancer.  
 
In England, between July 2013 and June 2014, well over 154,000 patients 
received drug treatment for cancer (Chemotherapy Intelligence Unit, 2014). 
This is a large number of patients and represents a significant burden of 
disease. According to Cancer Research UK, in 2013/14, 28% of patients 
diagnosed with cancer, received chemotherapy (Cancer Research UK 2015d). 
A national dataset of chemotherapy now exists in the UK and records 43 data 
fields around each cycle of chemotherapy, which must be submitted for 
national review (NHS England, 2018). The dataset is currently producing basic 
reports of the national picture in the UK. In 2014, breast cancer was the cancer 
most commonly treated with chemotherapy, followed by lower gastrointestinal 
(GI) and lung cancer.  
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1.1.1 Commissioning of Chemotherapy 
In England, the main provider of chemotherapy is the National Health Service 
(NHS). Within the NHS, chemotherapy is considered a specialised service and 
so is commissioned by NHS England (Staines et al., 2014). All commissioning 
decisions are therefore made on a national level, under guidance from the 
Chemotherapy Clinical Reference Group (CRG). The National Institute for 
Health and Care Excellence (NICE) considers all new and emerging therapies. 
NICE can either decide to enter a new therapy into baseline commissioning or 
to fund a therapy under the Cancer Drugs Fund (CDF), which was established 
in  2010 and funds new and innovative cancer treatments (Department of 
Health, 2011).  
 
1.1.2 Toxicity 
Chemotherapy is known to be commonly associated with various toxicities of 
different grade, type and significance, since chemotherapeutic agents are 
rarely totally selective for cancer cells. These toxicities can require 
interventions ranging from self-care to critical care admission and it is generally 
accepted that chemotherapy toxicity necessitates the use of high levels of 
healthcare resource. 
 
Local experience suggested that a large proportion of toxicities is experienced 
with the first cycle of chemotherapy and this is supported by Extermann et al., 
who pooled several studies of chemotherapy in different diseases, that found a 
greater proportion of toxicity in the first cycle (Extermann et al., 2012).  
 
As part of an initiative to reduce the number of readmissions to hospital of 
oncology patients at Nottingham University Hospitals (NUH), various measures 
have been put in place. One such measure was to establish the cancer 
admissions and triage team (CATT), which is a team of nurses who work to 
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reduce cancer admissions. The CATT team is a team of specialist nurses who 
run a variety of initiatives and were employed in 2014, as part of the wider 
acute oncology service at NUH. The acute oncology service aims to improve 
the care of patients admitted with oncological emergencies, many of which are 
a result of chemotherapy toxicity. The CATT team enabled further 
improvements to be made by adding the required resource to the team. The 
CATT nurses are responsible for managing oncology inpatient flow at NUH and 
monitor inpatients, especially on non-oncology wards to ensure timely senior 
review. The CATT team also staff the 24 hour rapid response telephone line 
that patients are encouraged to use when on chemotherapy, should they 
experience any difficulty or have any questions.    
 
One scheme facilitated by the CATT team was started in January 2015 and is a 
chemotherapy telephone assessment service. The day following the 
administration of a first cycle of chemotherapy, every patient receives a 
telephone call where an assessment of chemotherapy toxicity is undertaken. 
The standard operating procedure for the telephone service is included in 
Appendix 1. The standard operating procedure is based on the UKONS 
oncology/haematology 24 hour triage tool, which is the tool employed by the 
CATT team nurses when taking triage calls from chemotherapy patients (Jones 
et al., 2010). Advice can be given in order to facilitate self-management of 
toxicity and referrals made as needed. Depending on the needs of the patient 
and the chemotherapy regimen, a further call is arranged in a few days’ time to 
assess the progress of the patient. The nurses can arrange medical 
assessment for the patient or hospital admission if required for treatment of a 
toxicity.  
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1.2 Literature Review 
A thorough literature search was conducted in order to identify what was 
already known about chemotherapy toxicity and the factors influencing it. A 
scoping literature review was utilised due to the broad nature of the subject 
matter. In many cases, the literature around certain subjects was sparse, 
meaning that a more in-depth review such as a systematic review or meta-
analysis could not be employed. The key aim of the review was to identify the 
gaps in the data and it was felt that a scoping review would best achieve this.  
Medline® and EMBASE® databases were used for the search, which followed a 
defined search strategy (shown in Appendix 5). The search strategy highlights 
the systematic nature of the review. Papers® (Mekentosj BV) was the reference 
management system chosen to organize references. Where possible thesaurus 
or controlled vocabulary (such as MeSH) search terms were used and if large 
amounts of data were identified, restrictions were applied to filter data found in 
certain fields such as the title. Randomised controlled trials and meta-analyses 
were preferred but not always found. No date limits were applied. The literature 
review was originally conducted in 2015 at the time of writing the research 
proposal. It was repeated in 2018 at the time of writing up the thesis, to identify 
any new evidence.  
 
1.2.1 Incidence 
Finding data on the overall incidence of toxicity in patients on chemotherapy, 
across all tumour sites and treatments did not prove possible. This probably 
reflected the heterogeneous nature of chemotherapy and would require a 
number of systematic reviews across different diseases and treatments in order 
to fully clarify the wider picture. Different chemotherapies used in different 
diseases all carry distinct sets of toxicities. A 2008 UK report looked at deaths 
within 30 days of receiving systemic anti-cancer therapy (SACT). It was noted 
that 43% of patients who had died within 30 days of receiving SACT had 
experienced a grade 3 or 4 toxicity according to CTCAE (common terminology 
criteria for adverse events) criteria related to their treatment (Mort et al., 2008).  
CTCAE criteria are commonly used in clinical practice to grade the severity of 
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toxicity. Toxicity is classified according to the toxicity being described, however 
the general rule is thus: 
Grade 0 = no toxicity 
Grade 1 = Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated 
Grade 2 = Moderate; minimal, local or non-invasive intervention indicated; 
limiting age-appropriate instrumental activities of daily living (ADL)  
Grader 3 = Severe or medically significant but not immediately life-threatening; 
hospitalisation or prolongation of hospitalisation indicated; disabling; limiting 
self-care ADL 
Grade 4 = Life-threatening consequences; urgent intervention indicated 
Grade 5 = Death related to AE 
(National Cancer Institute, 2010) 
 
Mort et al. performed this observational study using voluntary questionnaire 
completion by UK hospital trusts so may not have been representative of the 
worldwide population. However, it did suggest an association between high-
grade toxicity and death of chemotherapy patients. Sophisticated statistical 
analysis was not applied and so it was difficult to use the report as anything 
other than a snapshot review, which was used in the UK to highlight concerns 
around the safety of cancer chemotherapy. 
 
Reporting of toxicity relies on patients reporting their experience to healthcare 
professionals. This can be done in a variety of different ways, from reporting in 
the clinic, to using technology to report.  A single-centre study of patient 
reported outcome measures in 71 patients with breast, colorectal and upper GI 
cancers reported surveyed chemotherapy toxicity (Jenner et al., 2010). 
Surveys were completed by patients without healthcare professional 
intervention, prior to each cycle of chemotherapy. High rates of questionnaire 
completion were seen. Grade 3 or 4 toxicities were seen in 21 (29%) of 
patients but an overall toxicity rate was not reported.  It was felt that the method 
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of assessment empowered and informed patients and allowed for real-time 
reporting of symptoms and could be used to structure clinic reviews.  
 
1.2.2 Economic Effects 
A search looking at the economic effects of toxicity only revealed very specific 
literature, relating to specific drugs or specific patient groups, which suggested 
that the overall economic impact of chemotherapy toxicity may not be fully 
understood and would be difficult to describe. A German study looked at 
chemotherapy toxicity in patients with lymphoproliferative disorders and non-
small cell lung cancer (NSCLC) (Paessens et al., 2011). All interventions 
associated with toxicity including drug treatment, laboratory tests and 
necessary scans were included in the study. Of the 1004 cycles of 
chemotherapy looked at, 50% were associated with a grade 3 or 4 toxicity.  A 
mean value for toxicity related costs of €1032 per cycle (2007 euro value) is 
reported. Costs rose exponentially with the grade of toxicity and those 
associated with infection requiring intensive care were higher. Those cycles 
associated with 4 or more toxicities had the highest costs associated with them. 
Whilst this was a useful study, it was limited to two very specific disease states 
and looked only at one healthcare economy, so it is difficult to extrapolate it to 
other populations. However, it identified that significant costs are associated 
with chemotherapy toxicity. 
 
Latremouille et al. looked at 4158 patients with metastatic colorectal cancer 
who had had at least one treatment episode over a 5 year period, from an 
administrative claims database (Latremouille-Viau et al., 2017). Haematological 
adverse effects of treatment had an average cost of $1480USD, respiratory 
$1253USD, endocrine/metabolic $1213USD, central nervous system 
$1136USD and cardiovascular $1036USD. This study was in US practice only 
and so may not be applicable to UK practice.  
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A 2016 retrospective study of 729 patients with metastatic breast cancer looked 
at patients receiving biologic or chemotherapy with or without endocrine 
therapy (Irwin et al., 2016). The analysis found that the average treatment 
related healthcare costs in this population for haematological toxicities were 
$1524USD per patient per month, with neutropenia or leucopenia costing an 
average of $550USD and anaemia $942USD. Gastrointestinal adverse effects 
costed an average of $839USD. Adjusted all-cause monthly costs increased 
with the number of adverse effects, with the average cost for patients with >7 
adverse effects being $19,701USD, compared to $5908USD for patients 
reporting no adverse effects (p<0.01). This clearly demonstrated that toxicity is 
associated with higher healthcare costs, although the study was limited to one 
tumour site treated within one healthcare economy, so may be difficult to apply 
to NHS practice. It did however provide similar costs for haematological 
adverse effects as Latremouille et al., suggesting adverse effect costs may be 
similar across different disease states.  
 
1.2.3 Effects of Toxicity 
Various studies have highlighted the potential effects of toxicity on patients and 
disease, including need for dose reduction, discontinuation of chemotherapy, 
effects on clinical trials and even death (Kalsi et al., 2014; Mort et al., 2008). An 
observational study in a London hospital found that early treatment 
discontinuation was required in 23 (21.3%)  of elderly patients receiving 
chemotherapy for various cancers due to toxicity (Kalsi et al., 2014). The 
NCEPOD report (Mort et al. 2008) could be interpreted to suggest that toxicity 
increased the risk of death, however there was no ratified statistical evidence of 
this in this report and indeed this is not what the report set out to be able to 
prove. It did mention that toxicity assessment was not always recorded, with 
documented toxicity assessment being seen in only 170 (64%) of cases and a 
toxicity checklist being used in only 26 (10%) of cases.  
 
There was conflicting data, with some sources stating that toxicity can predict 
outcomes in certain sub-groups, namely breast cancer, osteosarcoma and 
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colorectal cancer (McTiernan et al., 2012; Chintamani et al., 2004; Klepin et al., 
2014; Schuell et al., 2005; Rambach, 2014). A group looking at chemotherapy 
in patients with localized extremity osteosarcoma over a long period of time 
concluded that chemotherapy toxicity predicts survival in this sub-group. This 
used a multivariate analysis and showed that differing toxicities of differing 
grades predicted survival (McTiernan et al., 2012). Chintamani et al. suggested 
that toxicity in breast cancer in the neo-adjuvant setting (chemotherapy given 
prior to another intervention such as surgery, with a curative intent) predicts 
response (Chintamani et al., 2004). This was a small study in a very specific 
patient group and so it was difficult to extrapolate to other areas. It was also 
intensive chemotherapy with curative intent and this is likely to have had an 
effect on the level of toxicity experienced. Indeed contradictory evidence was 
shown in patients with breast cancer where toxicity of grade 3-5 was not 
thought to have an effect on overall survival (Klepin et al., 2014).  A further 
study claimed that toxicity can be used as a predictor of survival in patients on 
chemotherapy for colorectal cancer (Schuell et al., 2005). Univariate and 
multivariate analyses revealed toxicity as an independent prognostic indicator. 
It was claimed that the occurrence of just one adverse event, increases the 
incidence of response or stable disease by 34%. The correlation between 
toxicity and therapeutic benefit was noted despite type and degree of toxicity. 
Further French evidence supports the theory of toxicity predicting survival in 
colorectal cancer (Rambach, 2014). A retrospective analysis of 399 patients 
who received chemotherapy for metastatic colorectal cancer in a 10-year 
period concluded that the occurrence of neutropenia or thrombocytopenia in 
the first or second cycle of chemotherapy predicts better survival. In contrast, 
anaemia during chemotherapy was associated with a poorer overall survival. It 
could be theorised that the occurrence of particular toxicity is due to effects of 
chemotherapy on non-malignant tissue and as such could be an indicator of 
the effect of that therapy on malignant tissue. This required careful 
consideration in this research.  
 
A small Canadian study looked at how the risk of chemotherapy toxicity 
affected patient preferences with respect to choosing chemotherapy regimens 
(Beusterien et al., 2014). 102 women were asked to complete a single web-
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based questionnaire to elicit preferences for 17 grade 1-4 toxicities associated 
with available chemotherapies. A 5% reduction in the risk of grade I – II 
sensory neuropathy, nausea and motor neuropathy had the highest influence 
on patient preference. Grade III-IV motor neuropathy, nausea and vomiting and 
myalgia made the most difference for more severe grades of toxicity. Patients 
were willing to receive an intravenous regimen as opposed to an oral regimen 
in order to avoid a 5% increase in the risk of the majority of toxicity. Although 
this did not comment on toxicity occurrence, it did give an insight into the 
opinions of patients with regards to toxicity. Of course this is one patient group 
in one centre. 
 
A 2005 breast cancer trial was forced to close a high dose arm early due to 
toxicity (Brain et al., 2011). High rates of skin toxicity (32.4% rate of grade 3 /4 
toxicity) were reported in the high dose arm of this randomized phase II trial, 
which investigated the sequential approach of anthracycline and taxane based 
adjuvant chemotherapy in patients with high risk breast cancer. This study 
highlights the problematic nature of toxicity and highlights the potential effects 
on trials and potentially curative chemotherapy. 
 
A 2017 study investigated 766 patients with metastatic malignancies in a single 
centre (Basch et al., 2017). Patients were assigned to self-record a toxicity 
assessment on a tablet or to usual care. Once reported on the tablet, toxicity 
details were made available to physicians caring for the patient.  It was found 
that median overall survival was 5 months longer in those patients who self-
reported toxicity, leading the authors to conclude that systematic self-reporting 
of toxicity confers a survival advantage. Of course many factors affect survival, 
but the authors stated that a multivariable model produced statistically 
significant results.  
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1.2.4 Hospitalisation 
Acute, unplanned admission to hospital was considered. General literature 
around acute hospital admission was reviewed in addition to literature around 
admission due to chemotherapy toxicity.  
 
A French study looked at 2692 hospital admissions to French hospitals over a 
six-month period (Bénard-Laribière et al., 2015). It was found that 97 (3.6%) of 
admissions were due to an adverse drug reaction.  Older patients were 
significantly more likely to experience an adverse drug reaction than younger 
patient (p<0.001). Antineoplastic agents were responsible for 12 (12.6%) of 
adverse drug reaction related admissions. The authors used their data to 
predict the rate of admission across France. It may be possible to do this for 
other healthcare systems, but consideration would need to be given to 
differences in healthcare systems between nations.  
 
A longitudinal study of lung cancer patients found that more admissions were 
due to disease than treatment effects (Cuppens et al., 2016). The study looked 
at all unplanned hospital admissions in a single tertiary centre in a 6-month 
period. Two hundred and seven admissions were seen and mean length of 
stay was 9.5 days (SD not stated). The study found that patients with a poor 
performance status, uncontrolled cancer and cancer related events had worse 
outcomes. This is a single centre study in a specific population so is not 
generalizable to a wider population as there may be differences in local 
practice that this would not account for and other populations could have other 
differences such as socioeconomic variance and different ethnicities.  
 
Another single-centred longitudinal study of elderly patients found that mortality 
was higher in patients with a primary diagnosis of cancer (Walsh et al., 2012).  
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A 2017 American review of hospital admissions in patients with prostate cancer 
found that patients with prostate cancer were more likely to be admitted to 
hospital than their peers who did not have a diagnosis of prostate cancer and 
were also more likely to have recurrent admissions (Gnanaraj et al., 2017). Co-
morbidity with congestive heart failure and the presence of metastases were 
found to be risk factors for admission.  This study was specific to the diagnosis 
of prostate cancer and so is not generalizable to a wider population.  
 
A large study of elderly patients representative of community-dwelling 
individuals found that impairment of activities of daily living were twice as likely 
to be admitted to hospital as those without impairment (Aliyu et al., 2003). This 
study was not specific to cancer and chemotherapy but suggested that 
functional status does affect the risk of hospital admission.  
 
Various factors affecting length of stay were identified in 1996 by Clarke 
(Clarke, 1996). Although a dated review, it suggested some reasons for 
variation in length of stay in hospital that are applicable to current clinical 
practice. The review was also around admissions for any reason, so is not 
directly applicable to chemotherapy toxicity, but some useful information was 
gained from the analysis. Clarke suggested that there is often a geographical 
variation in length of stay, with length of stay varying between different 
countries and healthcare systems. The other reasons cited for variations in 
length of stay were categorised as supply factors and demand factors. 
 Supply factors 
o Individual practice style 
o Discharge policies; level of illness at which hospital care is 
considered desirable 
o Bed supply, hospital competition and the quality and availability of 
primary, community or convalescent care 
o Method of payment – prepayment or fee for service 
 Demand factors 
o Socioeconomic status 
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o Disease severity 
o Comorbidity 
o Direct or indirect costs to patients or their carers 
Clarke analysed several reviews, which included thousands of patients to 
establish the above factors. These were of clinical relevance and pertinent to 
this research.  
 
Little data was found regarding hospitalisation due to chemotherapy toxicity. 
This suggests that it has not been studied widely within the context of 
published literature. This helps to justify the reason for undertaking this 
research. Some data was seen around hospitalisation in studies looking at 
other aspects of toxicity but no studies were seen that looked at the risk of 
hospital admission specifically due to toxicity. Data on a wider cancer patient 
population looking at admission was not found, suggesting that this is an area 
of interest for future research.  
 
1.2.5 Predicting Toxicity 
Two fairly large studies were found looking at predicting chemotherapy toxicity, 
both of which have aimed to produce predictive tools (Extermann et al., 2004; 
Extermann et al., 2012). The tools each used a number of factors to predict 
toxicity, some of which were common to both tools. Both patient and treatment 
factors were considered. One tool looked only at older patients and considered 
a large number of different chemotherapy regimens, whereas the other looked 
at a wider age range but within a much more limited number of regimens.  
 
A prospective, multi-centre study was conducted assessing toxicity in 582 
patients over 70 years of age using 24 parameters (Extermann et al., 2011). 
The authors developed their own predictive score called the Chemotherapy 
Risk Assessment Score for High Age patients (CRASH). They also divided into 
sub scores for haematological and non-haematological toxicity. The score 
classifies patients as low, medium-low, medium-high and high risk of toxicity. 
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The score uses haemoglobin, creatinine clearance, albumin, self- rated health, 
Eastern Cooperative Oncology Group (ECOG) performance, Mini-Mental 
Status score, Mini-Nutritional Assessment score, and Chemotox as predictors 
of toxicity. A bootstrap internal validation and independent sample validation 
demonstrated stable risk categorization, meaning that the score could be used 
effectively to predict the risk of toxicity. An aim of the study was to develop a 
score that could be used across all regimens. The score uses a combination of 
patient and treatment factors to predict overall toxicity risk. The MAX-2 method 
was used to calculate regimen toxicity risk. The study looked at 121 different 
chemotherapy schedules and various different diseases. This study gives a 
reliable, tested predictor for elderly patients, however the study population was 
only recruited from 4 centres in a similar area, so generalization to other 
populations may be difficult, due to potential differences in populations such as 
ethnicity or socioeconomic status. 
 
The MAX-2 index is of particular interest and is very pertinent to this research. 
The MAX-2 index was developed as a predictor of toxicity, and combines both 
patient and chemotherapy factors when calculating risk.  MAX-2 uses the most 
frequently reported haematological toxicity and the most frequently reported 
non-haematological toxicity to come up with a risk score for overall toxicity of a 
regimen (Extermann et al., 2004). Extermann et al. decided to test the MAX-2 
index on a large scale and so used the ECOG trial database to do this. Four 
trials were included in the review, which included 2515 patients eligible for 
analysis. 410 (16%) of patients were over 70 years old and 12 different 
treatment regimens were tested, which were quite different in nature. The trials 
were for breast, lung and bowel cancer. A simple linear regression model and a 
logistic regression analysis were used. The prevalence of toxicities was looked 
at in each study and the MAX-2 score calculated. The regression models were 
then used to evaluate the association of the MAX-2 index with the percentage 
of patients experiencing at least one grade 4 haematological or one grade 3 or 
4 non-haematological toxicity. The MAX-2 index was found to have a high 
association with the global incidence of severe toxicity. The authors concluded 
that the MAX-2 index is a reliable way of summarizing the toxicity form a 
chemotherapy regimen on a per patient basis. They stated that the index would 
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be very helpful in comparing the toxicity of several chemotherapy regimens. 
This could be applied to this research, as although the authors claimed to have 
validated MAX-2 there are still many regimens and patient groups that it has 
not been tested in, and there is more work that could be done to look at various 
sub-group analyses.  
 
Hurria et al. looked at 500 chemotherapy patients aged 65-91 years and 
suggests that the risk of toxicity increases with increasing age (Hurria et al., 
2011). They demonstrated that 115 (23%) of patients were admitted during 
treatment, although it is not known if this was due to chemotherapy toxicity. A 
predictive model for toxicity was developed using: geriatric assessment 
variables; laboratory test values; patient, tumour and treatment characteristics. 
The score was then used to stratify patients as at low, intermediate or high risk 
of toxicity. Several risk factors for toxicity were identified and confirmed as 
clinically significant. These included age over 72 years, cancer type 
(gastrointestinal or genitourinary), standard dosing of chemotherapy, poly-
chemotherapy, haemoglobin (males < 11 g/dL; females <10g/dL), creatinine 
clearance less than 34 mL/min, hearing impairment described as fair or worse, 
greater than or equal to one fall in the last 6 months, limited in walking one 
block, need for assistance in taking medications, and decreased social 
activities because of physical or emotional health. This study was of interest as 
it described factors influencing the occurrence of toxicity.  
 
A 2016 study of 1463 patients receiving capecitabine based chemotherapy 
found that 234 (16%) of patients experienced an early-onset grade ≥3 toxicity 
(Meulendijks et al., 2016). Authors found that renal function carried an odds 
ratio of experiencing a grade ≥3 toxicity of 0.85 per 1.73ml/min/1.73m 
(p=0.0007 95% CI 0.78-0.94), body surface area 0.33 per m2 (p=0.0053 95% 
CI [0.15-0.72]), and age 1.14 per decade (p=0.0891 95% CI [0.98-1.34]). Age 
was also found to be significantly associated with fatal treatment-related toxicity 
with an odds ratio of 5.75 (p=0.0008). The authors suggested that age, renal 
function and body surface area can all be used as predictors of capecitabine 
toxicity. It was not possible to know if these predictors would also apply to other 
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antineoplastic agents. 
 
Chase et al. used a logistic regression model to look at specific predictors of 
grade 3 or 4 toxicity in patients undergoing chemotherapy for advanced or 
relapsed cervical cancer (Chase et al., 2015). Six hundred and seventy three 
patients were considered. Higher performance status predicted grade 3 or 4 
toxicity with an odds ratio of 2.78 (95% [CI 1.66-4.68]). Exposure to previous 
radiation and treatment regimen were associated with the reporting of grade 3 
or 4 leucopenia (p<0.05) and anaemia (p<0.005). Performance status and 
treatment regimen were associated with the development of grade 3 or 4 
thrombocytopenia (p<0.05).  Age and treatment regimen were associated with 
the development of 3 or 4 neutropenia (P<0.05).  The study was confined to 
single tumour site so may not be applicable to all treatments, however it did 
give an indication of the factors that may predict toxicity.  
 
1.2.6 Patient Factors 
1.2.6.1 Age 
The risk of cancer increases with age. Figure 1 illustrated the incidence of 
cancer in the UK. 
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(Cancer Research UK, 2015e) 
Figure 1. Incidence of Cancer in the UK (2013-14) 
 
This shows that cancer incidence increases with age and there is a sharp rise 
in incidence at 55-59 years. Highest rates are seen in people over 75 years old. 
Cancer incidence does not necessarily correlate with chemotherapy usage, as 
not all patients with cancer will receive chemotherapy for a variety of reasons. 
As the above graph includes all cancer diagnoses, many patients will receive a 
different treatment modality and some patients may receive no treatment at all.  
 
It is well documented that there are changes in physiological processes that 
occur with age. Balducci and Extermann argue that the most consequential 
changes that occur are in volume of distribution and renal excretion of drugs 
(Balducci and Extermann, 2000). Volume of distribution decreases with age for 
water-soluble drugs and can predispose patients to toxicity. Renal function 
decreases with age and this can reduce excretion of drugs excreted by this 
route, resulting in more toxicity. These principles apply to chemotherapy. It is 
also thought that changes in the hepatic metabolism of drugs changes with 
age, although the exact effects on chemotherapy are not well documented. 
Tissue may be more susceptible to the effects of chemotherapy in older 
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patients. Older patients have a lower stem cell reserve, so are more 
susceptible to haematological toxicity. They also have a reduced ability to 
catabolise cytotoxic drugs and repair cell damage caused by these agents. 
There is a critical reduction in functional tissue in older patients so that damage 
to these tissues may be of greater consequence than in younger patients who 
have a higher reserve.  
 
It has been suggested that older patients derive the same benefit from 
chemotherapy as younger patients (Muss et al., 2005). A multivariate analysis 
of 6487 patients with breast cancer who received chemotherapy, found that 
disease free survival was not affected by age. It was, however, shown that 
younger patients had a longer overall survival, and older patients had a 1.5% 
higher treatment related mortality. This study only focussed on breast cancer, 
but the potential effect of age on outcomes of chemotherapy is of interest. In a 
further analysis of patients with node positive breast cancer, treated with 
chemotherapy, Muss suggests that older patients again derived the same 
benefit from chemotherapy as younger patients in a review of 6642 patients 
across 3 trials (Muss et al., 2007). Older patients had a significantly higher rate 
of grade 4 haematologic toxicity but no difference was found in the incidence of 
grade 3 to 4 non-haematologic toxicities. This study is of interest to this 
research, but is limited to one tumour site, which limits the treatments used and 
also only reports grade>3 toxicity.  
 
A combined analysis of phase III clinical trials in metastatic colorectal cancer 
found that older patients derived the same degree of benefit from the addition 
of irinotecan to 5-fluoruracil and folinic acid as younger patients (Folprecht et 
al., 2008). The study found that in general, older patients did not have a higher 
incidence of toxicity than younger patients, with the exception of hepatotoxicity, 
however repeat of their regression model with age as a continuous variable did 
not confirm these findings. Older patients were also found to have a greater 
risk of sever neutropenia. As with the Muss study, this paper only included 
patients with a single diagnosis, so extrapolation to a whole population is not 
possible (Muss et al., 2007).  
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Other studies have identified interesting facts about the effect of age on 
toxicity. Nie et al. validated the tool developed by Hurria et al., in 120 lung 
cancer patients (Nie et al. 2013) and Reinsich et al. suggested that the range 
and intensity of toxicity increases with age in breast cancer (Reinisch et al. 
2013). Kalsi et al. found that dose reduction of chemotherapy was required 
frequently in elderly patients (Kalsi et al., 2014). Dose reduction due to toxicity 
was required in 60 (55.6%) of patients, 21(35%) of whom had a maximum 
grade 2 toxicity. Treatment was discontinued early in 23 (21.3%) of patients, 8 
(39.1%) of whom had no greater than a grade 2 toxicity. 
 
A review of 65 elderly patients on chemotherapy, led Wildes et al. to conclude 
that performing a geriatric assessment prior to chemotherapy is associated with 
completing a planned number of cycles of chemotherapy (Wildes et al., 2013). 
The authors drew several conclusions from their data around the factors 
influencing the completion of treatment. No control was used in this trial and 
sub groups contained very small numbers of patients. The study found that 20 
(31.1%) of patients experienced a grade 3 or 4 non-haematologic toxicity and 
curative intent therapy, ECOG performance status 2-3 and renal function were 
associated with therapy completion.  
 
LoConte et al. found that age is not predictive of dose limiting toxicity in phase I 
clinical trials of chemotherapy (LoConte et al., 2009) . This was a small study in 
a very specific group of patients and patients chosen for clinical trials may be 
required to fulfil criteria that may not be applicable to a wider population.  
 
Balducci and Extermann suggested in a review of a number of prior studies, 
that increasing age increases the reporting of a number of toxicities including 
myelosuppression, mucositis, cardiodepression, peripheral neuropathy and 
central neurotoxicity (Balducci and Extermann, 2000).  A number of trials of 
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differing design were included in the review and pointed towards age as a 
predictor of toxicity.  
 
A study of all breast cancer trials open in a Canadian cancer centre between 
1999 and 2012 looked at 799 patients (Mariano et al., 2015). Older and 
younger patients experienced similar numbers of toxicities, however the older 
patients were more likely to be enrolled in endocrine or bone related treatment 
arms and younger patients more likely to receive chemotherapy. A multivariate 
analysis showed that treatment type was the strongest predictor of toxicity and 
of the patients receiving chemotherapy, there was no difference in incidence of 
toxicity. This contradicted other evidence which suggested that toxicity 
increases with age.  
 
In a small study of breast cancer patients, Dees et al. found that there 
appeared to be no difference in haematological and non-haematological toxicity 
incidence between older and younger patients, but this study only looked at 44 
patients and so it was difficult to extrapolate these results to a larger population 
(Dees et al., 2000).  
 
1.2.6.2 Co-morbidity 
No specific literature was found pertaining to the effect of Karnofsky or ECOG 
performance status on toxicity (Oken et al., 1982). Performance status is a tool 
used in clinical practice as a quick assessment of the overall health and 
functional status of a patient (Oken et al., 1982).  At NUH, the ECOG 
performance status is recorded prior to each cycle of chemotherapy prescribed. 
Table 1 shows the definition of each grade of the performance status, as 
described by Oken et al. 
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Table 1. ECOG Performance Status 
GRADE ECOG PERFORMANCE STATUS 
0 
Fully active, able to carry on all pre-disease performance without 
restriction 
1 
Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g., light house work, 
office work 
2 
Ambulatory and capable of all self-care but unable to carry out any 
work activities; up and about more than 50% of waking hours 
3 
Capable of only limited self-care; confined to bed or chair more than 
50% of waking hours 
4 
Completely disabled; cannot carry on any self-care; totally confined to 
bed or chair 
5 Dead 
 
 
In 2009 a national report was produced by the National Confidential Enquiry 
into Patient Outcomes and Deaths, which looked at patient deaths within 30 
days of chemotherapy (Mort et al., 2008). The authors stated that the use of 
palliative chemotherapy in patients with a performance status of 3 or 4 should 
be done so with caution and after discussion with the multidisciplinary team 
(MDT).  
 
Performance status has been shown to affect survival in different cancer 
diagnoses (Kelly and Shahronki, 2016). Several large studies have suggested 
that the patients with a lower performance status have a longer duration of 
survival than those whose performance status is greater than 1 (Simmons et 
al., 2015; Stone and Lund, 2007; Kao et al., 2015).  
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A large scale review of 9 clinical trials with 6286 patients with metastatic 
colorectal cancer was conducted by Sargent et al..(Sargent et al., 2009). They 
found that patients with performance status 2 had significantly higher rates of 
grade ≥3 nausea and vomiting and 60 day all-cause mortality was 12% 
compared to 2.8% for patients who were performance status<2 (p<0.0001). 
Performance status 2 was prognostic for a lower progression free survival and 
response rate to chemotherapy.  
 
Only one study was identified concerning the effect of co-morbidity on overall 
chemotherapy toxicity. LoConte et al. aimed to identify clinical and non-clinical 
factors that influence the occurrence of dose-limiting toxicity in phase I trials 
(LoConte et al., 2009). The authors reviewed 242 patients from 24 different 
phase I studies where the maximum tolerated dose was reached. In a bivariate 
analysis, mean age, household income, weight, body surface area, dose of 
drug, alkaline phosphatase, haemoglobin and lactate dehydrogenase were 
found to be significantly associated with dose limiting toxicity. Multivariate 
analysis showed that dose level and distance from the trial centre were 
significant predictors of dose limiting toxicity. Age and comorbidity did not 
predict the development of dose limiting toxicity. As the population in this study 
was so heterogeneous, given the small numbers involved, it was difficult to rely 
on the results. A prospective study to confirm the results was recommended.  
 
An Australian study investigated the impact of obesity on toxicity in over 500 
women treated with adjuvant chemotherapy for breast cancer (Carroll et al., 
2014). It was concluded that obesity was not statistically related to risk of 
chemotherapy related admission or risk of febrile neutropenia. There was also 
no evidence of increased toxicity in obese women with either full or adjusted 
chemotherapy doses.  
 
Lee et al. concluded that in women with advanced breast cancer, physical 
wellbeing and appetite are significant predictors of toxicity and also survival 
(Lee et al., 2010).  
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A retrospective study of patients with a GI malignancy found that malnourished 
patients received less chemotherapy due to toxicity related dose reductions 
(Klute et al., 2015). Multivariable logistic regression modelling was used to 
show that malnutrition was an independent predictor of receiving less than 80% 
of the standard dose of chemotherapy. This suggests that malnutrition has an 
effect on toxicity. It is probable that malnutrition is linked to performance status, 
but Klute et al. controlled for performance status and age in the regression 
model.  
 
Wendrich et al. found that low skeletal muscle mass was an independent 
predictor of dose limiting toxicity in patients receiving chemotherapy for head 
and neck cancers (Wendrich et al., 2017). The study included 112 patients with 
locally advanced disease who were enrolled in clinical trials. It was not possible 
to extrapolate this data to a more generalised population as disease and other 
variables would be very different. Patients enrolled in clinical trials would have 
to fulfil entry criteria and many patients in a general population would have 
factors that exclude them from trials, that may affect toxicity, such as 
performance status, prior treatment or co-morbidity.  
 
A study of 151 patients over 70 years of age receiving chemotherapy for a 
variety of diseases, found that performance status was predictive of toxicity and 
patients with a performance status of 2 or higher or co-morbidities, experienced 
more adverse events and were more likely to discontinue chemotherapy due to 
toxicity (Phaibulvatanapong et al., 2018).Higher performance status was also 
associated with a poorer quality of life. As this study only included patients over 
70 years of age, it may not be possible to extrapolate the results to a 
population with a wider age range.  
 
1.2.6.3 Genetic mutations 
A Swiss study of early breast cancer patients concluded that the BRCA1/2 
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mutation status was a risk factor for febrile neutropenia after the first cycle of 
anthracycline based chemotherapy (Huszno et al., 2013). The analysis of 270 
patients showed that although the risk of febrile neutropenia was increased in 
the BRCA1/2 positive group, this group seemed to not have an increased risk 
of other toxicities. This study may have suggested that genetic factors can 
have an effect on chemotherapy toxicity, however only a small population was 
used and only one genetic mutation in one disease is investigated. Shanley et 
al. partly concurred with these findings, in that they concluded that BRCA1/2 
mutations are not associated with increased toxicity, however they also 
suggested that this applies to haematological toxicity and even stated that 
BRCA2 carriers appeared to have a lower incidence of neutropenia (Shanley et 
al., 2006). The two studies have slightly contradictory results, which could be 
as a result of different populations. Also the Shanley et al. study used patients 
treated much earlier than those in the Huszno et al. study, suggesting that 
treatments and supportive care available may have been very different. 
 
1.2.7 Treatment Factors 
Many different treatments are used in cancer treatment and are associated with 
different toxicities as described in trial data and listed in summaries of product 
characteristics. No literature was identified that explored the general 
relationship between treatment and toxicity.  
 
1.2.7.1 Dose 
Dose has long been known to affect the efficacy of chemotherapy, with most 
agents having a steep dose-response curve (Frei and Canellos, 1980). Indeed 
Frei described this as early as 1980, when far fewer treatments were available 
than now. Dose is less critical with certain drugs such as 5-fluorouracil but the 
review pointed out that in adjuvant therapy, dose-response is steep. There was 
also strong evidence that dose is strongly related to toxicity.  
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1.2.7.2 Intent of Treatment 
The intent of anticancer treatment is crucial in the planning of effective of care 
of the cancer patient (Neal and Hoskin, 2009). The intent of treatment will be 
dictated by the potential outcomes, namely cure or palliation. The three main 
intentions of chemotherapy are: 
 Adjuvant (in addition to another treatment modality with the aim of 
preventing spread or recurrence) 
 Neoadjuvant (similar in intention to adjuvant chemotherapy, but given 
prior to another treatment modality, for example chemotherapy given 
prior to surgery. This can also have the intention of making a cancer 
operable or facilitating a different kind of surgery such as breast 
conserving surgery rather than mastectomy) 
 Palliative (not aimed at cure, but at relief of symptoms but also 
prolonging life, without eradicating the cancer) 
Different diseases are treated differently and with different intentions. The 
treatment intent and disease treated will dictate the type of chemotherapy 
used. It may often be necessary to choose treatments with fewer toxicities for 
treatment of palliative intent, when quality of life can become of greater 
importance.  
 
Phaibulvatanpong et al. suggested that amongst other factors, patients 
receiving chemotherapy of palliative intent had a higher risk of toxicity, which 
resulted in those patient having a higher risk of discontinuing chemotherapy 
due to toxicity (Phaibulvatanapong et al., 2018). This study only involved 
patients over 70 years of age and so may not apply to a population with 
younger patients.  
 
A meta-analysis of randomised controlled trials comparing low-dose to 
conventional dose chemotherapy in a number of different malignancies (Xie et 
al., 2017), suggested the opposite of Phaibulvatanpong et al., in that low-dose 
chemotherapy can achieve similar overall survival rates and response rates to 
 26
conventional dose chemotherapy.  Rates of certain toxicities were significantly 
less in the low-dose arms, which included mucositis (RR=0.31, 95%CI [0.19, 
0.53], P<0.001), thrombocytopenia (RR=0.45, 95%CI [0.32, 0.64], P<0.0001), 
anaemia (RR=0.52, 95%CI [0.37, 0.73], P=0.001), febrile neutropenia 
(RR=0.73, 95%CI [0.58, 0.90], P=0.004). For diarrhoea (RR=1.78, 95%CI[0.35, 
8.94], P=0.49), leucopenia (RR=0.50, 95%CI[0.21, 1.17], P=0.11), neutropenia 
(RR=0.91, 95%CI[0.52, 1.59], P=0.74), nausea/vomiting (RR=0.68, 
95%CI[0.37, 1.24], P=0.21) and treatment-related death (RR=0.35, 
95%CI[0.04, 3.31], P=0.36), there was no apparent differences between low 
and conventional dose chemotherapy. This evidence could have a significant 
impact on clinical practice as it suggested patients can achieve the same 
responses to chemotherapy with fewer side effects.  
 
The 3 cancer diagnoses that received the most chemotherapy in the UK in 
2014 were explored based on SACT data submitted by NHS trusts 
(Chemotherapy Intelligence Unit, 2014).  
 
1.2.8 Breast Cancer 
Data from 2013-15 showed that there were around 54,900 cases each year in 
the UK of invasive breast cancer, making it the first most common cancer in the 
UK (Cancer Research UK, 2015c). Since the early 1990’s, incidence has 
increased in women by 25%. Early stage breast cancers accounted for 79-87% 
of new breast cancer diagnoses, with breast cancer having a favourable 
prognosis. More than 65% of patients with breast cancer will be alive in 20 
years’ time, with nearly 90% of patients surviving to five years. In 2014, 30,918 
cycles of chemotherapy were given for breast cancer in the UK from trusts 
reporting SACT data (Chemotherapy Intelligence Unit, 2014).  
 
Some interesting themes have emerged from the research around breast 
cancer. Hospital admission rates were reported but it is not known if these were 
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due to toxicity or other causes. The risk of death associated with specific 
treatments in specific groups of patients was also reported.  
 
A single-centre Canadian study investigated all patients treated with curative 
chemotherapy for breast cancer (Pittman et al., 2015). Out of 149 patients, 88 
(53%) required an emergency room visit and 19 (13%) required a hospital 
admission. The stage of breast cancer was found to be the only factor that was 
significantly associated with emergency room visits. Tumour size, lower 
number of chemotherapy cycles and adjuvant therapy were significantly 
associated with hospital admission. Of course this was a small study and may 
not be generalizable, however it did show some information regarding 
admission.  
 
Petrelli et al. compared the relative toxicity of adjuvant anthracycline based 
chemotherapy to that of adjuvant taxane based chemotherapy in patients with 
breast cancer (Petrelli et al., 2012). This large meta-analysis included 15 
randomised controlled trials with a combined patient population of 27039. The 
analysis reported an incidence of 4.5% of all-grade cardiotoxicity in breast 
cancer chemotherapy. The mean risk of death without breast cancer 
recurrence in all experimental arms was 0.94% versus 0.87% in control arms. 
The incidence of neurotoxicity was 5.4% in experimental groups versus 0.4% 
control arms. This study showed the relative incidences of several toxicities in 
breast cancer chemotherapy and was a good grounding for further research, 
however it did only include a limited number of toxicities.   
 
A single centre US study reviewed 62 patients over 70 years old who received 
chemotherapy for breast cancer (Garg et al., 2009). A logistic regression model 
showed that increasing age was not associated with early termination of 
chemotherapy. However, increasing age, lower functional status and higher 
comorbidity in this patient group were associated with dose reduction and 
breaks in chemotherapy. Whilst this was a very small study, it did highlight 
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some of the potential consequences of toxicity and some factors which may 
influence it. 
 
A prospective study of 143 patients in several centres who received 766 cycles 
of chemotherapy for breast cancer, were given diaries to record the frequency 
and severity of any nausea and vomiting (Booth et al., 2007).  The following 
risk factors were found to be associated with nausea and vomiting; age 
younger than 40 years, nausea expectation, not eating before treatment and 
low alcohol use. Although this was a relatively small-scale study and the 
chemotherapy administered was not described in detail, it was useful in 
providing an overview of the prevalence of nausea and vomiting in breast 
cancer chemotherapy. It also concurred with the findings of studies looking at 
chemotherapy-induced nausea and vomiting, which are discussed later on in 
Section 1.2.12.  
 
An American survey of 1945 women with early breast cancer treated with 
chemotherapy showed that 872 (45%) reported a toxicity rated as severe/very 
severe (Friese et al., 2017). Unscheduled clinic visits were required by 175 
(9%) of patients for toxicity management and 97 (5%) visited a hospital or 
emergency department. Latina ethnicity, and receipt of chemotherapy and 
radiotherapy were predictors of toxicity. This study illustrated rates of patient 
reported toxicity and provided a good picture or the potential impact of toxicity.  
 
FEC (Fluorouracil, Epirubicin, Cyclophosphamide) is a widely used regimen in 
breast cancer, so articles pertaining to the toxicity associated with FEC were 
searched. A German review of 1496 patients with breast cancer undergoing 
FEC chemotherapy, found that 639 (99.1%) of patients in the FEC arm 
reported a toxicity of some grade (Schönherr et al., 2012). Toxicities of grade 1 
and 2 were seen in 83 (12.9%) of patients and of grade 3 and 4 in 1126 
(86.2%) of patients. Toxicities were grouped as haematological and non-
haematological. Severe (grade 3 or 4) non-haematological toxicities were rarely 
found, whereas grade 3 or 4 haematological toxicities were frequently 
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observed. Only 497 (77.1%) of FEC patients received the full course of 
chemotherapy, with many patients requiring dose reduction or discontinuation 
of therapy. The rate of early termination of chemotherapy was 8%. This trial 
gave some useful information around patients on adjuvant chemotherapy in 
breast cancer. The trial was very clinically focussed and did not report on any 
effects of that toxicity on the wider healthcare system or on the consequences 
of toxicity beyond those pertaining to the chemotherapy.  
 
 
1.2.9 Lung Cancer 
Lung cancer is the third commonest cancer seen in the UK with 46,700 new 
cases seen each year in 2013-15 (Cancer Research UK, 2015f). The second 
commonest cancer in the UK is prostate cancer (Cancer Research UK, 2014) 
however more cycles of chemotherapy were given in breast, lung and 
colorectal cancer, so prostate cancer was not included in the literature review 
(Chemotherapy Intelligence Unit, 2014). Overall, since the 1990s, lung cancer 
incidence has reduced by 8%. Lung cancer remains a difficult disease to cure 
with over 75% of patients being diagnosed at a late stage. Only 5% of people 
with lung cancer survive to 10 years, with 10% surviving 5 years or more. 
Smoking is the cause of 72% of lung cancers. In 2014, lung cancer was the 3rd 
commonest disease that chemotherapy was given for, with 18,216 cycles of 
chemotherapy being given in 2014 in the UK in trusts that reported SACT data 
(Chemotherapy Intelligence Unit, 2014). 
 
Only one study of value was identified that looked specifically at toxicity in 
patients receiving chemotherapy for lung cancer. A large scale review was 
undertaken by Hardy et al. of patients with lung cancer treated with 
chemotherapy between 1991 to 2002 identified by an epidemiology database 
(Hardy et al., 2010). The study looked at 14 chemotherapy regimens and 50 
toxicities, both long and short term. The most common short-term toxicities 
were anaemia, nausea and neutropenia with incidences between 9.2 and 60%. 
The most common long-term toxicities were anaemia, respiratory failure, 
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pulmonary fibrosis, dehydration, neutropenia, nausea and fever. Multivariate 
analysis for certain therapies showed that long term toxicity was more likely in 
women, minority populations and patients with fewer baseline comorbidities 
across disease stages. The study included over 70,000 patients. Although the 
study was relatively old, it still remained useful due to the very large population 
investigated. 
 
1.2.10 Colorectal Cancer 
Colorectal cancer is the fourth commonest cancer in the UK, seeing 41,700 
new cases each year in 2013-15 (Cancer Research UK, 2015a). Since the 
1990s, incidence of bowel cancer has increased by less than 5%. Almost 60% 
of patients diagnosed with colorectal cancer in the UK will live for 10 years or 
more, with a similar figure living for 5 years or more. Early stage bowel cancer 
accounts for 52-56% of diagnoses. Colorectal cancer was the second 
commonest cancer for which chemotherapy was given in 2014 in the UK from 
trusts reporting SACT data, with 20,884 cycles of chemotherapy being given 
(Chemotherapy Intelligence Unit, 2015). 
 
A large Australian review article looked at various factors influencing survival 
and toxicity in chemotherapy for colorectal cancer (Chua et al., 2011). The 
group used pooled analyses and reviews of a large number of trials and meta-
analyses to look at the various factors.  
 
Age was the first thing to be investigated, data was reviewed from over 80 trials 
of patients treated with 5-fluorouracil, or oxaliplatin / irinotecan doublet 
regimens. Evidence was found in some studies to suggest an increased 
incidence of toxicity in the elderly population, especially in grade 3 or higher 
haematological toxicity. This would concur with the findings of other studies 
discussed above, outside of the colorectal setting. No difference in 60-day 
mortality was seen in different age groups. Less data was available to enable 
the authors to look at gender as a factor affecting toxicity. However numerous 
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large-scale trials have found severe mucositis to be more prevalent in female 
patients (22% versus 12% in males [p=0.0006]). Leucopenia is also seen more 
frequently in females. The group pooled data from large fluorouracil based 
randomized trials to look at performance status (PS). Several trials showed that 
patients with a higher performance status were more likely to experience non-
haematological toxicity. The pooled analysis also showed that PS2 patients 
had a significantly greater 60-day, all-cause mortality (12% vs 2.8% 
[p<0.0001]). Studies involving patients being treated in the adjuvant setting 
were used to examine data on race and ethnicity. A large review of nearly 
20,000 patients showed that African-Americans with colorectal cancer had a 
significantly higher mortality than other ethnic groups (HR 1.21-1.45 – 
confidence intervals not reported), although a smaller trial of 3380 patients did 
not demonstrate any difference in survival or toxicity rates. A 
pharmacogenomic study of 1412 patients treated for metastatic disease 
revealed few differences in survival but higher rates of grade 3 or higher 
adverse events in white patients.  
 
Following common diseases, some common toxicities were explored in the 
literature. 
 
1.2.11 Nausea and Vomiting 
Chemotherapy-induced nausea and vomiting (CINV) are two of the most 
common and troublesome side effects experienced by cancer patients 
(Janelsins et al., 2013). 
 
Chemotherapy induced nausea and vomiting (CINV) appeared to be well 
studied with several international guidelines in existence. Nausea and vomiting 
are two distinct symptoms, closely related (Janelsins et al., 2013). Nausea can 
be defined as an unpleasant sensation experienced at the back of the throat 
and epigastrium, that can result in vomiting. Vomiting is the motor reflex 
resulting from forceful upward expulsion of the contents of the stomach. CINV 
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is classified as acute, delayed or anticipatory. Acute CINV occurs in the first 24 
hours after chemotherapy is administered and lasts for a maximum of 5-6 
hours. Delayed CINV occurs 24 hours after chemotherapy and can last for 5-7 
days. Anticipatory CINV is a conditioned response that occurs prior to the 
administration of chemotherapy and is based on a patient’s prior experience of 
chemotherapy, being triggered by olfactory, visual, psychological or auditory 
stimuli.  
 
The CINV process is triggered by a number of physiological pathways after 
administration of the chemotherapeutic agent (Janelsins et al., 2013). The 
central nervous system plays an important role in CINV, receiving a variety of 
emetic stimuli and generating efferent signals to a number of tissues resulting 
in nausea and vomiting. Multiple emetic pathways exist and operate by a 
variety of mechanisms.  The three main neurotransmitters are shown in Table 
2 along with the receptors with which they are associated.  
 
Table 2. Neurotransmitters and Receptors 
Neurotransmitter Receptor 
Serotonin (5HT) 5-hydroxytryptamine (5HT3) 
Substance P Neurokinin – 1 (NK1) 
Dopamine Dopamine receptors 
 
Serotonin is the primary mediator of neural signals from the gut to the nucleus 
of the solitary tract (NTS) and activates 5HT3 receptors in the gut and NTS. 
Substance P transits signals from the vagus nerve to NK1 receptors in the 
chemoreceptor trigger zone in the area postrema on the floor of the fourth 
ventricle of the brain. Dopamine is likely to have anti-dyspeptic effects. 
Chemotherapy agents are toxic to the enterochromaffin cells lining the GI tract, 
causing formation of free radicals, which cause enterochromaffin cells to 
release excessive serotonin. The serotonin binds to 5HT3 receptors on vagal 
nerve afferents, relaying information to the brain which either initiates emesis 
directly or sensitizes the vagus nerve to other substances released from 
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enterochromaffin cells, or resulting from cell death, resulting in delayed CINV. 
Substance P is distributed throughout the central and peripheral nervous 
systems and is the preferred ligand for NK1 receptors, which are located in the 
gut, area postrema and NTS regions. Release is mediated by chemotherapy 
agents but substance P tends to bind largely to centrally located NK1 
receptors, which signal vagal afferent nerves to the chemoreceptor trigger zone 
and the vomiting centre in the medulla oblongata. It is likely that centrally 
located signalling is most significant for CINV. It has been suggested that there 
is some cross talking between 5HT3 and NK1 receptor signalling pathways, in 
that once one receptor is activated by its ligand, it affects the cellular responses 
of another receptor system, resulting in a synergistic action, however this 
remains theoretical and has not yet been elucidated. There is emerging 
evidence that delayed CINV is largely associated with the activity of substance 
P. Other pathways that are less well understood are involved in CINV. The 
main anti-emetic drugs used in CINV work on the pathways described above. 
Their efficacy in treating CINV suggests that these are the primary mechanisms 
responsible for the reaction. For example the dopamine receptor antagonists 
domperidone and metoclopramide have a well-established role in the 
management of CINV, suggesting the role of dopamine in triggering CINV.  
 
CINV is graded using the common terminology criteria for adverse events 
(CTCAE) as described by the US national cancer institute (National Cancer 
Institute, 2010). It is graded as in Tables 3 and 4. 
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Table 3. Nausea and CTCAE Grade 
Nausea 
CTCAE grade  
1 Loss of appetite without alteration 
in eating habits 
2 Oral intake decreased without 
significant weight loss, 
dehydration or malnutrition 
3 Inadequate oral caloric or fluid 
intake: tube feeding, TPN or 
hospitalisation indicated 
4 - 
5 - 
 
Table 4. Vomiting and CTCAE Grade 
Vomiting 
CTCAE grade  
1 1 - 2 episodes (separated by 5 
minutes) in 24 hrs 
2 3 - 5 episodes (separated by 5 
minutes) in 24 hrs 
3 >=6 episodes (separated by 5 
minutes) in 24 hrs; tube feeding, 
TPN or hospitalisation indicated 
4 Life-threatening consequences; 
urgent intervention indicated 
5 Death 
 
It is known that the likelihood of nausea and vomiting is increased by the 
agents used, but also by a number of patient factors as described below.  
 
The American Society of Clinical Oncology (ASCO) publish guidelines for the 
management of CINV (Hesketh et al., 2017a). Anticancer agents are graded as 
to their emetogenicity and are graded as high, moderate, low and minimal with 
the risk of CINV being >90%, 30-90%, 10-30% and <10% respectively. 
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A longitudinal review of 200 patients receiving different chemotherapies for 
several cancers showed an incidence of nausea and/or vomiting in 123 (62%) 
of patients (Pirri et al., 2013). This was a relatively small study with a very 
heterogeneous population, however gave an indication of the incidence of 
nausea and vomiting in chemotherapy patients. Patients reporting nausea 
and/or vomiting reported a significantly impaired quality of life compared to 
those not experiencing nausea and vomiting. In a separate article, the same 
data is used to identify pre-treatment risk factors for nausea and vomiting (Pirri 
et al., 2011). In 77% of cases, the following risk factors predicted 
chemotherapy induced nausea and vomiting: female gender, 
premorbid/anticipatory vomiting, moderate to highly emetogenic chemotherapy, 
cancer resection and pre-treatment low role functioning.  
 
Another, larger study identified variables which can be used to predict the risk 
of nausea and vomiting in chemotherapy patients, which included low social 
functioning, pre-chemotherapy nausea, female gender, highly emetogenic 
chemotherapy, low alcohol use and lack of maintenance antiemetics, which 
were all associated with a higher incidence of nausea and vomiting (Osoba et 
al., 1997). Risk factor analysis showed that the incidence of post chemotherapy 
nausea and vomiting increased from 20% in patients with no risk factors, to 
76% in those with 4 or more risk factors.  
 
The European Society of Medical Oncology (ESMO) and the Multinational 
Association of Supportive Care in Cancer (MASCC) stated in their antiemetic 
guidelines, that despite recent advances, nausea and vomiting remain a 
problem in chemotherapy patients (Roila et al., 2010). The guidelines classified 
chemotherapy agents into four groups for their emetogenicity and could be 
used to judge the likelihood of nausea or vomiting occurring based on drug 
factors alone. The guidelines are widely used in clinical practice. The 
guidelines also reviewed the evidence for antiemetic drugs and made 
recommendations as to which drugs to use when.  
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The American Society for Clinical Oncology (ASCO) guidelines followed a 
similar format to the MASCC guidelines and used literature reviews of 
randomized controlled trials to develop guidelines for use in clinical practice 
(Basch et al., 2011). The MASCC guidelines agreed with most of the drug 
classifications (Roila et al., 2010). As these guidelines were so extensive, 
included large numbers of randomized controlled trials and were internationally 
utilised; it could have been supposed that it was most likely to see nausea and 
vomiting in patients receiving the highly emetogenic drugs. However, these 
guidelines did not consider patient influences as part of these classifications.  
 
A 2016 secondary review of a trial looked at the use of gabapentin in the 
prevention of CINV in 413 patients receiving highly emetogenic chemotherapy 
(Kottschade et al., 2016). The authors found that 145 (35%) of patients 
reported nausea and 78 (19%) at least one emetic episode. CINV on day 1 of 
cisplatin therapy and history of motion sickness significantly predicted delayed 
CINV. Age, combination of highly and moderately emetogenic chemotherapy 
and being treated for breast cancer, predicted CINV on day 1. These results 
concurred with other studies suggesting these factors as predictive of CINV.  
 
Escobar et al. looked at the incidence of CINV in 240 patients receiving 
moderately emetogenic chemotherapy (Escobar et al., 2015). Vomiting 
occurred within 5 days of chemotherapy in 50 (20.8%) of patients and nausea 
in 100 (42%). This suggested that CINV was problematic in this population of 
patients.  
 
A small study aimed to investigate the impact of CINV on patients’ quality of life 
(Lindley et al., 1992). Patient diaries, a functional living index – cancer tool, a 
functional living index – emesis tool and an item checklist for cost implications 
were used prior to and after chemotherapy for a variety of indications in 122 
patients. CINV was reported by 68 (56%) of patients. Statistically significant 
reductions in quality of life scores were seen in patients who experienced CINV 
but not in those who did not. Patients who experienced CINV found that their 
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ability to complete household tasks, enjoy meals, spend time with family and 
friends and to maintain daily function and recreation was impaired. Although 
this was a small study, it highlighted the potential consequences of CINV and 
confirms that it was generally considered to be a negative symptom.  
 
A German study of 208 chemotherapy cycles of emetogenic chemotherapy for 
a number of different cancers found that 68 (32.8%) of patients experienced 
acute CINV (Ihbe-Heffinger et al., 2004). Rates of delayed CINV were much 
higher at 60.7% (126 patients). Healthcare resources were utilised by 68 
(32.6%) of patients due to CINV. Only one patient required hospitalisation and 
only 3 patients lost work days due to CINV. High costs for management of 
CINV were seen in patients who received a cisplatin containing regimen, those 
who had a worse experience of CINV and those who experienced delayed 
CINV.  Although this was a small study it gave an indication as to the resource 
implications for the health care system of CINV, confirming that it was a 
significant toxicity and that there was value in researching the risk factors 
associated with it. The study only took place in one country with a single health 
system, so may not be generalisable to other health systems internationally.  
 
A large scale review article of the pathophysiology and treatment of CINV 
suggested that younger age and female gender were predictors of toxicity 
(Hesketh, 2008), although this was based on evidence from trials looking at 
cisplatin based chemotherapy, so may not have been applicable to all 
treatments. Hesketh also suggested that emetogenicity of treatment and dose 
would affect the risk of CINV. Patients who have a high alcohol consumption 
were less likely to experience CINV.  
 
1.2.12 Diarrhoea 
Mucositis is a common side effect of chemotherapy. When it affects the lower 
gastrointestinal tract it can result in diarrhoea. The mechanisms of damage to 
the gut by chemotherapy are not fully understood (Gibson and Keefe, 2006). It 
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is thought that the effects of chemotherapy on the different parts of the 
gastrointestinal (GI) epithelium are via different mechanisms, as the colorectal 
epithelium is mainly columnar in structure, whereas higher up the GI tract the 
epithelium consists of a renewing stratified squamous mucosa. Diarrhoea can 
be defined as an increased frequency and decreased consistency of bowel 
motions, which may be associated with blood, pain and mucous. 
 
Several different types of diarrhoea can be caused by chemotherapy (Gibson 
and Keefe, 2006): 
 Secretory – occurs when absorptive capacity of the mucosa is exceeded 
by secretory activity, increasing luminal contents. It is associated with 
increased secretion of electrolytes 
 Osmotic – occurs when there is a higher concentration of osmotically 
active or non-absorbable solutes in the lumen 
 Malabsorption – can result from alterations to the microflora, or damage 
to the villi of the GI tract. Rebound crypt hyperplasia can occur, where 
immature crypt cells develop in the colon, which produce immature 
enzymes, which can reduce water absorption. In the crypt wall, water 
absorption follows chloride ions. When the crypt cells are damaged, 
chloride is not absorbed and so water remains in the lumen, resulting in 
diarrhoea. 
 Exudative – can increase mucus secretions 
 Dysmotility – occurs when gut motility is increased. If transit time is 
increased, less water can be absorbed, resulting in diarrhoea 
 Infectious – occurs when a pathogen is present and can be secretory or 
osmotic 
 Inflammatory – can occur when medications result in inflammation of the 
GI tract 
 Steatorrhoea – can result from deranged secretions of bile salts 
 
Precise mechanisms of diarrhoea induced by chemotherapy have not been 
fully explored, although there was limited evidence that elucidated this.  It has 
 39
been theorised that diarrhoea is caused by a combination of mechanical and 
biochemical changes caused by chemotherapy, resulting as a direct toxicity of 
the chemotherapy on colonic crypt cells (Gibson and Keefe, 2006). It is also 
thought that the villi in the small intestine may be unable to absorb fluids 
correctly and other changes may be associated with intestinal inflammation, 
which leads to secretion of mucosal and submucosal factors. It has been 
suggested that chemotherapy destroys brush border enzymes and causes 
more gut wall secretions to occur (G. Richardson and Dobish, 2016).  Another 
possible mechanism is that chemotherapy alters the bacterial microflora and 
results in bacterial overgrowth, with a resultant increase in enterotoxins, 
leading to a direct secretory effect on the intestinal mucosa. 
 
Targeted anticancer agents were also associated with diarrhoea (Stein et al., 
2010). Epidermal growth factor receptor (EGFR) targeted agents have a rate of 
grade 3-4 diarrhoea of less than 10%, however EGFR targeted monoclonal 
antibodies (MABs) can have higher rates, up to 60% of all grade diarrhoea. 
Multi-targeted tyrosine kinase inhibitors (TKIs) can have a rate of all-grade 
diarrhoea of 30-50%. mTOR inhibitors cause diarrhoea in up to 40% of 
patients. The mechanisms by which diarrhoea is induced by these newer 
agents are not yet fully understood. One potential mechanism is an alteration of 
intestinal motility (Stein et al., 2010).  
 
Diarrhoea is commonly graded using the CTCAE system, as in Table 5 
(National Cancer Institute, 2010). 
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Table 5. Diarrhoea and CTCAE Grading 
Diarrhoea 
CTCAE grade  
1 Increase of <4 stools per day 
over baseline; mild increase in 
ostomy output compared to 
baseline 
2 Increase of 4 - 6 stools per day 
over baseline; moderate increase 
in ostomy output compared to 
baseline 
3 Increase of >=7 stools per day 
over baseline; incontinence; 
hospitalisation indicated; severe 
increase in ostomy output 
compared to baseline; limiting 
self-care ADL 
4 Life-threatening consequences; 
urgent intervention indicated 
5 Death 
 
Irinotecan is a chemotherapeutic agent, which is associated with high rates of 
diarrhoea (60-80% of patients) (Gibson and Keefe, 2006). Two distinct types of 
diarrhoea are seen with irinotecan, an early secretory diarrhoea, which is a 
manifestation of a cholinergic reaction to the irinotecan, and a delayed 
diarrhoea. A study of jejunal and colonic histology following irinotecan 
administration suggests that it increases apoptosis in crypts of the GI tract and 
causes villous atrophy and crypt hypoplasia resulting in increased mucus 
secretion and changes in absorption rates (Gibson et al., 2003). Irinotecan is 
metabolised to SN-38, the active metabolite, by carboxylesterase. SN-38 is 
further metabolised to SN-38 glucuronide (SN-38G). When SN-38G is secreted 
into bile, it has to pass through the intestine, where bacteria convert some of it 
back to SN-38, by bacterial β-gluronidase, where it can cause further gut-
toxicity.  
 
5-fluourouracil is another common chemotherapeutic agent that is commonly 
associated with diarrhoea (Gibson and Keefe, 2006). Few animal models have 
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been conducted to explore the mechanism by which 5-fluorouracil causes 
diarrhoea, so it is not possible to elucidate this at present.  
 
Data on rates of diarrhoea was difficult to find outside of trials investigating 
individual agents or regimens. It is thought that diarrhoea can occur in 50-80% 
of patients depending on the regimen used (Stein et al., 2010). A 2011 meta-
analysis reviewed randomized controlled trials comparing targeted agents to 
standard FDA approved chemotherapy regimens for all cancers (Elting et al., 
2013). The incidence of diarrhoea was higher in nearly all trials with the 
targeted agents with relative risks ranging from 1.5 to 4.5. As targeted 
therapies are now widely used, this study highlighted the potential burden of 
diarrhoea as a toxicity. 
 
Andreyev et al., conducted a large review of the literature around 
chemotherapy induced diarrhoea and concluded that there was a lack of 
randomized controlled trials (Andreyev et al., 2014). The authors developed UK 
multi-disciplinary guidelines for the management of diarrhoea based on the 
evidence reviewed.   
 
A review of 18 trials of anti-epidermal growth factor receptor monoclonal 
antibodies in patients with colorectal cancer found that these patients had a 
relative risk of diarrhoea of 1.66 (95% CI [1.52-1.8]) (Miroddi et al., 2015). The 
relative risk of mucositis was 3.44 (95% CI [2.66-4.44]). Although this study 
focused on a single tumour site and class of drugs, it demonstrated the risk of 
diarrhoea in this patient group.  
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1.2.13 Fatigue 
The national cancer institute defines fatigue as: 
“A condition marked by extreme tiredness and inability to function due to lack of 
energy. Fatigue may be acute or chronic.” 
      (National Cancer Institute, 2018) 
 
Fatigue is known to be a very common symptom in patients with advanced 
cancer (Barnes and Bruera, 2002). The aetiology of fatigue is unclear but it  
has been shown to have physical and cognitive effects. Fatigue is a subjective 
sensation and so assessment can be difficult. Many factors are thought to 
contribute to fatigue including cancer, cancer treatment, cancer or treatment 
complications, medication and other physical or psychosocial conditions. There 
are many fatigue assessment tools available that can help to identify and 
manage fatigue. Fatigue rates of up to 99% have been reported in some trials, 
but many of these did not focus on chemotherapy patients, but cancer patients 
as a population. Management of fatigue can involve specific or symptomatic 
interventions. Specific interventions include: 
 correcting anaemia or metabolic abnormalities 
 managing pain 
 managing insomnia 
 managing depression and anxiety 
Symptomatic measures include: 
 Education 
 Counselling 
 Pharmacologic treatment – including corticosteroids, progestational 
agents and psychostimulants 
 Non-pharmacological interventions – including psychosocial 
interventions and physical activity 
(Barnes and 
Bruera, 2002) 
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Fatigue can be graded in accordance with CTCAE criteria as in Table 6. 
Table 6. Fatigue and CTCAE Grading 
Fatigue 
CTCAE Grade Description 
1 Fatigue relieved by rest 
2 Fatigue not relieved by rest limiting instrumental ADL 
3 Fatigue not relieved by rest limiting self-care ADL 
4 - 
5 - 
       
(National Cancer Institute, 2010) 
This is a very subjective way of measuring fatigue as fatigue is a personal 
phenomenon that may be felt differently by different patients. As such, a 
standardised means of measuring fatigue has not been reached by consensus 
(Hauser et al., 2008). 
 
There did not appear to be one clear pathophysiology of fatigue in cancer and 
many studies have focussed on factors that contribute to it rather than the 
mechanism of fatigue development (Wang, 2008). Various hypotheses around 
the pathophysiology of fatigue have been proposed. The central governor 
model proposed that the subconscious brain regulates power output by 
modulating motor unit recruitment to preserve whole body homeostasis, in 
order to prevent catastrophic physiological failure (Weir et al., 2006). Although 
this model suggested a purpose and mechanism for fatigue, it had little 
evidence to back it up. Chaudhuri and Behan implicated metabolic and 
structural lesions that disrupt the usual process of activation in pathways 
interconnecting the basal ganglia, thalamus and limbic system and higher 
cortical centre in the pathophysiological process of “central” fatigue (Chaudhuri 
and Behan, 2004). Wang suggested that cancer related fatigue fits well in to 
Chaudhuri and Behan’s model, in which fatigue was a complex emotion 
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affected by motivation and drive, fear and anger and memory of prior activity 
(Wang, 2008).  
 
Ryan et al. conducted a review of many studies investigating potential 
mechanisms to explain the pathophysiology of cancer related fatigue. The 
review stated that fatigue mechanisms have been proposed in various 
conditions and often these were extrapolated to cancer (Ryan et al., 2007). 
Another proposed mechanism of fatigue was serotonin (5-HT) dysregulation. It 
was suggested that cancer or cancer treatment causes an increase in 
serotonin in the brain and /or upregulation of 5-HT receptors, which results in 
reduced somatomotor drive, modified hypothalamic-pituitary-adrenal axis 
(HPA) function and a sensation of reduced capacity to perform physical work. 
The effect on dysregulation on the various functions of serotonin can also 
explain fatigue, including appetite control, sleep, memory, learning, 
temperature regulation, mood, behaviour, cardiovascular function, muscle 
contraction, endocrine regulation and depression. Serotonin is also implicated 
in exercise-induced fatigue in chronic fatigue syndrome. Ryan et al. went on to 
link the serotonin theory to cancer related fatigue. There was evidence that 
proinflammatory cytokines such as TNF-α seen in cancer, can increase 5-HT 
metabolism, with existence of a feedback loop between TNF-α, that results in 
increased 5-HT being released into the synapse. It is also suggested that TNF-
α can increase 5-HT transporter function, resulting in clearance of 5-HT from 
the synapse. It is also thought that TNF-α synthesis can be reduced by 5-HT. 
Pathologic conditions or treatment could dysregulate this feedback loop. 
 
Ryan et al. cited HPA axis dysfunction as another possible mechanism to 
explain cancer related fatigue. Low levels of cortisol have been observed in 
patients with chronic fatigue syndrome, and it is suggested that cancer or 
cancer treatment could alter the function of the HPA axis, which causes 
endocrine changes that could be responsible for fatigue. The HPA axis 
regulates cortisol levels and cortisol is known to have a number of effects 
included blood pressure regulation, cardiovascular function, carbohydrate 
metabolism and immune function. Although the link between the HPA axis and 
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cancer related fatigue remains unclear, some evidence did indicate that HPA 
axis function is altered in cancer related fatigue, with one study finding lower 
serum cortisol levels in women with breast cancer who reported fatigue 
compared to those who did not report fatigue (Bower et al., 2002). This study 
only looked at breast cancer survivors and was post chemotherapy not during 
treatment.  
 
A further mechanism to explain fatigue was circadian rhythm disruption (Ryan 
et al., 2007). Several studies have demonstrated alterations to circadian rhythm 
in cancer. These can include changes in endocrine rhythms such as cortisol, 
metabolic process such as circulating protein levels, the immune system such 
as levels of circulating cytokines and rest-activity patterns. These studies have 
shown that in patients with advanced cancer, greater rhythm alterations are 
demonstrated compared to healthy individuals.  
 
Ryan et al. also argued that muscle metabolism and ATP disruption could 
explain cancer related fatigue. Various studies have confirmed that there is a 
negative correlation between cancer related fatigue and physical performance. 
A possible explanation was that cancer or its treatment leads to a defect in the 
mechanism for regenerating ATP in skeletal muscle, which compromises the 
ability to perform mechanical tasks.  
 
Vagal afferent nerve activation was also suggested, by Ryan et al., as a 
possible mechanism of cancer related fatigue. The hypothesis proposed that 
cancer or its treatment causes a peripheral release of neuroactive agents that 
activate vagal afferent nerves, leading to suppression of somatic muscle 
activity.  
 
Ryan et al. also suggested that cytokine dysregulation could play a role in 
cancer related fatigue. Various studies have found that administration of 
proinflammatory cytokines like TNFα, can induce fatigue. TNF has been 
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associated with alterations in neurotransmission, causing behavioural changes 
such as lethargy and anorexia. Cancer and cancer treatments are associated 
with increases in plasma levels of cytokines and have been correlated with 
fatigue in cancer patients.  
 
Fatigue often presents in cancer patients as a syndrome of several symptoms 
(Ryan et al., 2007). It can occur concurrently with conditions that are likely to 
contribute to fatigue, including anaemia, cachexia, depression and sleep 
disorders. As much chemotherapy is myelosuppressive, anaemia is a common 
side effect (Neal and Hoskin, 2009). Cachexia is thought to affect up to 50% of 
all cancer patients and the mechanism is not clearly understood (Ryan et al., 
2007). Depression is seen commonly in cancer patients and has been shown in 
several studies to be associated with fatigue. Sleep disorders can also be seen 
frequently amongst cancer patients and there are a variety of mechanisms by 
which cancer or cancer treatment can disturb sleep.  
 
A 2008 review of 531 patients who underwent chemotherapy for a number of 
different cancers in the advanced setting, suggested that fatigue was the top 
ranked symptom that impacted on patients’ lives (Butt et al., 2008). Patient 
fatigue ratings were strongly associated with malaise, difficulties with activities 
of daily living, pain and quality of life.  
 
A Cochrane review of studies investigating the use of exercise in the 
management of fatigue, suggested that exercise is effective in reducing fatigue 
during or post adjuvant cancer therapy in breast and prostate cancer (Cramp 
and Bryon-Daniel, 2012). This was a large review including 4068 patients and 
suggests a useful non-pharmacological management of fatigue. It did however 
leave the question of effective management of fatigue in patients receiving 
palliative chemotherapy, unanswered.  
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Poort et al. suggested that patients with advanced cancer receiving palliative 
chemotherapy, are likely to be ill for a long period of time, meaning that fatigue 
can have a prolonged and profound effect on quality of life (Poort et al., 2017). 
This made it an area of interest for research, as effective prediction and 
management may result in improved quality of life.  
 
Hauser et al. suggested that cancer related fatigue is a frequently reported 
symptom that is affected by the diagnostic criteria and stage of disease 
(Hauser et al., 2008). Fatigue has many potential causes and Hauser et al. 
listed all types of cancer treatment as being associated with fatigue. One 
hundred and seventy one advanced cancer patients referred to the palliative 
medicine service in a single centre were surveyed, and 100 patients completed 
the survey. The mean age of the population was 65 years and there was a 
reasonable distribution of patients with different diagnoses. Although 
chemotherapy could not be associated with fatigue, Hauser et al. found that 
fatigue was associated with a higher performance status and worse physical 
function. Interference with work, enjoyment of life, mood, sleep and walking 
were also attributed to cancer related fatigue. Fatigue was greater in those with 
brain metastases and lower in those who had received prior radiotherapy 
treatment. Although this study was not specific to chemotherapy, it provided a 
useful overview of cancer related fatigue in a fairly heterogeneous population.  
 
A Dutch review of 22 studies looking at fatigue in cancer patients on treatment 
found that the rate of fatigue reporting tended to differ with the different tools 
used (Servaes et al., 2008). One study reviewed reported that 60 (61%) of a 
mixed sample of cancer patients reported clinical fatigue during chemotherapy 
or radiotherapy (Graydon et al., 1995). In two studies where patient diaries 
were used, fatigue prevalence rates of 99% (76 patients) and 90% (116 
patients) were reported at some point in chemotherapy (A. Richardson and 
Ream, 1996; Blesch et al., 1991). Six studies were found that compared cancer 
patients with healthy control patients and cancer patients reported more 
frequent and more severe fatigue than the control group (Stone, Richards, et 
al., 2000; Stone, Hardy, et al., 2000; Jacobsen et al., 1999; Hann et al., 1999; 
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Glaus, 1993). Ten studies were reviewed that compared pre and post -
treatment fatigue scores and patients were significantly more fatigue mid- or 
post-treatment, although this included patients on other treatment modalities as 
well as chemotherapy (Stone, Richards, et al., 2000; Smets et al., 1998; Irvine 
et al., 1998; Irvine et al., 1994; Ahsberg and Furst, 1991; Hann et al., 1999; 
Dean et al., 1995; Monga et al., 1999; Jacobsen et al., 1999). Most studies 
failed to find relationships between fatigue and disease-related variables. No 
conclusions around fatigue and treatment-related factors were drawn as the 
authors stated that these relationships have rarely been investigated. In 10 out 
of 12 studies investigating interventions around fatigue, positive effects were 
reported on fatigue immediately after the intervention (Cimprich, 1993; Mock et 
al., 1997; Dimeo et al., 1999; A. Schwartz, 2000; Oyama et al., 2000; Spiegel 
et al., 1981; Worden and Weisman, 1984; Forrester et al., 1985; Houts et al., 
1986; Fawzy, 1995; Cousins et al., 1990; Gaston-Johansson et al., 2000). The 
interventions included individual counselling, a walking or exercise programme 
or group meetings. In 3 studies the positive effect of the intervention was still 
apparent 3 to 6 months later (Worden and Weisman, 1984; Fawzy, 1995). This 
review provided very useful data on fatigue and highlighted that it is a 
troublesome side effect of chemotherapy, but can be successfully managed.  
 
Much of the literature around fatigue appeared to be in patients with advanced 
cancer and little literature was found that looked at patients treated in the 
curative setting with adjuvant or neoadjuvant chemotherapy. This left an area 
of interest for this research.  
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1.3 Conclusions from the literature 
Much literature has been identified around chemotherapy toxicity. Generalised 
data on chemotherapy toxicity did not seem to be available and it was difficult 
to ascertain an overall incidence or prevalence across all diseases and 
treatments. Data pertaining to the economic effects of chemotherapy toxicity 
was sparse and data on the risk of hospital admission due to toxicity could not 
be identified. Various studies highlighted the potential consequences of toxicity, 
which included morbidity, treatment adjustment and death. Indeed, toxicity has 
been shown to be a prognostic indicator in certain circumstances.  
 
Various risk prediction tools have been developed for toxicity and some 
pertained to different sub-populations. All were validated or tested to different 
extents. Multiple studies were found that looked at age as a factor in toxicity. A 
number of other patient factors were investigated and found to influence toxicity 
to different extents. The top three most common cancers were explored and 
literature found that looked at chemotherapy toxicity in these populations. 
Frequently occurring toxicities were also researched and literature found that 
explained the pathophysiology of these toxicities and their occurrence with 
chemotherapy.  
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2.0 Aims and Objectives 
The main aim of the research was to identify what factors influence the 
likelihood of patients experiencing acute chemotherapy toxicity and the 
likelihood of that toxicity leading to hospitalisation. It was hoped that this 
research would be able to give treating clinicians and institutions an idea of the 
impact of toxicity on both patients and the wider healthcare system. 
 
The aims of the research were divided into the following objectives: 
 To establish the overall incidence of toxicity 
 To establish the incidence of hospitalisation due to toxicity 
 To establish how the occurrence / severity of toxicity, the risk of 
hospitalisation is affected by the following 
o Age 
o Performance status 
o Treatment intent 
o Disease being treated 
o Treatment given (when grouped in different ways) 
 
 
The research aimed to perform an analysis of the economic impact of toxicity 
and its consequences. This required the overall incidence of chemotherapy 
toxicity across all tumour sites to be elucidated. Once done, it was compared to 
the overall incidence of hospital admission. Toxicity is generally felt to be a 
negative phenomenon for the patient, although some literature, described 
above, suggested a correlation between toxicity and improved outcomes of 
treatment. However there was also much literature described above to suggest 
that toxicity can be detrimental and as such, the ability to predict and thus 
reduce that toxicity is seen as a positive action. Once factors affecting toxicity 
had been identified, it was then necessary to consider what actions can be 
taken to minimise the risk. This was not within the remit of this research. 
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2.1 Hypotheses 
From the literature, it was possible to make various predictions about the 
outcome measures. Although no literature was found that would allow direct 
comparisons to this study, data was found that allowed comparisons to be 
made.  
 
It was anticipated that the population would be heterogeneous, with a wide age 
range, as NUH is a large teaching centre, which treats all type of cancers 
across the East Midlands region of the UK (Nottingham University Hospitals 
2014). It was thought likely that most patients would be performance status 0 to 
2 as chemotherapy is less frequently given to patients of performance status >2 
as discussed in the NCEPOD report, due to the possibility that risk could 
outweigh benefit (Mort et al., 2008). Data from Cancer Research UK and the 
national SACT data submissions, suggested that breast, colorectal and lung 
were likely to be the most common diseases (Cancer Research UK, 2014). 
Palliative intent was expected to account for a large proportion of the 
treatments given, due to the regimens available at NUH and a significantly 
larger number of palliative regimens being available and used. This data can 
be found internally on the NUH Chemocare® system (CIS, 2014). Due to the 
number of different regimens available at NUH, it was likely that a large number 
of treatments would appear in the data and that methods of grouping would be 
required in order to analyse the data in a meaningful way. It was anticipated 
that treatments could be grouped according to cytotoxicity, emetogenicity, the 
number of drugs used in the regimen, the class of drugs and the 
commissioning status of the drug. These were discussed in detail in the 
methodology.  
 
The literature did not identify any data from an entire chemotherapy population 
that reported an overall incidence of toxicity. Jenner et al. found a rate of 29% 
grade 3 or 4 toxicity in a population limited to a small number of disease types 
(Jenner et al., 2010). This included acute and delayed toxicities, however it was 
felt that the toxicity rate seen in this research was likely to be higher than this 
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as it would include grade 1 and 2 toxicities as well as grade 3 and 4. It was 
hypothesised that nausea and vomiting would be reported frequently and may 
be the highest reported toxicities seen based on the rates of CINV quoted by 
Pirri et al., Osoba et al., Kottschade et al., Escobar et al., Lindley et al. and 
Ihbe-Heffinger et al. (Pirri et al., 2013), (Osoba et al., 1997), (Kottschade et al., 
2016), (Escobar et al., 2015), (Lindley et al., 1992), (Ihbe-Heffinger et al., 
2013).  The data from Stein et al. and Mirrodi et al. suggested that diarrhoea 
was likely to be frequently reported and may have been one of the most 
frequent toxicities seen (Stein et al., 2010), (Miroddi et al., 2015).  The data 
presented by Barnes and Servaes et al. would suggest that the incidence of 
fatigue would be very high and fatigue may have been the most frequently 
reported toxicity (Barnes and Bruera, 2002), (Servaes et al., 2008).   
 
Age was expected to have an effect on the occurrence of toxicity, but this effect 
was unclear as the data found in the literature was contradictory. As such, a 
relationship with age and toxicity was expected but the direction of that 
relationship was unclear, however given the physiological changes seen in 
ageing patients, it was anticipated that age would increase the likelihood of 
toxicity (Balducci and Extermann, 2000).  
 
Different cancer types are associated with different symptoms (Neal and 
Hoskin, 2009), so it was hypothesised that disease would have an effect on 
toxicity, however it was unclear what that effect would be as no data was found 
in the literature which explored this.  
 
Sargent et al. and Phaibulvatanapong et al. both found that toxicity increased 
with performance status (Sargent et al., 2009; Phaibulvatanapong et al., 2018). 
These studies were not in populations with the same characteristics as was 
planned in this study, and looked at delayed as well as acute toxicity, however 
it was anticipated that higher rates of toxicity would be seen in the higher 
performance status patients.  
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Much of the literature cited treatment characteristics as predictors of toxicity. It 
is known that different treatments are associated with differing rates of 
toxicities. However, this research aimed to group the treatments and little 
literature was found that provided a basis for any hypotheses, so the 
hypotheses around treatment were more difficult to establish, but the following 
hypotheses were made: 
 Treatment intent was felt likely to influence the occurrence of toxicity, as 
if the goal of treatment is cure, higher doses or more intensive 
chemotherapy may be used (Neal and Hoskin, 2009).  
 It was theorised that cytotoxic treatment would result in higher rates of 
toxicity than non-cytotoxic and those regimens with a cytotoxic and non-
cytotoxic agent would cause the highest rates of toxicity due to the 
additive effect of the agents. It is well-established that cytotoxic 
chemotherapy is associated with toxicity, both acute and delayed (Neal 
and Hoskin, 2009). It is also known that the targeted agents, which 
make up the majority of the non-cytotoxic treatment group, are 
associated with toxicity, but it is suspected that this is to a lesser extent 
than cytotoxic chemotherapy.   
 It was hypothesised that the higher the number of drugs, the higher the 
rate of toxicity, as multiple agents could have an additive effect.  
 No hypothesis was made about commissioning status of drugs as this 
had no scientific basis or background in the literature, but is of interest to 
the health economy.   
 No hypothesis could be made about the effect of drug class on toxicity, 
although it was suspected that different classes of drug would be 
associated with different rates of toxicity, due to the side effect profiles of 
the drug class.  
 It was hypothesised that toxicity would be higher, the higher the 
emetogenic potential of a regimen. Different agents are known to be 
associated with different rates of toxicity (Hesketh, et al., 2017a). If CINV 
is higher in highly emetogenic treatments, then this would increase the 
overall incidence of toxicity. 
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It was more difficult to find data on grade of toxicity outside of clinical trials of 
individual drugs or regimens. As such, making hypotheses around the grade of 
toxicity was more difficult. It was expected that more low grade (1 or 2) 
toxicities would be seen than higher grade (3 or 4) as this study only looked at 
acute toxicity and more severe toxicity may take longer to develop, although 
acute emesis is a well-documented side effect of chemotherapy, which may 
have meant that higher grades of nausea or vomiting would be seen (Hesketh, 
2008). It was considered that as the rate of toxicity increased, so would the 
severity, although no data was found to support this theory. Higher grades of 
toxicity were expected in patients with a higher performance status, as these 
patients would have a lower functional state and so a toxicity in addition to 
symptoms of a condition or co-morbidity may have been more severe. The 
same was suspected of treatments containing more than one drug as it was 
anticipated that the toxicities of individual agents in these regimens could have 
an additive effect.  
 
Hospital admission was an expected consequence of chemotherapy toxicity in 
some cases. Admission within 30 days of chemotherapy seemed an 
appropriate measure due to the NCEPOD report findings and 
recommendations (Mort et al., 2008) and also as admission within 30 days of 
chemotherapy had been the main focus of the CATT team. No data was found 
on admission rates in patients on chemotherapy, so no basis was available for 
predictions to be made. It was suspected that as more toxicity was seen, higher 
rates of admission would be seen. By definition, a grade 3 toxicity is severe or 
medically significant and hospitalisation or prolongation of hospitalisation is 
indicated (National Cancer Institute, 2010). A grade 4 toxicity is defined as life-
threatening. Predicting length of stay was more difficult as there appeared to be 
so many factors that can contribute to this (Clarke, 1996) and there was a lack 
of literature around length of stay in admission due to chemotherapy toxicity.  
 
In terms of the sub-group analyses, it was anticipated that these sub-
populations would follow a similar pattern to the whole study population, as 
there was no data to suggest otherwise. It was acknowledged that there may 
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have been interactions between variables, for example the proportions of 
patients in the treatment intent groups was likely to differ as would treatment 
used. It was anticipated that more toxicity would be seen in the breast cancer 
patients as more treatment of adjuvant or neoadjuvant intent was likely to be 
used (Cancer Research UK, 2015c). Lung cancer patients were expected to 
have a higher performance status and thus report more toxicity (Cancer 
Research UK, 2015f). 
 
The secondary outcome measures were expected to be fatigue, nausea and 
vomiting as described above. Diarrhoea was possibly expected to be one of the 
top 3 reported toxicities. Nausea and vomiting were expected to follow the 
same pattern and occur at similar rates as they are closely related symptoms 
(Hesketh, 2008). Given the data from Kottschade et al. and Hesketh, younger 
patients were expected to report more CINV (Kottschade et  al., 2016; Hesketh, 
2008). Incidence was expected to be higher in patients with poorer 
performance status as Pirri et al. suggested that low role functioning is 
predictive of CINV (Pirri et al., 2013). It was also expected that incidence would 
be higher in the adjuvant and neoadjuvant treatments due to the higher 
intensity. Treatments with more than one drug were expected to have higher 
rates of nausea and vomiting due to the additive effect and different drugs 
classes were expected to have higher rates according to side effect profiles. 
The higher emetogenic agents were expected to result in more nausea and 
vomiting due to the evidence base used in the guidelines (Basch et al., 2011). 
Nausea and vomiting is a side effect associated with cytotoxic chemotherapy 
(Neal and Hoskin, 2009) and as such it was anticipated that higher rates would 
be seen with these treatments.  
 
It was anticipated that fatigue or diarrhoea would be the third most commonly 
occurring toxicity. It was felt that either would be affected by the same 
predictors as toxicity and would follow similar patterns.  
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3.0 Methodology 
3.1 Data Collection 
The CATT telephone assessment service at NUH provided a unique 
opportunity to study acute chemotherapy toxicity. One of the main drivers for 
establishing the service was that the within 30 days of the first cycle of 
chemotherapy, the risk of admission due to toxicity was felt to be highest, 
based on clinical experience. As such the CATT team was established along 
with the telephone call back service which involved setting up an automated 
report from Chemocare®, the electronic chemotherapy prescribing system in 
use at NUH, which identified all oncology patients who had received a first 
cycle of chemotherapy in the previous 24 hours. As per the standard operating 
procedure in appendix 1, a nurse from the CATT team would place a telephone 
call to the patient in the 24 hours after chemotherapy and perform a thorough 
toxicity analysis as detailed in appendix 1. The fields shown in appendix 2 were 
based on the UKONS chemotherapy toxicity assessment tool as this is 
something that the nurses were used to working with within NUH (Jones et al., 
2010).  
 
A database was created in an Excel® (Microsoft, 2011) spread sheet, which 
was completed by the nurse undertaking the first telephone call. The spread 
sheet was stored in the acute oncology shared drive on NUH computers that 
could only by accessed by members of the acute oncology team. Prior to 
undertaking the call back service, all nurses within the CATT team received a 
short training session from a pharmacist, setting out the expectations of the 
service and the data that required collecting. It was intended to be as user 
friendly as possible and was set up with drop down menus for each toxicity 
along with descriptions of each grade of toxicity to allow for ease of data 
collection. Different tumour sites were set up with individual spread sheets. 
Patient demographics were recorded and the tab for the appropriate 
chemotherapy regimen was selected. 
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ECOG performance status was collected from the electronic prescribing 
system used to generate all chemotherapy prescriptions. This is a mandatory 
field and must be completed by the prescriber prior to prescribing any 
chemotherapy. 
 
Treatment intent was evident from the Chemocare® record for each patient, as 
the care episode requires the prescriber to enter an intention of treatment. The 
treatment given was also obvious from Chemocare®.  
 
Periodically, admission data was reviewed from the trust patient administration 
system. The patient details and reason for admission of all oncology patients at 
NUH was received. It was then necessary to exclude patients admitted for a 
reason other than chemotherapy toxicity. This was then amalgamated with the 
toxicity database to show which patients have had an admission following 
chemotherapy and for what reason. 
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3.2 Data Analysis 
Once the call back service had been in operation for one year, the data for 
January to December 2015 was analysed. For the purposes of investigation 
patient identifiers were removed from the Excel® spread sheet and data was 
reviewed to ensure correct recording. It was then converted into alphanumeric 
data that would be suitable for SPSS® (IBM, 2013). The data was transferred 
into the SPSS® software for analysis and use in the research. 
 
Much of the research was based on exploratory analysis. The initial data 
analysis plan was used and other areas explored according to findings.  
 
The first step was to review and describe the study population using descriptive 
statistics around age, disease type, intent of treatment, types of treatment 
given and performance status. This established the context of the study.  
 
Age was determined from the date of birth and date of chemotherapy entered 
into the spread sheet, using the Excel® tool.  Age was then grouped in the 
following manner in order to facilitate analysis: 
 <21 years 
 21-40 
 41-50 
 51-60 
 61-70 
 71-80 
 >80 years 
 
Even intervals were chosen in addition to the upper and lower extremes of the 
ages. Age was treated as continuous data in some analyses but also grouped 
and treated as ordinal data as done by Hurria et al. (Hurria et al., 2011). 
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It was anticipated that a heterogeneous population would be studied and that 
there would be a wide range of cancer diagnoses treated. In order to aid data 
analysis, the diseases were grouped according to the multidisciplinary team 
tumour sites used in clinical practice at NUH. These were: 
 Central Nervous System (CNS) 
 Breast 
 Lower Gastrointestinal (GI) 
 Gynaecology 
 Cancer of Unknown Primary (CUP) 
 Head and Neck 
 Upper GI 
 Lung 
 Skin 
 Sarcoma 
 Urology 
 
For drug treatment used, it was anticipated that there would be a large number 
of possible regimens used. It was therefore decided to group the treatments 
according to several different factors that related to clinical use and to treat 
these as separate variables. Treatments were grouped by: 
 Number of anticancer drugs in the regimen. It was anticipated that the 
higher the number of drugs used, the higher the likelihood of toxicity, as 
the side effect profiles of the drugs would be additive.  
 Commissioning status of the regimen. This was either baseline 
commissioned treatment or cancer drugs fund commissioned. It was felt 
that any differences in tolerance to treatments by commissioning status 
would be an interesting finding for clinical practice.  
 Emetogenicity of the regimen in accordance with international guidelines 
(Hesketh et al., 2017a). This was anticipated to reveal differences in 
nausea and vomiting, but admission rates were of particular interest with 
respect to emetogenicity and also the effect of emetogenicity on 
toxicities other than nausea and vomiting.  
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 Cytotoxic status of agents. Treatments were grouped as cytotoxic, non-
cytotoxic or mixed. This was expected to highlight any differences 
between the traditional cytotoxic chemotherapy and the targeted 
therapies.  
 BNF class of drug (Baxter, 2018). It was anticipated that the class of 
drug would have an impact on toxicity, as class effects could exist.  
 
The first part of the analysis was to consider the overall incidence of toxicity 
across all treatments and all disease states.  
 
The following primary outcome measures were investigated: 
 Toxicity as a binary measure (experienced or not experienced). It was 
necessary to create a new variable in SPSS® of toxicity, which included 
all of the toxicities reported and enabled the number of patients reporting 
a toxicity of any grade to be collated.  
 Grade of toxicity. This also necessitated the creation of a new variable in 
SPSS®, that grouped together all toxicities of the same grade.  
 Hospital admission within 30 days of chemotherapy as a binary measure 
(admitted or not). 
 Length of stay for those patients admitted 
 
The following sub-group analyses were explored: 
 The three diseases for which chemotherapy was given most commonly. 
These were explored as sub-populations for breast, colorectal and lung 
cancer, looking at the outcomes as in the whole population.  
 Individual toxicities as a sub-analysis of the three most commonly 
reported toxicities. Nausea, vomiting and fatigue were investigated with 
the factors contributing to them being explored.  
 
Analysis of the factors affecting toxicity was undertaken. The literature 
highlighted various factors that were thought to influence toxicity. These were 
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considered as potential predictors of toxicity along with others. The following 
independent variables were considered for their effect on occurrence of toxicity, 
grade of toxicity experienced and hospitalisation within 30 days of 
chemotherapy: 
 Age, as a continuous variable and as a categorical variable 
 ECOG performance status (Oken et al., 1982) 
 Treatment used (drug regimen), grouped according to 
o BNF class 
o Emetogenicity 
o Cytotoxicity 
o Number of drugs 
o Commissioning status 
 Disease being treated, according to disease group 
 Intent of treatment (adjuvant, neoadjuvant or palliative) 
 
Descriptive statistics were used to elucidate any initial relationship or 
correlations, with Pearson’s Χ2 test being used for the binary outcome 
measures (toxicity and admission) and Kruskall-Wallis test being used in the 
ordinal datasets (grade of toxicity). Length of stay was continuous data and so 
Kruskall-Wallis was used to test the significance of any variance. Where 
possible the correlation coefficient was calculated.  
 
Regression analysis was undertaken. Multivariable logistic regression was 
used to explore the relationships between the predictors and toxicity and 
between the predictors and hospital admission. Ordinal logistic regression 
analysis was used to explore the relationships between the predictors and 
grade of toxicity. Regression analysis was not used to explore length of stay as 
it was felt to be too complex. Only descriptive statistics were used in this 
situation.  Multivariable regression was undertaken following individual 
regression analysis and descriptive statistics, which were used to establish any 
possible relationships between predictors and outcomes. Only those variables 
that the individual analyses showed to have an effect on the outcome, were 
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included in the multivariable regression. It was also necessary to exclude some 
of the fields for certain predictors that had very small numbers of patients.  
 
ECOG performance status was treated as ordinal data and explored 
accordingly. Intent of treatment was nominal data.  
 
The probable sample size for the database was well over the anticipated size 
of 1000 patients. The anticipated four larger tumour groups, breast, lung, 
colorectal and urology, provided the most data and as such allowed for more in 
depth analysis. Regression analysis was used to explore in depth for breast, 
lung and colorectal diagnoses but urology was not included due to low rates of 
toxicity reporting and low patient numbers.  
 
Hospital admission was of particular interest. Hospital admission figures were 
obtained from the trust patient administration system by a data analyst. Reason 
for admission was reported on the system as well as length of stay, and the 
data was linked to Chemocare®4 information regarding chemotherapy and a 
spread sheet produced of those patients admitted within 30 days of the first 
cycle of chemotherapy. The data was then reviewed manually and any 
admissions for reasons other than chemotherapy toxicity excluded. This data 
was then transferred to the main database for input into SPSS®. It was beyond 
the reaches of this research to calculate the exact cost of an admission, 
however it was anticipated that it may have be possible to look at local and 
national tariffs to perform a top down costing.  
 
Length of stay was assessed and admissions analysed to identify any common 
contributing factors in a similar way to the occurrence of toxicity. The cut off of 
30 days was used, as it mirrored one of the measures investigated in the 
national NCEPOD report (Mort et al. 2008). Care was taken to ascertain the 
reason for admission as it was recognised that patients may be admitted for 
various reasons in the prescribed period and indeed reasons for admission can 
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be multi-factorial. Only admissions due to symptoms of chemotherapy toxicity 
were explored. In every case, it was not clear if admission was due to toxicity 
or other causes of those symptoms. Length of stay was explored using 
descriptive statistics to identify any differences between the groups of patients 
when considering the different predictors.  
 
Sub-group analyses were also undertaken. The three largest disease groups 
were explored as sub-populations and compared to each other and the 
population as a whole. The effect of the predictors on the outcomes used when 
looking at the whole population were used to look at the sub-populations and 
the same regression analysis was applied where appropriate. The three most 
commonly reported toxicities were also explored as individual secondary 
outcomes. It was necessary to create new variables for each toxicity, in order 
to investigate them as binary variables, as occurred and did not occur. The 
grades of the toxicities were also explored and regression analysis was applied 
where appropriate, in the same way as was done for the primary outcome 
measures. Admission rates and length of stay was also explored within each 
toxicity.  
 
The structure of the analysis strategy is summarised in table 7. 
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Table 7. Analysis Strategy 
  
Outcome 
Toxicity Severity Admission Length of stay 
Predictor   
Age Categorical 
Descriptive         
Univariable         
Multivariable         
Age Continuous 
Descriptive         
Univariable         
Multivariable         
PS 
Descriptive         
Univariable         
Multivariable         
Disease 
Descriptive         
Univariable         
Multivariable         
 Intent 
Descriptive         
Univariable         
Multivariable         
Treatment - Cytotoxicity 
Descriptive         
Univariable         
Multivariable         
Treatment - Number of Drugs 
Descriptive         
Univariable         
Multivariable         
Treatment - Commissioning 
Descriptive         
Univariable         
Multivariable         
Treatment - Emetogenicity 
Descriptive         
Univariable         
Multivariable         
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3.3 Exclusions 
Due to the nature of the service implemented by the CATT team there were 
various exclusions. Patients who received their first cycle of chemotherapy as 
an inpatient did not receive a phone call, as most would still be an inpatient the 
day following chemotherapy. The consequence of this was that most patients 
with certain diagnoses were not included in the data as most of the 
chemotherapy given was given as an inpatient. This included germ cell 
tumours and sarcoma. It was anticipated that small numbers of patients with 
these diagnoses would be included in the data. Renal cell and melanoma 
patients have a dedicated clinical nurse specialist at NUH and as such receive 
their first cycle phone call from the clinical nurse specialist, who did not record 
the toxicity assessment in the CATT team’s database. As such very few of 
these patients were included in the analysis.  
 
As the study only collected data on toxicity within 24 hours of chemotherapy, 
only acute toxicity was assessed in the study. No long term, chronic or late 
effects are included in the data, as there was no mechanism in place to collect 
such data at NUH.  
 
When completing toxicity assessments, the CATT team found that some 
patients were unreachable by telephone. The number of these patients was not 
recorded, but speaking to the CATT team, the nurses stated that this number is 
minimal.  
 
Oral chemotherapy included in the data raised an interesting question. With 
parenteral regimens, the entire dose had been administered by the time of the 
telephone call. With oral chemotherapy, often only one or two doses may have 
been taken, out of a 21 or 28-day cycle. It is likely that few toxicities would have 
occurred at the time of the telephone call, as drug exposure would have been 
minimal and steady state serum concentrations not reached.  
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Gender was not recorded in the database when nurses completed the 
telephone call. As such, it was not possible to include gender in the analysis to 
investigate its effects on the outcome measures. To enter gender would have 
meant reviewing each record individually, which was felt to be too time 
consuming for this study.  
 
The CATT team is an oncology service and is not currently extended to 
haematology patients at NUH, so no patients receiving chemotherapy for a 
haematological malignancy were included in the data.  
 
Paediatric chemotherapy is delivered at Queen’s Medical Centre, the other 
campus of NUH. It is delivered by a dedicated specialist team. As such, 
paediatric chemotherapy was not included in the data.  
 
Incomplete entries in the database were excluded from analysis.  
 
Some patients may have been admitted to hospital within 30 days of 
chemotherapy, but to a different hospital trust other than NUH. NUH is a 
regional centre and as such covers a large population of 3.5 million people for 
provision of specialist services (Nottingham University Hospitals, 2014). This 
means that geographically, it may result in hospital admissions to other trusts. 
This admission data is not readily available, hence only admissions to NUH 
were included in the data.  
 
Fever and extravasation were reported as yes or no. As they were not graded 
as other toxicities were, they were not included in analysis.  
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Only toxicities in the UKONS 24 hour triage tool were included in the 
assessment. A free text box was available for nurses to add in any other 
toxicity not covered, however this was not included in the analysis.  
 
Some sub-groups of the population had very small numbers of patients and as 
such it is not possible to draw robust conclusions about these groups.  
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3.4 Ethics 
Data pertaining to patients was being used in this research and so it was 
essential to ensure that the appropriate ethical approval had been sought and 
granted. Ethics approval was sought from the University of Bradford and also 
from Nottingham University Hospitals NHS trust. Both ethics committees 
required the approval of the other in order to grant approval to the research. 
Data was collected as part of an NHS service in order to assess that service. 
Data was not being collected solely for the purpose of research. For the 
purposes of research, data was anonymised and patients were not identifiable. 
Data stored on a personal computer did not contain any patient identifiers, and 
was held on a password protected device, with a password protected 
document. As such, consent was not sought from patients. In no way did the 
research have any effect on the patients whose data was used. The research 
had the potential to make recommendations to practice and as such may have 
eventually had an effect on patient treatment decisions. Any recommendations 
made would be thoroughly evidence based. 
 
A University of Bradford Ethics Checklist was completed and is attached in 
appendix 3. This confirms that full ethical approval from the University ethics 
committee was not required as the data was being collected as part of a 
service and was anonymised for the purposes of research.  
 
A new approval process for NHS research was being rolled out by the Health 
Research Authority (HRA) (Health Research Authority, 2015) at the time of 
submitting the research proposal.  However at the time of writing, this research 
fell into a category which could not yet be approved by the HRA so the 
traditional channels of approval were followed. In order to ascertain what 
ethical approval was required from the NHS an IRAS checklist was completed 
on the Health Research authority website (Health Research Authority and 
Medical Research Council, 2015b.). The checklist confirmed that this study 
would be considered research and so the next step was to decide if NHS 
research ethics committee (REC) approval was required. In order to do this, 
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another decision tool was used. Completion of the NRES tool (Health Research 
Authority and Medical Research Council, 2015b) indicated that REC approval 
was not required. However, as the study was being conducted at Nottingham 
University Hospitals, approval from the research and development department 
was required, so a copy of the proposal was submitted and no research 
undertaken until confirmation from research and development of approval. 
NUH required that an IRAS form be submitted, so this was completed and can 
be found in appendix 4. The dataset was already in existence by this time, but 
it was maintained on NUH trust computers and not removed from the hospital 
site, as data was collected by the CATT nurses, as part of a service. Once 
ethical approval was granted, data was anonymised on trust IT infrastructure, it 
was then transferred to a personal computer for analysis in a password 
protected document on a password protected device. At no point could any 
patient be identified from the data once this had happened. This was in 
accordance with NUH information governance regulations.  
 
The IRAS identification number for this study was 179907. 
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4.0 Results 
4.1 Population and Descriptive Statistics 
A total of 1577 patients had data recorded from the call back service from 
January to December 2015. Some patients did not have complete entries in the 
database so these were excluded from analysis. This gave a population of 
1539 (97.6%) for analysis. The mean age of the population was 63.2 years (SD 
= 11.4) and median age of the population was 65 years old (range 24 to 90). 
The distribution of the age of the population had a minimum value of 24 years, 
first quartile 56, median 65, third quartile 71.25 and a maximum of 90.  
 
A histogram (figure 2) demonstrated the distribution of age, which was slightly 
negatively skewed, however age would not be expected to be normally 
distributed.  
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Figure 2. Age of Study Population 
 
As seen in Figure 2, there was a wide variance in the age of patients treated. 
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Table 8. Age and Performance Status 
  
  Age Group (years) 
Total 
  21-40 41-50 51-60 61-70 71-80 >80 
Performance 
status  
0 
n 33 111 174 262 179 23 783 
% 54.1 69.4 53.5 48 46.3 43.4 51.1 
1 
n 25 40 128 255 185 25 658 
% 41 25 39.4 46.7 47.8 47.2 42.9 
2 
n 3 9 21 26 22 5 86 
% 4.9 5.6 6.5 4.8 5.7 9.4 5.6 
3 
n 0 0 2 3 1 0 6 
% 0 0 0.6 0.5 0.3 0 0.4 
Total 
  61 160 325 546 387 53 1533 
                
 
           
Table 8 showed the relationship between age and performance status. A 
higher proportion of older patients had a higher performance status at the start 
of treatment than in younger patients. Conversely the youngest patient group 
had the highest proportion of PS 0 patients compared to other age groups. As 
age increased, so did performance status. Spearman’s test gave a correlation 
coefficient of 0.09 (p=0.01), suggesting a slight positive correlation between 
age and performance status.  
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Figure 3. Performance Status of Study Population 
 
Table 9. Performance Status of Study Population 
  n 
Valid 
% 
Performance 
status 
0 783 51.1 
1 658 42.9 
2 86 5.6 
3 6 0.4 
Total 1533 100 
 
 
The ECOG performance status at the time of administration was recorded and 
had the distribution as described in Figure 3 and Table 9. The majority of 
patients were PS 0 or 1. There were very small numbers of patients with a 
performance status higher than 1 and no patients were performance status 4, 
making the size of the groups fairly uneven.  
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Chemotherapy was used to treat 38 different cancer diagnoses. As predicted, 
breast, colorectal and lung cancer were the most frequently treated tumour 
sites. For the purposes of data analysis, the diseases were grouped according 
to body system. 
 
Table 10. Distribution of Patients in Disease Groups 
    n Valid % 
Disease 
Breast 438 28.5 
Colorectal 329 21.4 
Lung 242 15.7 
Upper GI 170 11.1 
Gynaecology 151 9.8 
Urology 107 7 
Head&Neck 47 3.1 
CNS 39 2.5 
Sarcoma 12 0.8 
CUP 1 0.1 
Skin 2 0.1 
Total 1538 100 
Missing 1   
Total   1539   
 
 
Table 11. Intent of Chemotherapy Given  
    n Valid % 
Intent of Chemotherapy 
Palliative 833 54.2 
Adjuvant 464 30.2 
Neoadjuvant 239 15.6 
Total 1536 100 
Missing 3   
Total   1539   
 
 
Just over half of treatments were palliative, meaning that the remaining 
treatments were of curative intent. 
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In the studied population, 118 different anticancer treatments were received, 
including multi-drug and single agent regimens. The most common regimen 
used was FEC75, which is used in breast cancer (East Midlands Cancer 
Alliance 2018). Treatments were grouped in various different ways for analysis 
and comparison. 
 
The first method was to group into cytotoxic, non-cytotoxic and mixed 
chemotherapies. Cytotoxic treatment was given in 1422 (92.4%) of cases, non-
cytotoxic accounted for 51 (3.3%) of treatments and 66 (4.3%) of treatments 
were a combination of cytotoxic and non-cytotoxic drugs.  
 
The second way the treatments were grouped was by number of anticancer 
drugs contained within the regimen as shown in Table 12. 
 
Table 12. Treatment Grouped by Number of Drugs  
    n Valid % 
Number of Drugs 
1 560 37 
2 533 35.2 
3 420 27.8 
Total 1513 100 
Missing 26   
Total   1539   
 
 
There was a fairly even distribution amongst the groups. 
 
A third way of categorising the treatment used was to divide the them into 
those subject to baseline commissioning and those funded by the cancer drugs 
fund (CDF) as shown in Table 13. 
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Table 13. Commissioning Status of Treatment  
    n Valid % 
Commissioning Status 
Baseline 1432 93.1 
CDF 106 6.9 
Total 1538 100 
Missing 1   
Total   1539   
 
 
Only a small number of treatments were funded by the CDF, with the majority 
of treatments being baseline commissioned, which made the sizes of the 
groups extremely uneven. 
 
The next way the treatments were grouped was by drug class, according to 
BNF classifications as shown in Table 14 (Baxter, 2018). 
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Table 14. Treatment Grouped by Drug Class  
    n Valid % 
Drug Class 
Platinum 586 38.1 
Antimetabolites 527 34.3 
Taxane 133 8.6 
Topoisomerase I inhibitor 100 6.5 
Other 73 4.7 
Monoclonal Antibodies 45 2.9 
Alkylating Agent 30 2 
Anthracycline /Cytotoxic Antibiotic 23 1.5 
Vinca Alkaloid /Etoposide 19 1.2 
Immune therapy 2 0.1 
Total 1538 100 
Missing 1   
Total   1539   
 
 
The method of grouping in SPSS® was not reliable. Only one drug class was 
assigned to each patient, but many patients received more than one agent, so 
this could not be used to produce reliable data. It was therefore omitted from 
further analysis.  
 
Drugs are frequently grouped in practice by emetogenic potential (Hesketh et 
al., 2017a). There were a number of sources that provide classifications of 
drugs by emetogenicity. For the purposes of this research, the ASCO 
classification was used (Basch et al.,  2011). 
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Table 15. Treatment Grouped by Emetogenicity 
    n Valid % 
Emetogenicity 
Moderate 544 37.5 
High 464 32 
Low 409 28.2 
Minimal 33 2.3 
Total 1450 100 
Missing 89   
Total   1539   
 
 
There was a fairly even distribution of patients amongst the groups of 
treatments, with the exception of the minimal group, which only had a small 
number of patients.  
 
Table 16. Grades of Toxicity Reported 
    n Valid % 
Toxicity Grade 
0 976 64.8 
1 434 28.8 
2 89 5.9 
3 6 0.4 
4 1 0.1 
Total 1506 100 
Missing 33   
Total   1539   
 
 
Table 16 showed the number of toxicities that were experienced and the 
percentage of patients reporting that grade of toxicity. The majority of patients 
did not report any toxicity (grade 0). Grade 1 toxicities were reported by 434 
(28.8%) of patients and accounted for 81.9% of the total toxicities reported (i.e. 
grades 1-4), with 16.8% being grade 2, 1.1% being grade 3 and only 1 patient 
reporting a grade 4 toxicity (0.2%). This made the distribution between the 
groups fairly uneven. At least one any grade toxicity was reported by 35.6% of 
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patients. 
 
Table 17. Percentage of Patients Reporting Each Grade of Toxicity 
  
  
  
Number Experiencing Grade of 
Toxicity (% of Total Patients Who 
Experienced Toxicity >grade 0) 
  
  
Number of 
Patients 
Who 
Reported 
Any Grade 
(%) 
1 2 3 4 
Toxicity 
Nausea 
249    
(15.9%) 
214 
(13.9%) 
28 
(1.8%) 
3 
(0.2%) 
  
Fatigue 
159       
(10.%) 
151 
(9.8%) 
8     
(0.5%) 
    
Vomiting 
89         
(5.8%) 
52     
(3.4%) 
35    
(2.3%) 
2      
(0.1%) 
  
Constipation 
60         
(3.9%) 
46      
(3.0%) 
14       
(0.9%) 
    
Arthralgia / 
Pain 
49         
(3.2%) 
40       
(2.6%) 
9   
(0.6%) 
    
Sensory 
Neuropathy 
55         
(3.6%) 
53     
(3.4%) 
2      
(0.1%) 
    
Diarrhoea 
49          
(3.2%) 
43     
(2.8%) 
5     
(0.3%) 
1      
(0.1%) 
  
Anorexia 
38         
(2.5%) 
25    
(1.6%) 
12       
(0.8%) 
1     
(0.1%) 
  
SOB 
11          
(0.7%) 
8        
(0.5%) 
2      
(0.1%) 
  
1       
(0.1%) 
Stomatitis 
9            
(0.6%) 
8      
(0.5%) 
1      
(0.1%) 
    
Bleeding 
2           
(0.1%) 
1        
(0.1%) 
1      
(0.1%) 
    
Motor 
Neuropathy 
2           
(0.1%) 
2      
(0.1%) 
      
Bruising 
0            
(0%) 
        
 
 
Grade 1 toxicities were by far the most common of the toxicities reported, with 
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only a single grade 4 toxicity reported. Nausea, vomiting and fatigue were the 
most frequently reported toxicities Fever was reported by 1.9% of patients and 
extravasation by 3 patients (0.2%). These were not reported by grade so were 
not included in the analysis.  
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4.2 Primary Outcome Measures 
The various factors that were thought to predict the outcomes of toxicity, grade 
of toxicity, admission and length of stay were explored.  
 
4.2.1 Toxicity 
Toxicity was explored as a binary variable; experienced or not and included 
any toxicity that was reported. The various predictors were investigated to 
ascertain their effect on the occurrence of toxicity.  
 
4.2.1.1 Toxicity and Age 
The relationship between age and the occurrence of any grade toxicity was 
explored. The age group reporting the most toxicities was the 51-60 year olds, 
who had a rate of 38.2% toxicity (123 patients). However, this rate did not differ 
greatly from other groups and a χ2 test shows that there was no significant 
difference in the overall rate of toxicity reporting between age groups (χ2=3.7 
(p=0.599)). 
 
The mean age of patients experiencing a toxicity of any grade was 62.8 years 
(SD=11.1) compared to 63.3 years (SD=11.6) for those experiencing no 
toxicity. There was little difference between these values.  
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4.2.1.2 Toxicity and Performance Status 
Table 18.  Toxicity Rate by Performance Status 
    
Number 
experiencing 
toxicity 
% of 
Performance 
Status 
Group 
Performance status 
0 306 39.5% 
1 210 35.4% 
2 25 29.1% 
3 1 16.7% 
Total   542 35.7% 
Pearson’s Χ2=10.59 (p=0.01) 
 
The number of patients experiencing a toxicity of any grade reduced as 
performance status increased. Spearman’s correlation coefficient is –0.082 
(p<0.01) suggesting a statistically significant negative correlation.  
 
Table 19. Logistic Regression of Toxicity and Performance Status Controlled 
for Age 
  B S.E. Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Toxicity 
Age 
(continuous) 
-
0.002 
0.005 0.659 0.998 0.989 1.007 
Performance 
Status 
    0.019       
1 
-
0.301 
0.112 0.007 0.74 0.594 0.922 
2 
-
0.462 
0.249 0.063 0.63 0.387 1.026 
3 -1.18 1.098 0.283 0.307 0.036 2.644 
Constant 
-
0.299 
0.302 0.323 0.742     
Pseudo R2<0.01 
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Table 19 used performance status 0 as the reference group and suggested 
that patients with performance status 1 were 26% less likely to experience a 
toxicity than those who were performance status 0. The effect for performance 
status 2 was of a similar magnitude but was of borderline statistical significance 
(p=0.06). The performance status 3 group was small, so not powered to 
establish a predictive relationship. Pseudo R2, suggested a minimal effect 
 
4.2.1.3 Toxicity and Disease 
Table 20. Toxicity Rates and Disease 
    
Number 
experiencing 
toxicity          
 % of Disease 
Group 
Disease 
CNS 13 33% 
Skin 1 50% 
Upper GI 74 44.3% 
Breast 186 42.9% 
Colorectal 116 36.4% 
Head&Neck 16 34% 
Gynaecology 49 32.5% 
Urology 25 26.6% 
Lung 61 25.4% 
Sarcoma 1 8.3% 
CUP 0 0% 
Total   542 35.7% 
Pearson’s Χ2=38.47 (p<0.01) 
 
Toxicity appeared highest in the breast, upper GI and colorectal groups and a 
Pearson’s χ2 test suggested that the differences between these groups was 
significant (p<0.01).  
 
As CUP, Skin and Sarcoma groups had small numbers of patients, these were 
excluded from any regression analysis, as it would not be possible to draw any 
conclusions from such small numbers.  
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Table 21. Logistic Regression Analysis for Toxicity and Disease Controlled for 
Age 
  B S.E. Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Toxicity 
Age 
(continuous) 0.001 0.005 0.81 1.001 0.991 1.011 
Disease     0       
CNS 0.501 0.417 0.229 1.651 0.729 3.737 
Breast 0.895 0.254 0 2.447 1.488 4.026 
Colorectal 0.622 0.258 0.016 1.862 1.123 3.087 
Gynaecology 0.449 0.289 0.12 1.567 0.89 2.759 
Head and Neck 0.526 0.387 0.174 1.692 0.793 3.609 
Upper GI 0.952 0.277 0.001 2.59 1.504 4.462 
Lung 0.102 0.273 0.709 1.107 0.649 1.89 
Constant -1.26 0.421 0.003 0.284     
Pseudo R2 =0.02 
 
The regression analysis in Table 21 used urology as the reference group. 
Breast cancer patients appeared 145% more likely to experience a toxicity than 
urology cancer patients (p<0.01) and upper GI cancer patients 159% more 
likely (p<0.01). Pseudo R2 suggested that the analysis explained some of the 
variance in toxicity, but there was still a great deal unexplained, which could 
mean that other variables played a role in explaining that variance and thus 
had an effect on toxicity.   
 
4.2.1.4 Toxicity and Treatment Intent  
There was little difference in the percentage of patients experiencing a toxicity 
between the different treatment intents, although neoadjuvant patients had a 
higher rate of toxicity reporting than palliative and adjuvant patients. However 
the differences between the groups was not statistically significant according to 
Pearson’s χ2 (p>0.1).  
 
 86
4.2.1.5 Toxicity and Treatment 
As described above, treatments were grouped by different methods for the 
purposes of analysis. 
 
When grouped according to cytotoxicity, the group who received a combination 
of drugs reported the highest rate of toxicity and the lowest rate of any grade 
toxicity was in the non-cytotoxic group, but the differences were not statistically 
significant (p>0.1).  The groups were not evenly distributed and as such any 
comparison would be difficult.  
 
Table 22. Toxicity Rates by Treatment Grouped According to the Number of 
Drugs 
    
Number 
experiencing 
toxicity 
% of 
Treatment 
Group 
Number of 
Drugs 
3 203 49.0% 
2 173 35.7% 
1 157 28.5% 
Missing 9   
Total   542 35.7% 
Pearson’s χ2=46.4 (p<0.01) 
 
Table 22 showed the rate of toxicity by the number of drugs contained in the 
regimen. The highest reporters of toxicity were those patients who received a 
combination containing 3 drugs. It appeared that as the number of treatments 
increased, so did the number of toxicities. A Spearman’s correlation coefficient 
was calculated as 0.163 (p<0.01) suggesting a positive correlation that is 
statistically significant.  
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Table 23. Logistic Regression Analysis of Toxicity and Treatment Grouped by 
the Number of Drugs 
  B S.E. Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Toxicity 
Age 
(continuous) 
0.004 0.005 0.432 1.004 0.994 1.014 
Number of 
drugs 
    0       
1 -0.896 0.139 0 0.408 0.311 0.536 
2 -0.701 0.138 0 0.496 0.378 0.651 
Constant -0.273 0.308 0.376 0.761     
Pseudo R2 = 0.03  
 
Pseudo R2 in table 23 suggested that the data explained a small amount of the 
variance in toxicity. The 3-drug group was used as the reference as it was the 
largest group. The analysis suggested that patients on two drugs were 50% 
(p<0.01) less likely to experience a toxicity, compared to those receiving three 
drugs and those on one drug were 59% (p<0.01) less likely to experience a 
toxicity than those on a single agent. The data would suggest that the more 
drugs used, the more likely a toxicity is to occur.  
 
When grouped according to commissioning status, there appeared to be no 
statistically significant difference in the percentage of patients reporting a 
toxicity between the groups (p>0.1). 
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Table 24. Toxicity Rate and Treatment Grouped by Emetogenicity 
    
Number 
experiencing 
toxicity 
% of 
Treatment 
Group 
Emetogenicity 
High 197 42.9% 
Moderate 188 34.9% 
Low 122 30.6% 
Minimal 7 21.2% 
  Missing 28   
Total   542 35.70% 
Pearson’s χ2 = 18.07 (p<0.01) 
 
It should be noted that in table 24 this was any toxicity of any grade and not 
just limited to nausea and vomiting. Toxicity was clearly reported more 
frequently by those patients receiving highly emetogenic chemotherapy. 
 
Table 25. Logistic Regression Analysis of Toxicity and Treatment Grouped by 
Emetogenicity 
  B S.E. Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Toxicity 
Age 
(continuous) 
0.001 0.005 0.81 1.001 0.992 1.011 
Emetogenicity     0.001       
Moderate 
-
0.337 
0.131 0.01 0.714 0.552 0.923 
Low 
-
0.535 
0.146 0 0.585 0.44 0.779 
Minimal 
-
1.029 
0.437 0.019 0.357 0.152 0.842 
Constant 
-
0.361 
0.31 0.244 0.697     
Pseudo R2=0.012 
 
Regression analysis used highly emetogenic treatments as the reference 
group, as it had a large number of patients and was clinically significant 
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(p<0.01). All of the steps in the analysis were statistically significant (p<0.01). 
The analysis suggested that patients on moderately emetogenic chemotherapy 
were 29% less likely to experience a toxicity than those on highly emetogenic 
chemotherapy (p=0.01). Those on low emetogenic chemotherapy were 41% 
less likely to experience a toxicity (p<0.01) and those on minimally emetogenic 
chemotherapy, 64% less likely (p=0.02). The analysis only had a small effect 
on explaining the variance of toxicity.  
 
4.2.1.6 Multivariable Logistic Regression of Toxicity 
Multivariable logistic regression was undertaken of the above predictors, using 
only those predictors shown to have an effect on toxicity. These were 
performance status, diagnosis, treatment by drug class, treatment by 
emetogenicity and the number of drugs received. Age was controlled for. 
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Table 26. Multivariable Logistic Regression Analysis for Toxicity 
  
  B S.E. Sig. Exp(B) 
95% C.I.for 
EXP(B) 
  
          
Lowe
r 
Upper 
Age (continuous)  
0.008 0.005 0.142 1.008 0.997 1.019 
Performance 
Status 
      0.7       
  1 0.517 1.136 0.649 1.678 0.181 15.538 
  2 0.379 1.134 0.738 1.461 0.158 13.494 
  3 0.347 1.157 0.764 1.415 0.147 13.653 
Disease  
    0.012       
  CNS 0.526 0.463 0.257 1.691 0.682 4.195 
  Breast 0.597 0.312 0.055 1.817 0.987 3.347 
  Colorectal 0.546 0.307 0.076 1.726 0.945 3.151 
  Gynaecology 0.432 0.336 0.198 1.54 0.798 2.972 
  
Head & Neck 0.677 0.459 0.14 1.968 0.801 4.835 
  Upper GI 0.781 0.33 0.018 2.183 1.143 4.168 
  Lung -0.066 0.331 0.842 0.936 0.489 1.791 
Emetogenicity  
    0.942       
  High 0.238 0.531 0.654 1.269 0.448 3.592 
  Moderate 0.258 0.503 0.608 1.295 0.483 3.472 
  Low 0.171 0.494 0.729 1.187 0.451 3.124 
Number of drugs  
0.352 0.119 0.003 1.422 1.127 1.794 
  1 -0.704 0.237 0.003 0.495 0.311 0.787 
  2 0.374 0.209 0.073 0.688 0.457 1.036 
Constant   -2.889 1.291 0.025 0.056     
Pseudo R2 = 0.04 
 
The multivariable logistic regression for toxicity controlled for age had pseudo 
R2 =0.04 which was slightly larger than any of the values seen in the individual 
regression analyses. This value was still pretty small, but suggested that the 
analysis went some way to explaining the variance in toxicity. When all other 
variables were taken into account, age still had no statistically significant effect 
on toxicity (p>0.1).  The analysis suggested the following: 
 Breast cancer patients were 82% more likely to report a toxicity than 
urology cancer patients , this was of borderline statistical significance 
(p=0.06) 
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 Upper GI cancer patients were 118% more likely to see a toxicity than 
urology cancer patients (p=0.02) 
 Patients who received 2 drugs were 31% less likely to experience a 
toxicity than those who received 3 drugs (p=0.07). This was of borderline 
significance. 
 Patients who received 1 drug were 50% less likely to experience a 
toxicity than those who received 3 drugs (p<0.01).  
The emetogenicity of a drug, did not yield any statistically significant 
relationships in the multivariable analysis, which might suggest an interaction of 
this variable with others (p>0.1).  
 
4.2.2 Grade of toxicity 
The grade of toxicity was explored in order to assess the severity of toxicities 
being reported. Table 16 showed the frequencies of each grade of toxicity, with 
the majority of the population not reporting any toxicity (grade 0). These 
patients were still included in the analyses of toxicity severity, in order to 
maintain the statistical power of the data. The same predictors were 
investigated for severity of toxicity as were used to assess occurrence of 
toxicity. As there were only small numbers of grade 3 and 4 toxicities, these 
were too low to draw any conclusions from. 
 
4.2.2.1 Age and Grade of Toxicity 
Age was explored as a continuous and categorical variable.  
 92
Table 27. Mean Age of Patients Reporting Each Grade of Toxicity 
  
Mean age N Std. Deviation 
Grade of toxicity 
0 63.3 976 11.6 
1 63.2 433 10.8 
2 59.9 89 12.0 
3 68.3 6 3.4 
4 72.0 1 . 
  
Total 
63.1 1505 11.4 
Kruskall-Wallis p=0.03 
 
The age of patients experiencing a grade 2 toxicity was slightly lower than that 
of patients reporting a grade 1 toxicity. The grade 3 and 4 groups were too 
small to draw conclusions from. Kruskall-Wallis would suggest that these 
differences were statistically significant and that there was an effect on grade of 
toxicity from age (p=0.03).  
 
There was no statistically significant correlation of age and grade of toxicity 
when using Spearman’s correlation coefficient (p>0.1).  
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Figure 4. The Distribution of Age in Patients Reporting Each Grade of Toxicity 
 
Figure 4 illustrated the similar means and standard deviations of age in each 
group of toxicity, suggesting that there was no large difference between the 
groups. 
 
When age was grouped, the differences between the groups were not 
statistically significant (p>0.1). There appeared to be no pattern or a 
relationship between age as a continuous variable and grade of toxicity. 
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Table 28. Ordinal Logistic Regression Analysis of Grade of Toxicity and Age 
 
Grade 
of 
toxicity 
B 
Std. 
Error 
 Sig. Exp(B) 
95% Profile 
Likelihood 
Confidence Interval 
for Exp(B) 
Lower              
Upper 
Upper 
Threshold 1 0.259 0.6177 0.674 1.296 0.392 4.445 
  2 3.074 0.7116 0 21.637 5.563 91.436 
  3 5.03 1.1681 0 152.96 21.61 3186.1 
Age 
(continuous) 
  -0.02 0.0099 0.043 0.98 0.961 0.999  
 
 
The analysis would suggest that as age increased, there was a slight decrease 
in the grade of toxicity experienced. An ordinal regression analysis for grade of 
toxicity and age, when grouped as a categorical variable showed no significant 
relationship (p>0.1).  
 
4.2.2.2 Toxicity by Grade and Performance Status 
As there were small numbers of patients in the performance status 3 and 4 
groups, they were not included in the analysis.  
 
Table 29. Grade of Toxicity and Performance Status 
  
Grade of Toxicity 
0 1 2 
Performance 
status  
0 468 254 43 
  61.1% 33.2% 5.6% 
1 438 159 42 
  68.1% 24.7% 6.5% 
2 61 19 4 
  70.9% 22.1% 4.7% 
Total   972 433 89 
Pearson χ2 = 34.95 (p<0.01) 
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The rate of grade 1 toxicity seemed to decrease with performance status. 
There did not appear to be a pattern with grade 2 although, the rate of patients 
not experiencing toxicity increased with performance status. These differences 
did appear to be statistically significant (p<0.01). Univariable regression 
analysis did not yield any statistically significant data (p>0.1).  
 
4.2.2.3 Grade of Toxicity and Disease 
As with toxicity, skin, CUP and sarcoma were omitted for analysis, due to small 
numbers of patients. Grade 3 and 4 toxicities were also excluded due low 
numbers.  
 
Table 30. Grade of Toxicity and Disease 
  
Grade of Toxicity 
0 1 2 
Disease 
CNS 26 8 3 
  66.7% 20.5% 7.7% 
Breast 248 149 31 
  57.9% 34.8% 7.2% 
Colorectal 203 98 16 
  63.8% 30.8% 5% 
Gynaecology 102 41 7 
  68% 27.3% 4.7% 
Head&Neck 31 13 2 
  67.4% 28.3% 4.3% 
Upper GI 93 56 13 
  56.4% 33.9% 7.9% 
Lung 179 49 10 
  74.9% 20.5% 4.2% 
Urology 81 19 5 
  77.1% 18.1% 4.8% 
Total   963 433 87 
    64.6% 29.1% 5.8% 
Pearson’s χ2=73.69 (p<0.01) 
 
The differences between the disease groups appeared statistically significant 
(p<0.01), but the relationship did not appear to be linear. An ordinal logistic 
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regression analysis of grade of toxicity with disease controlled for age, showed 
no statistically significant relationships (p>0.1).  
 
4.2.2.4 Grade of Toxicity by Intent of Treatment 
When considering the rates of each grade of toxicity by treatment intent, 
Pearson’s χ2 test suggested that the differences between the groups were not 
significant (p>0.1) and an ordinal regression analysis showed no significant 
predictions (p>0.1).  
 
4.2.2.5 Grade of Toxicity and Treatment 
The potential effect of treatment on the severity of toxicity was investigated, 
using the groupings as previously. None of the methods of grouping treatments 
revealed any statistically significant differences (p>0.1), apart from the number 
of drugs (p=0.04). 
  
The rates of each grade of toxicity by treatment grouped according to the 
number of drugs in the regimen produced a Pearson’s χ2 test that revealed no 
statistically significant difference between the groups (p>0.1). However a 
Spearman’s correlation coefficient was calculated as 0.168 (p<0.01), 
suggesting a positive correlation of number of drugs with grade of toxicity. An 
ordinal logistic regression analysis suggested no significant predictions (p>0.1).  
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 Table 31. Multivariable Ordinal Logistic Regression of Grade of Toxicity 
  
  B 
Std. 
Error 
Sig. Exp(B) 
95% Profile 
Likelihood 
Confidence 
Interval for 
Exp(B) 
   
        Lower Upper 
  
Grade 4 -6.968 1.0466 0 0.001 
5.14E
-05 
0.005 
  Grade 3 -5.018 0.488 0 0.007 0.002 0.016 
  Grade 2 -2.355 0.3262 0 0.095 0.05 0.179 
  Grade 1 -0.236 0.3145 0.452 0.789 0.425 1.458 
Age 
(continuous)  
0.002 0.0051 0.73 1.002 0.992 1.012 
Disease 
 
            
  Urology 0.843 0.2558 0.001 2.324 1.427 3.904 
  CNS 0.24 0.3566 0.501 1.272 0.643 2.632 
  Colorectal 0.235 0.1517 0.121 1.265 0.941 1.706 
  Gynaecology 0.417 0.199 0.036 1.517 1.032 2.255 
  Head & Neck 0.403 0.3248 0.215 1.496 0.806 2.903 
  Upper GI -0.118 0.1836 0.521 0.889 0.621 1.276 
  Lung 0.73 0.181 0 2.075 1.462 2.974 
  Breast 0a . . 1 . . 
 
 
The analysis in Table 31 used grade 0 toxicity and breast cancer patients as a 
reference group. The analysis went some way to explain the variance in toxicity 
grade but still left a large amount of variance unaccounted for. No significant 
relationships between performance status and toxicity was identified in the 
analysis, which could suggest that there was a type I error when looking at the 
differences between performance status groups (p>0.1).  It did, however, 
reveal some significant predictors of grade of toxicity. These were: 
 Urology cancer patients reported on average an 84% higher grade of 
toxicity than breast cancer patients (p<0.01) 
 Gynaecology cancer patients reported on average a 42% higher grade 
toxicity than breast cancer patients (p=0.04) 
 Lung cancer patients reported on average a 73% higher grade toxicity 
than breast cancer patients (p<0.01) 
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Referring back to Table 30 can help to further understand the regression 
analysis. The breast group was used as the reference group and had one of 
the lower percentages of grade 0 toxicities.  Lung, gynaecology and urology 
cancer patients all had higher rates of grade 0 toxicity than breast. This was a 
complex analysis, but it suggested that disease had an effect on the severity of 
toxicity. 
 
4.2.3 Hospital Admission 
There were 203 admissions due to chemotherapy toxicity in the population 
studied. This translated as an admission rate of 13.1% across the entire 
population studied. The mean number of days after chemotherapy when 
patients were admitted was 8.2 (SD=5.4) and the mean length of stay was 4.4 
days (SD= 4.4).  
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Figure 5. Length of Stay in Patients Admitted. 
 
The histogram in Figure 5 showed the distribution of length of stay, showing a 
positive skew. Median length of stay was 3 days with a range of 1 to 28 days.  
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Figure 6. Number of Days After Chemotherapy Patients Were Admitted 
 
The histogram in figure 6 showed the distribution of the number of days after 
chemotherapy, patients were admitted. There was a peak at 5 days. The 
median number of days after chemotherapy patients were admitted was 7 with 
a range of 0 to 27.  
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Table 32.  Reasons for Admission 
Reason Admitted n Valid % 
Pyrexia/?Neutropenic Sepsis 56 27.6 
Multiple Reasons 25 12.3 
Nausea and or Vomiting 20 9.9 
Unknown 16 7.9 
Abdominal Pain 11 5.4 
Diarrhoea 10 4.9 
SOB 8 3.9 
Generally unwell 8 3.9 
Diarrhoea and Vomiting 5 2.5 
Collapse/Fall 4 2 
Chest pain 4 2 
Confusion 3 1.5 
Urinary Symptoms 3 1.5 
Pain 3 1.5 
Bleeding 3 1.5 
Acute Kidney Injury 3 1.5 
Weakness/Lethargy 2 1 
Leg Swelling 2 1 
? Bowel Obstruction 2 1 
Chest Infection 2 1 
Cytopenia 2 1 
Deranged LFTs 2 1 
Dental 1 0.5 
Mucositis 1 0.5 
Pleural effusion 1 0.5 
Neurological Symptoms 1 0.5 
Dysphagia 1 0.5 
Constipation 1 0.5 
Skin problems 1 0.5 
Dehydration 1 0.5 
Reduced oral intake 1 0.5 
 
 
Table 32 showed that there were 31 individual reasons for admission, showing 
a varied list of symptoms that could have been associated with disease or 
chemotherapy.  
 
Hospital admission was treated as a binary variable with patients either being 
admitted or not admitted within 30 days of chemotherapy. The relationship 
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between the various predictors and hospital admission were studied.  
 
4.2.3.1 Hospital Admission and Age 
The mean age of patients admitted within 30 days of chemotherapy was 63 
(SD= 10.9) years compared to a mean age of 63.2 years (SD= 11.5) for 
patients not admitted. Clearly there was no difference in mean age between the 
two groups.   
 
When age was treated as a categorical variable, the rate of admission was 
lowest in the 41-50 age group and highest in the 51-60 age group. A χ2 test 
showed that the differences between the age groups was not statistically 
significant (p>0.1).  
 
4.2.3.2 Hospital Admission and Performance Status 
The relationship between hospital admission and performance status was 
explored.  
 
Table 33. Hospital Admission Rates and Performance Status 
    
Number 
admitted 
% of 
Performance 
Status Group 
Performance status  
2 17 19.8% 
3 1 16.7% 
1 102 15.5% 
0 81 10.3% 
Missing 2  
Total   201 13.10% 
Pearson’s χ2 = 11.97 (P<0.01) 
 
The highest admission rate was in patients who were performance status 2 and 
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the lowest in patients who were performance status 0. Although these 
differences were statistically significant (p<0.01), a logistic regression analysis 
failed to identify any statistically significant predictions, suggesting that 
performance status as a whole was not a significant predictor of hospital 
admission (p>0.1). It is possible that this highlighted a type 1 error issue with 
the χ2 test, which could falsely suggest that there were significant differences 
between the groups.  
 
4.2.3.3 Hospital Admission and Disease 
Table 34. Hospital Admission Rates and Disease 
    Number Admitted % of Disease Group 
Disease 
Head&Neck 10 21.3% 
Upper GI 31 18.2% 
Lung 44 18.2% 
Gynaecology 24 15.9% 
CNS 5 12.8% 
Colorectal 37 11.2% 
Breast 45 10.3% 
Urology 6 5.6% 
Missing 1   
Total   202 13.3% 
Pearson’s χ2 = 22.3 (p<0.01) 
 
The highest rate of admission was seen in the head and neck cancer patients 
and skin, sarcoma and CUP had no admissions, although these groups all had 
small numbers of patients, so the sample may not have been representative of 
these populations.  As such, skin, sarcoma and CUP were omitted from further 
analysis.  
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Table 35. Logistic Regression Analysis of Admission and Disease Controlled 
for Age 
  B S.E. Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Age 
(continuous) 
  
-
0.006 
0.007 0.403 0.994 0.98 1.008 
Disease 
 
    0.003       
  CNS 0.814 0.647 0.208 2.258 0.635 8.023 
  Breast 0.598 0.455 0.189 1.818 0.746 4.433 
  Colorectal 0.729 0.456 0.11 2.074 0.848 5.072 
  Gynaecology 1.125 0.477 0.018 3.081 1.21 7.849 
  Head&Neck 1.46 0.555 0.008 4.306 1.452 12.775 
  Upper GI 1.301 0.466 0.005 3.673 1.475 9.147 
  Lung 1.306 0.452 0.004 3.693 1.522 8.962 
Constant   
-
2.411 
0.647 0 0.09     
Pseudo R2=0.015 
 
The regression analysis in Table 35 used urology as the reference group. The 
analysis suggested that gynaecology cancer patients had 208% increased 
chance of being admitted compared to urology cancer patients (p=0.02). Head 
and neck cancer patients appeared to have a 330% higher chance of 
admission compared to urology cancer patients (p<0.01). Upper GI cancer 
patients were 267% more likely to be admitted than urology cancer patients 
(p<0.01), and lung cancer patients 269% more likely to be admitted than 
urology cancer patients (p<0.01).  
 
4.2.3.4 Hospital Admission and Intent of Treatment 
There appeared to be little difference in the percentage of patients admitted 
within 30 days of the first cycle of chemotherapy according to treatment intent 
(p>0.1).  
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4.2.3.5 Hospital Admission and Treatment 
The potential effect of treatment on hospital admission rates was investigated 
using the methods of grouping toxicity as before.  
 
Table 36. Hospital Admission and Treatment Grouped According to 
Cytotoxicity 
    Number Admitted % of Treatment Group 
Cytotoxicity 
Mixed 12 18.2% 
Cytotoxic 189 13.3% 
Non-cytotoxic 1 2.0% 
Missing 1   
Total   202 13.1% 
Pearson’s χ2 = 7.09 (p=0.03) 
 
There was a large variance in admission rates in the number of patients in 
each group making comparison difficult.  A higher percentage of patients 
receiving the combination chemotherapy were admitted than those who 
received other treatment.  
 
 106
Table 37. Logistic Regression Analysis for Hospital Admission and Treatment 
by Cytotoxicity 
  B S.E. Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Age 
(continuous)  
-0.001 0.007 0.911 0.999 0.986 1.012 
Cytotoxicity       0.068       
  Cytotoxic -0.369 0.329 0.262 0.691 0.363 1.317 
  
Non-
cytotoxic 
-2.405 1.06 0.023 0.09 0.011 0.721 
Constant   -1.459 0.516 0.005 0.233     
Pseudo R2=0.06 
 
The analysis in Table 37 used mixed as the reference group. The analysis 
suggested patients on non-cytotoxic chemotherapy were 91% less likely to 
experience a toxicity compared to those on a combination regimen (p=0.02). 
The pseudo-R2 value suggested that the analysis explains a small amount of 
the variance.   
 
Table 38. Hospital Admission Rates and Treatment Grouped by Number of 
Drugs 
    Number Admitted % of Treatment Group 
Number of Drugs 
2 93 17.4% 
3 49 11.7% 
1 57 10.2% 
Missing 4   
Total   199 13.20% 
Pearson’s χ2=13.76 (p<0.01) 
 
The rate of admission was highest in those patients receiving two drugs and 
lowest in those receiving a single agent.  The pattern of the relationship did not 
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appear to be linear but the differences were statistically significant  
(p<0.01).  
 
Table 39. Logistic Regression Analysis for Hospital Admission and Treatment 
Grouped by Number of Drugs 
  B S.E. Sig. Exp(B) 
95% C.I.for EXP(B) 
Lower Upper 
Age (continuous)   -0.004 0.007 0.591 0.996 0.983 1.01 
Number of Drugs       0.001       
  1 -0.135 0.21 0.52 0.873 0.579 1.318 
  2 0.489 0.194 0.012 1.63 1.114 2.385 
Constant   -1.805 0.431 0 0.165     
Pseudo R2=0.02 
 
The analysis in Table 39 suggested that patients on 2 drugs were 63% more 
likely to be admitted than those on 3 drugs (p=0.01).  
 
When grouped according to commissioning status, a higher percentage of 
patients were admitted within 30 days of chemotherapy in the baseline 
commissioned group but this was not statistically significant (p>0.1).  
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Table 40. Hospital Admission Rates and Treatment Grouped by Emetogenicity 
    Number Admitted % of Treatment Group 
Emetogenicity 
Moderate 85 15.6% 
High 62 13.4% 
Low 44 10.8% 
Minimal 1 3.0% 
Missing 11   
Total   192 13.2% 
Pearson’s χ2=7.9 (p=0.05) 
 
In Table 40, the group who received chemotherapy of moderate emetogenicity 
had the highest rates of admission, however a logistic regression analysis was 
not able to show any statistically significant prediction about admission (p>0.1). 
This could suggest a type 1 error with the Pearson’s χ2 test. 
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4.2.3.6 Multivariable Logistic Regression of Admission 
Table 41. Multivariable Logistic Regression of Hospital Admission 
  
  
B S.E. Sig. 
Exp(B
) 
95% C.I.for 
EXP(B) 
    Lower Upper 
Age 
(continuous)  
-0.005 0.007 0.52 0.995 0.981 1.01 
Number of 
Drugs  
    0.008       
  1 -0.153 0.241 0.526 0.858 0.535 1.376 
  2 0.5 0.248 0.044 1.649 1.013 2.683 
Disease 
 
    0.009       
  CNS 1.074 0.657 0.102 2.928 0.808 10.609 
  Breast 0.741 0.476 0.119 2.099 0.826 5.331 
  Colorectal 0.664 0.462 0.151 1.942 0.785 4.801 
                      Gynaecology 1.117 0.479 0.02 3.055 1.195 7.814 
  Head & Neck 1.758 0.567 0.002 5.8 1.907 17.638 
  Upper GI 1.335 0.476 0.005 3.799 1.493 9.665 
  Lung 1.018 0.461 0.027 2.766 1.12 6.833 
Constant   -2.634 0.676 0 0.072     
Pseudo R2 = 0.02                                
 
A multivariable logistic regression for admission, using the variables shown to 
have an effect on admission rates, with groups excluded as in previous 
regression analyses and controlled for age was performed. The analysis 
contributed to the explanation of the variance in admission rates only minimally. 
The analysis suggested several predictions of statistical significance: 
 Patients who received treatment with 2 drugs were 65% more likely to 
be admitted than patients on 3 drugs (p=0.04) 
 Patients with gynaecological cancer were 206% more likely to be 
admitted than those with urological cancer (p=0.02) 
 Head and neck cancer patients were 408% more likely to be admitted 
than those with urological cancer (p<0.01) 
 Patients with an upper GI cancer were 279% more likely to be admitted 
than those with urological cancer (p<0.01) 
 Patients with lung cancer were 177% more likely to be admitted than 
those with urological cancer (p=0.03 
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4.2.3.7 Toxicity and Admission 
All admissions included in the data were due to symptoms of toxicity, however 
it was explored if this was affected by the reporting of toxicity at the point of the 
call back.  
 
Table 42. Toxicity and Admission 
  Number admitted 
% of Toxicity 
Group Admitted 
Toxicity 
Toxicity 125 12.80% 
No Toxicity 77 14.20% 
Missing 1   
Total   202 13.20% 
Pearson’s χ2=0.571 (p=0.45) 
 
Table 42 showed that there was a higher rate of admission in the experienced 
a toxicity group, however this could not be considered statistically significant 
(p=0.45).  
 
Table 43.  Admission Rates for Each Grade of Toxicity 
    
Number 
Admitted 
% of Grade Group 
Admitted 
Grade of Toxicity 
3 2 33.30% 
2 21 23.60% 
0 125 12.80% 
1 52 12% 
4 0 0% 
Mis
sing 
3 
  
Total   200 13.20% 
Pearson’s χ2= 11.3 (p=0.02) 
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The admission rate appeared to increase as the grade of toxicity increased and 
Pearson’s χ2 test suggested that this was statistically significant (p=0.02). 
Regression analysis did not show any statistically significant predictions 
(p>0.1). This could have been as a result of a type 1 error or due to the low 
numbers in some of the groups, for example in the grade 3 and 4 toxicity 
groups there were very small numbers of patients. A sample size large enough 
to allow for more patients in the grade 3 and 4 groups would be needed in 
order to elucidate this further.  
 
4.2.4 Length of stay 
The effects of the predictors on length of stay were analysed. 
 
 
Figure 7. Distribution of Log Length of Stay 
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The histogram in figure 7 showed the distribution of length of stay, which was 
positively skewed. This means that non-parametric tests were required to be 
used for analysis. Median length of stay was 3 days (1-28). 
 
In order to analyse length of stay it was necessary to exclude all of the patients 
who were not admitted. The mean length of stay was compared for the different 
groups in each of the variables.  
 
4.2.4.1 Length of Stay and Age 
Age was investigated as a categorical variable and a continuous variable to 
identify any relationship with length of stay.  
 
Kruskall-Wallis test suggested that there was no statistical difference between 
the age groups and length of stay (p>0.1). The number of patients admitted 
was quite different between each group, which meant that the average length 
of stay was affected and groups of equal size were not being compared.  
 
Median length of stay appeared to reduce as age increased. Using age as a 
continuous variable gave a Spearman’s correlation coefficient of -0.146 
(p=0.04), suggesting a significant inverse correlation between age and length 
of stay. All groups had a wide range length of stay.  
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4.2.4.2 Length of Stay and Performance Status 
Length of stay appeared to increase as performance status increased, with the 
exception of performance status 2. However only one patient in the 
performance status 3 group was admitted, so it was difficult to draw any 
conclusion. The range of length of stay was wide in all of the groups and 
Kruskall-Wallis confirmed that these differences were not significant (p>0.1). 
 
4.2.4.3 Length of Stay and Intent of Treatment 
Table 44. Median Length of Stay and Treatment Intent 
Intent of 
chemotherapy 
Median N Minimum Maximum 
Palliative 3 116 1 28 
Adjuvant 2 60 1 17 
Neoadjuvant 2 26 1 9 
Total 3 202 1 28 
Kruskall-Wallis P=0.08 
 
Length of stay was longest in the palliative chemotherapy group and shortest in 
the neoadjuvant group. However, each group was a very different size and so 
equally sized groups could not be compared. The range of length of stay was 
also very wide in all groups. Kruskall-Wallis gave a borderline p-value, so it was 
not possible to consider this effect statistically significant (p=0.08).  
 
4.2.4.4 Length of Stay and Disease 
Skin, sarcoma and CUP groups had no patients admitted. Length of stay 
appeared significantly longer in the gynaecology cancer patients and shortest 
in the head and neck cancer patients. Kruskall-Wallis suggested that it was not 
possible to consider these differences statistically significant (p>0.1). Again, the 
groups had a wide variance and were not of equal size.  
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4.2.4.5 Length of Stay and Treatment  
When grouped according to cytotoxicity and commissioning status, no 
statistically significant differences were seen in the median length of stay 
(p>0.1).  
 
Table 45. Median Length of Stay and Treatment Grouped According to the 
Number of Drugs 
Number of drugs Median N Minimum Maximum 
1 4 57 1 24 
2 2 93 1 17 
3 2 49 1 28 
Total 3 199 1 28 
Kruskall-Wallis P=0.05 
 
Although there was still a difference in size between the groups, this difference 
was less pronounced than when dividing treatment by other means. The length 
of stay appeared to reduce as the number of drugs increased. These 
differences were statistically significant according to Kruskall-Wallis. Length of 
stay and number of drugs had an inverse correlation with a Spearman’s 
correlation coefficient of -0.149 (p=0.04).  
 
Table 46. Median Length of Stay and Treatment Grouped According to 
Emetogenicity 
Emetogenicity Median N Minimum Maximum 
Minimal 9 1 9 9 
Low 4 44 1 24 
Moderate 3 85 1 28 
High 2 62 1 16 
Total 3 192 1 28 
Kruskall-Wallis P=0.03 
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Again, a large variance was seen between each group. The minimally 
emetogenic group only had one patient in it, so comparisons could not be 
drawn for this group. It appeared that the more emetogenic the chemotherapy, 
the shorter the length of stay.  
 
4.2.5 Summary of Primary Outcome Findings 
A summary table of the main findings for the primary outcome measures was 
produced.  
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Table 47. Summary of Primary Outcome Measure Findings 
  
Outcome 
Toxicity risk Severity (grade) Admission risk Length of Stay 
Predictor   
Age Categorical 
Descriptive Not significant (p>0.1) 
Not significant (p>0.1) Not significant (p>0.1) Not significant 
(p>0.1) 
Univariable Not significant (p>0.1) Not significant (p>0.1) Not significant (p>0.1)   
Multivariable Not significant (p>0.1) Not significant (p>0.1) Not significant (p>0.1)   
Age Continuous 
Descriptive 
Not significant (p>0.1) Kruskall- Wallis 
significant (p=0.03) 
Not significant (p>0.1) Negative correlation 
(p=0.04) 
Univariable 
Not significant (p>0.1) For every year age 
increased, grade of 
toxicity reduced by 2% 
(p=0.04) 
Not significant (p>0.1) 
  
Multivariable Not significant (p>0.1) Not significant (p>0.1) Not significant (p>0.1)   
PS 
Descriptive 
Negative correlation 
(p<0.01) Χ2 significant (p<0.01) 
Χ2 significant  
(p<0.01) 
Not significant 
(p>0.1) 
Univariable PS1 -26% (p<0.01) Not significant (p>0.1) 
Not significant (p>0.1) 
  
Multivariable Not significant (p>0.1) Not significant (p>0.1) 
Not significant (p>0.1) 
  
Disease 
Descriptive Χ2 significant  (p<0.01) Χ2 significant (p<0.01) Χ2 significant (p<0.01) 
Not significant 
(p>0.1) 
Univariable 
Breast +145% 
(p<0.01)         Upper 
GI +159% (p<0.01) Not significant (p>0.1) 
Gynae +208% (p=0.02)     
H&N +330% (p<0.01)           
Upper GI +267% 
(p<0.01)           Lung 
+269% (p<0.01)   
Multivariable 
Breast +82% 
(borderline)(p=0.06)          
Upper GI +118% 
(p=0.02) 
Urology +84% (p<0.01)           
Gynae +42%  (p=0.04)  
Lung +73% (p<0.01) 
Gynae +206% (p=0.02)        
H&N  +408% (p<0.01)         
Upper GI +279% 
(p<0.01)                   
Lung  + 177% (p=0.03)   
 Intent 
Descriptive 
Not significant (p>0.1) Not significant (p>0.1) Not significant (p>0.1) Not significant 
(p>0.1) 
Univariable 
Not significant (p>0.1) Not significant (p>0.1) Not significant (p>0.1) 
  
Multivariable 
Not significant (p>0.1) Not significant (p>0.1) Not significant (p>0.1) 
  
Treatment - Cytotoxicity 
Descriptive 
Not significant (p>0.1) Not significant (p>0.1) 
Χ2 significant (p=0.03) 
Not significant 
(p>0.1) 
Univariable 
Not significant (p>0.1) Not significant (p>0.1) 
Non cyto -91% (p=0.02)   
Multivariable 
Not significant (p>0.1) Not significant (p>0.1) 
Not significant (p>0.1)   
Treatment - Number of Drugs 
Descriptive 
Positive correlation 
(p<0.01) 
Positive correlation 
(p<0.01) Χ2 significant (p<0.01)        
Kruskall-Wallis 
borderline (p=0.05) 
Univariable 
2 drug -50% (p<0.01)                
1 drug -59% (p<0.01) 
Not significant (p>0.1) 
2 drug +63% (p=0.01)   
Multivariable 
2 drug -31%  
(borderline) (p=0.07)           
1drug -50%(p<0.01) 
Not significant (p>0.1) 
2 drug +65% (p=0.04)   
Treatment - Commissioning 
Descriptive 
Not significant (p>0.1) Not significant (p>0.1) Not significant (p>0.1) Not significant 
(p>0.1) 
Univariable 
Not significant (p>0.1) Not significant (p>0.1) Not significant (p>0.1) 
  
Multivariable 
Not significant (p>0.1) Not significant (p>0.1) Not significant (p>0.1) 
  
Treatment - Emetogenicity 
Descriptive Χ2 significant  (p<0.01) Not significant (p>0.1) Χ2 borderline (p=0.05) 
Kruskall-Wallis 
significant (p=0.03) 
Univariable 
mod -29% (p=0.01) 
low -41% (p<0.01)   
min -64% (p=0.02) 
Not significant (p>0.1) Not significant (p>0.1) 
  
Multivariable Not significant (p>0.1) 
Not significant (p>0.1) Not significant (p>0.1) 
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4.3 Sub-Group Analyses 
The three largest tumour groups were analysed as sub-populations. 
 
There were 438 patients with breast cancer in the study population. This 
represented 28.5% of the population. Toxicity was reported by 186 (42.5%) 
breast cancer patients.  
 
There were 329 patients with colorectal diagnoses which is 21.4% of the 
population studied. Toxicity was reported by 116 (35.3%) of colorectal cancer 
patients.  
 
There were 242 patients with a diagnosis of lung cancer, 15.7% of the study 
population. Toxicity was reported by 61 (25.2%) of lung cancer patients.  
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Figure 8. Distribution of Age Group in Breast cancer patients 
 
 
The histogram in figure 8 showed that the age of breast cancer patients 
appeared normally distributed with a peak in the aged 50-70 groups.  
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Figure 9. Distribution of Age Groups in Colorectal cancer patients 
 
The histogram in figure 9 had a slight negative skew and showed peak 
incidence in the 61-70 year old group. 
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Figure 10. Age Distribution in Lung cancer patients 
 
The histogram in figure 10 showed a negative skew and a peak at 61-70 
years.  
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Table 48. Distribution of Performance Status in Breast, Colorectal and Lung 
cancer patients 
Performance 
Status 
Breast Colorectal Lung 
Whole 
Population 
  n 
Valid 
% 
n 
Valid 
% 
n 
Valid 
% 
n 
 
Valid 
% 
0 320 73.2 160 48.9 55 22.9 783 51.1 
1 111 25.4 145 44.3 152 63.3 658 42.9 
2 6 1.4 21 6.4 30 12.5 86 5.6 
3     1 0.3 3 1.3 6 0.4 
  Total 437 100 327 100 240 100 
153
3 
100 
 
 
The majority of breast cancer patients were performance status 0. This was 
significantly higher than the population as a whole. The colorectal cancer 
patients had slightly fewer performance status 0 patients than the whole 
population, with lung cancer patients having the lowest percentage of 
performance status 0 patients. The lung group had the highest percentage of 
performance status 3 patients and performance status groups 1 and 2 had 
higher percentages of lung cancer patients compared to the whole population, 
which may have suggested that lung cancer patients were generally less fit 
than others. The data may also suggest that the breast cancer patients tended 
to be fitter than other disease groups.  
 
Table 49. Distribution of Treatment Intent in Breast, Colorectal and Lung 
cancer patients 
Treatment 
Intent 
Breast Colorectal Lung 
Whole 
Population 
n 
Valid 
% 
n 
Valid 
% 
n 
Valid 
% 
n 
 Valid 
% 
Palliative 155 35.4 177 53.8 200 82.6 833 54.2 
Adjuvant 192 43.8 107 32.5 29 12 464 30.2 
Neoadjuvant 91 20.8 42 12.8 13 5.4 239 15.6 
  438 100 326 100 242 100 1536 100 
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A higher proportion of breast cancer patients received adjuvant and 
neoadjuvant chemotherapy than in the overall population and the other tumour 
groups. In the colorectal group, the distribution in the treatment intent groups 
was similar to that of the whole population. A significantly higher proportion of 
palliative chemotherapy was given in the lung group compared to 54.1% in the 
population as a whole. 
 
Breast cancer patients received 25 different SACT regimens, 26 different 
regimens were used in the colorectal group and 20 different regimens were 
used in lung cancer patients. 
 
Table 50. Distribution of Treatment Grouped by Number of Drugs in Breast, 
Colorectal and Lung cancer patients 
Number 
of 
Drugs 
Breast Colorectal Lung Whole Population 
  n Valid % n Valid % n Valid % n  Valid % 
1 126 28.8 132 43.4 26 10.7 560 37 
2 34 7.8 138 45.4 209 86.4 533 35.2 
3 278 63.5 34 11.2 7 2.9 420 27.8 
Total 438 100 327 100 242 100 1533 100 
 
 
The proportion of breast cancer patients receiving 3 drugs was significantly 
higher than that for the population as a whole. The colorectal cancer patients 
had the highest percentages of patients on 1 and 2 drugs and significantly less 
patients on 3 drugs than the population as a whole and less than breast cancer 
patients. A significantly higher proportion of lung cancer patients received a 2-
drug regimen compared to the whole study population and very few patients 
received a triplet regimen. 
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Table 51. Distribution of Treatment Grouped According to Emetogenicity in 
Breast, Colorectal and Lung cancer patients 
Emetogenicity Breast Colorectal Lung Whole Population 
  n 
Valid 
% 
n 
Valid 
% 
n 
Valid 
% 
n 
 Valid 
% 
High 257 58.7 1 0.3 93 41.9 464 32 
Moderate 56 12.8 142 48.3 107 48.2 544 37.5 
Low 125 28.5 151 51.4 15 6.8 409 28.2 
Minimal         7 2.9 33 2.3 
  Total 438 100 294 100 222 100 1450 100 
 
Breast cancer patients received a significantly higher percentage of highly 
emetogenic chemotherapy than the population as a whole and the other 
tumour sites.  In the colorectal group, highly emetogenic treatment was only 
given to one patient, making the percentage significantly lower than in the 
whole population. Consequently rates of moderate and low emetogenic 
chemotherapy were higher than in the whole population. There was a higher 
proportion of highly emetogenic chemotherapy used in lung cancer patients 
compared to the whole population and a higher proportion of moderately 
emetogenic chemotherapy. There were no minimally emetogenic regimens 
used in the 3 tumour sites of interest and only a small percentage in the whole 
population. .  
 
4.3.1 Toxicity in Breast, Colorectal and Lung cancer patients 
Toxicity was explored as a binary outcome variable in the tumour sites of 
interest using the predictors previously shown to have an association with 
toxicity in the whole population.  
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Table 52. Multivariable Logistic Regression Analysis of Toxicity in Breast 
cancer patients 
  
  
B S.E. Sig. 
Exp(
B) 
95% C.I.for 
EXP(B) 
    Lower Upper 
Age 
(continuous)  
0.009 0.009 0.299 1.009 0.992 1.027 
Number of 
Drugs  
    0.048       
  1 -1.205 0.498 0.016 0.3 0.113 0.796 
  2 -0.664 0.584 0.256 0.515 0.164 1.618 
Performance 
Status  
    0.879       
  0 0.339 0.904 0.708 1.404 0.239 8.258 
  1 0.241 0.92 0.793 1.273 0.21 7.73 
Emetogenicity 
 
    0.582       
  High -0.226 0.497 0.649 0.798 0.301 2.111 
  Moderate -0.424 0.409 0.299 0.654 0.294 1.458 
Constant   -0.585 1.153 0.612 0.557     
Pseudo-R2 = 0.06 
 
Multivariable logistic regression analysis was undertaken using the same 
predictors shown to affect toxicity in the whole population. Only one statistically 
significant prediction was made by the regression analysis, and that was that 
patients on one drug were 70% less likely to experience a toxicity than those 
on 3 drugs (p=0.02).  
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Table 53. Multivariable Logistic Regression Analysis for Toxicity in Colorectal 
cancer patients 
  
  
B S.E. Sig. Exp(B) 
95% C.I.for 
EXP(B) 
    Lower Upper 
Age 
(continuous) 
  0 0.012 0.996 1 0.976 1.025 
Number of 
Drugs 
      0.727       
  1 0.426 0.54 0.431 1.531 0.531 4.414 
  2 0.224 0.425 0.599 1.251 0.544 2.876 
Performance 
Status 
      0.203       
  0 -21.22 40194 1 0 0 . 
  1 -21.7 40194 1 0 0 . 
  2 -22.04 40194 1 0 0 . 
Emetogenicity       0.215       
  
High 21.988 40193 1 
354363
0948 
0 . 
  Moderate 0.768 0.439 0.08 2.156 0.913 5.093 
Constant   20.207 40194 1 
596747
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Pseudo-R2=0.05 
 
The analysis in Table 53 also suggested that those on a moderately 
emetogenic regimen were 116% more likely to experience a toxicity than those 
on a low emetogenic chemotherapy (p=0.08), but this was of borderline 
significance.  
 
A logistic regression analysis for toxicity in the lung group, using predictors 
previously shown to have an effect on toxicity, controlled for age, showed no 
statistically significant predictions (p>0.1).  
 
4.3.2 Grade of Toxicity in Breast, Colorectal and Lung cancer patients 
The severity of toxicity in the patients in the 3 largest tumour sites was 
explored.  
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Table 54. Distribution of Grade of Toxicity in Breast, Colorectal and Lung 
cancer patients 
  Breast Colorectal Lung 
Whole 
Population 
Grade 
of 
Toxicity 
n 
Valid 
% 
n 
Valid 
% 
n 
Valid 
% 
n 
Valid 
% 
0 248 57.9 203 63.8 179 74.9 976 64.8 
1 149 34.8 98 30.8 49 20.5 434 28.8 
2 31 7.2 16 5 10 4.2 89 5.9 
3     1 0.3 1 0.4 6 0.4 
4             1 0.1 
Pearson’s χ2= 73.69 (p<0.01) 
 
Table 54 showed the grades of toxicities experienced by patients. The 
differences between the groups was statistically significant according to 
Pearson’s χ2 (p<0.01).  There were no grade 3 or 4 toxicities experienced by 
breast cancer patients and the rate of grade 1 toxicity reporting was higher than 
the rate for the population as a whole. The grade 2 toxicity rate was also higher 
than the population rate. In colorectal cancer patients the percentage of 
patients experiencing each grade of toxicity was fairly similar to those of the 
population as a whole. Lower proportions of all grades of toxicity were seen in 
lung cancer patients compared to the whole study population and there were 
no grade 4 toxicities and only one grade 3. Due to the small numbers, no 
meaningful regression analysis could be developed for grade of toxicity. 
Between the three disease groups, the lung cancer patients had the highest 
rate of grade 0 toxicity. For each grade of toxicity, the rate was highest in 
breast cancer patients, followed by colorectal then lung.  
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4.3.3 Hospital Admission within 30 days of Chemotherapy in Breast, 
Colorectal and Lung cancer patients 
Forty-five (10.3%) breast cancer patients were admitted within 30 days of 
chemotherapy. Median length of stay in breast cancer patients who were 
admitted was 3 days with a range of 1 to 17 days and quartiles of 1 and 6 days. 
The admission rate was slightly lower than that of the study population as a 
whole (13.1%) and median length of stay the same.  
 
There were 32 admissions in the colorectal group and these represented 
11.2% of the patients in that group. Median length of stay was 3 days, with a 
range of 1 to 15 and quartiles of 1 and 6.5 days which is very similar to that of 
the whole population.  
 
There were 44 admissions within 30 days of chemotherapy within the lung 
group, accounting for 18.2% of patients, higher than the 13.1% seen in the 
whole study population. Median length of stay in the lung group was 2 days 
with a range of 1 to 14 and quartiles of 1 and 6 days, which is lower than that of 
the whole population (3 days).  
 
Of the three tumour sites, lung cancer patients had the highest admission rate, 
which was significantly higher than that of the whole population. The lung 
cancer patients had the shortest length of stay, which was lower than the 
median of the whole population.  
 
Logistic regression analysis of admission in the three groups using predictors 
previously shown to have an effect on admission, controlled for age, all failed to 
show any statistically significant predictions (p>0.1). 
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4.4 Individual Toxicities 
The three most commonly reported toxicities were analysed.  
 
4.4.1 Nausea 
Nausea was explored as a single toxicity. Nausea was reported by 245 (15.9%) 
of patients 
Table 55. Grade of Nausea Reported 
    n Valid % 
Grade of Nausea 
0 1290 84 
1 214 13.9 
2 28 1.8 
3 3 0.2 
Missing 4   
Total   1539 100 
 
 
The majority of patients did not report nausea and grade 1 was the most 
common grade reported.  
 
The mean age of the patients reporting nausea was 61.6 years (SD= 11.3), 
with a range of 24 to 90 years and quartiles of 54 and 70.  The mean age of 
patients who did not report nausea was 63.49 years (SD= 11.4), slightly older 
than those patients who did report nausea. Neither value differed greatly from 
the mean age of the population, however Kruskall-Wallis test gave p<0.01, 
suggesting that the difference was statistically significant and nausea was seen 
more frequently in slightly younger patients.  Nausea rate and age gave a 
Spearman’s correlation coefficient of -0.07 (p=0.01) suggesting a very small 
inverse correlation.  
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Figure 11. Distribution of Age in Patients Reporting Nausea 
 
The histogram in figure 11 had a near normal distribution and peaks in the age 
61-70 group. This mirrored the distribution in the whole population.  
 
When age was considered as a categorical variable, nausea did appear to be 
reported more by younger patients, however this was not statistically significant 
(p>0.1). 
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Table 56. Performance Status of Patients Reporting Nausea 
    
Patients 
Reporting 
Nausea 
% Patients in 
Performance 
Status Group 
Performance status  
0 160 
20.5% 
2 10 11.6% 
1 75 11.4% 
Total   245   
Pearson’s χ2= 24.32 (p<0.01) 
 
No performance status 3 or 4 patients reported nausea. The rate of nausea 
was highest in the performance status 0 group and appeared to reduce as 
performance status increases. Pearson’s χ2 suggested that this was statistically 
significant (p<0.01).  
 
Table 57. Intent of Treatment in Patients Reporting Nausea 
    
Patients 
Reporting 
Nausea 
% Patients in 
Intent Group 
Intent of chemotherapy 
Neoadjuvant 54 22.60% 
Adjuvant 89 19.30% 
Palliative 102 12.20% 
Total   245   
Pearson’s  χ2= 20.24 ( p<0.01) 
 
The highest rate of nausea was seen in the neoadjuvant group and lowest in 
those patients receiving palliative chemotherapy.  Pearson’s χ2 suggested that 
these differences were statistically significant (p<0.01).  
 
The rates of nausea were explored in each disease group, omitting skin, CUP 
and sarcoma as previously, due to the low numbers in these groups.  
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Table 58. Disease Groups in Patients Reporting Nausea 
    
Patients Reporting 
Nausea 
% Patients in 
Disease Group 
Disease 
CNS 10 25.6% 
Breast 102 23.3% 
Upper GI 35 20.6% 
Gynaecology 19 12.6% 
Colorectal 40 12.3% 
Head&Neck 5 10.6% 
Lung 24 9.9% 
Urology 9 8.4% 
Missing 1   
Total   245   
Pearson’s χ2=39.69 (p<0.01) 
 
The rate of nausea was highest in the CNS group and lowest in the urology 
cancer patients. Breast and upper GI cancer patients also had high rates of 
nausea, which was statistically significant (p<0.01).  
 
Table 59. Treatment Grouped According to Cytotoxicity in Patients With 
Nausea 
    
Patients Reporting 
Nausea 
% Patients in 
Treatment Group 
Cytotoxicity 
Cytotoxic 237 16.7% 
Mixed 7 10.6% 
Non-cytotoxic 1 2% 
Total   245   
Pearson’s χ2= 9.46 (p <0.01) 
 
Pearson’s χ2 test showed statistical significance (p<0.01), however the 
numbers in the groups had a wide variance, making comparison difficult.  
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Table 60. Treatment Grouped According to Number of Drugs in Patients With 
Nausea 
    
Patients 
Reporting 
Nausea 
% Patients in 
Treatment Group 
Number of drugs 
3 119 28.4% 
2 69 13.0% 
1 51 9.1% 
Missing 6   
Total   245   
Pearson’s χ2= 71.68 (p<0.01) 
 
Nausea appeared to be reported by more patients in the group who received 3 
drugs and the rate seemed to increase as the number of drugs increased. 
These differences appeared to be statistically significant and there was a fairly 
even spread between the groups (p<0.01). Pearson’s correlation coefficient 
was 0.18 (p<0.01), suggesting a positive correlation between nausea rate and 
the number of drugs.  
 
Table 61. Treatment Grouped According to Commissioning Status in Patients 
With Nausea 
  
Patients 
Reporting 
Nausea 
% Patients in 
Treatment 
Group 
Commissioning Status 
Baseline 237 16.6% 
CDF 8 7.5% 
Total   245   
Pearson’s χ2=6.02 (p=0.01) 
 
The rate of nausea was much higher in the baseline-commissioning group, 
however there was a large size difference between the two groups making 
comparison difficult.  
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Table 62. Treatment Grouped According to Emetogenicity in Patients With 
Nausea 
  
Patients 
Reporting 
Nausea 
% Patients in 
Treatment Group 
Emetogenicity 
High 116 25.1% 
Moderate 74 13.6% 
Low 38 9.3% 
Minimal 1 3.0% 
Missing 16   
Total   245   
Pearson’s χ2= 48.46 (p<0.01) 
 
The data in Table 62 suggested that more emetogenic the chemotherapy the 
higher the rate of nausea.  
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Table 63. Multivariable Logistic Regression of Nausea 
  
  
B S.E. Sig. Exp(B) 
95% C.I.for 
EXP(B) 
    Lower Upper 
Age 
(continuous)  
-0.001 0.007 0.905 0.999 0.986 1.012 
Number of drugs 
 
    0       
  1 -1.233 0.289 0 0.292 0.165 0.514 
  2 -1.056 0.238 0 0.348 0.218 0.555 
Performance 
Status  
    0.15       
  0 19.201 16115 0.999 2.18E+08 0 . 
  1 18.799 16115 0.999 1.46E+08 0 . 
  2 18.989 16115 0.999 1.77E+08 0 . 
Emetogenicity       0.916       
  High -0.208 1.616 0.897 0.812 0.034 19.289 
  Moderate -0.138 1.604 0.932 0.872 0.038 20.213 
  Low -0.315 1.591 0.843 0.73 0.032 16.494 
Treatment Intent 
 
    0.895       
  Palliative -0.009 0.235 0.968 0.991 0.625 1.571 
  Adjuvant 0.073 0.211 0.731 1.075 0.711 1.626 
Commissioning 
Status  
            
  Baseline 0.054 0.589 0.927 1.055 0.332 3.35 
Cytotoxicity 
 
    0.163       
  Cytotoxic 1.085 0.618 0.079 2.959 0.881 9.943 
  
Non-
Cytotoxic 
-0.599 1.631 0.713 0.549 0.022 13.441 
Constant   -20.82 16115 0.999 0     
Pseudo R2 = 0.06 
 
The Pseudo R2 in the logistic regression shown in Table 63 was relatively 
small, suggesting that the analysis explained a small amount of the variance in 
nausea.  The analysis showed the following significant predictions for the 
number of drugs: 
 Patients on 1 drug were 71% less likely to experience nausea than 
those on 3 drugs (p<0.01) 
 Patients on 2 drugs were 65% less likely to experience nausea than 
those on 3 drugs (p<0.01) 
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The prediction for cytotoxicity appeared to be borderline significant 
(p=0.08), but due to the differences in the sizes of the groups, a relationship 
could not be reliably shown.  
 
4.4.1.1 Grade of Nausea 
There were no statistically significant differences between the age groups 
experiencing each grade of nausea, although the groups were not of a similar 
size (p>0.1). Performance status did not seem to affect the grade of nausea, 
with no significant difference (p>0.1), nor did intent of treatment or disease 
(p>0.1). 
 
When looking at treatment, none of the methods of grouping treatments 
showed any statistically significant difference in the rates of each grade of 
nausea (p>0.1). Group sizes were not equal and many groups had few of no 
patients in them. As no statistically significant relationships were identified in 
the descriptive statistics, regression analysis was not performed for grade of 
nausea. 
 
4.4.1.2 Nausea and Admission 
The number of patients who reported nausea, who were admitted within 30 
days of chemotherapy was 34 (13.9%). Patients who did not report nausea had 
an admission rate of 13%. This was very similar to the admission rate for the 
population as a whole, the patients reporting nausea had a median length of 
stay of 2 days (1-28), which was lower than the median for the entire study 
population (3 days [1-28]). Those not reporting nausea had a median length of 
stay of 3 days (1-28). No statistically significant predictions were found in a 
logistic regression analysis for admission rates (p>0.1).  
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4.4.2 Vomiting 
Vomiting was investigated in the same way as nausea. Vomiting was reported 
by 89 (5.8%) of patients.  
 
Table 64. Grade of Vomiting 
  n Valid % 
Grade of Vomiting 
0 1446 94.2 
1 52 3.4 
2 35 2.3 
3 2 0.1 
Total 1535 100 
  Missing 4   
Total 1539   
 
 
Grade 1 was the most frequently reported grade of vomiting with only 2 
patients reporting grade 3 and no grade 4 vomiting being reported.  
 
The mean age of those patients reporting vomiting was 59.5 years (SD= 13.2), 
with a range of 24 to 83 years and quartiles of 50.5 and 70 years. The mean 
age of those not reporting vomiting was 63.41 years (SD=11.2), which was 
almost identical to that of the whole population. Kruskall-Wallis gave p=0.01, 
suggesting that this difference was statistically significant and vomiting was 
seen in slightly younger patients.  
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Figure 12. Distribution of Age in Patients Experiencing Vomiting 
 
 
The histogram in figure 12 showed that there is a peak incidence at 61-70 
years. This was the same as the whole population and the same as nausea.  
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Table 65. Distribution of Age in Patients Reporting Vomiting 
    
Number 
Experiencing 
Vomiting  
% Patients in 
Age Group 
Age group (years) 
21-40 10 
16.4% 
41-50 12 7.5% 
51-60 18 5.5% 
61-70 30 5.5% 
71-80 18 4.6% 
>70 1 1.9% 
Total   89   
Pearson’s χ2=15.99 (p<0.01) 
 
The rate of vomiting appeared to decrease as age increased. Spearman’s 
correlation coefficient for age and vomiting is -0.081 (p=0.02) suggesting an 
inverse correlation.  
 
No statistically significant relationship was seen between performance status 
and vomiting (p>0.1). 
 
Table 66. Intent of Chemotherapy in Patients Reporting Vomiting 
    
Number 
Experiencing 
Vomiting 
% Patients in 
Intent Group 
Intent of chemotherapy 
Neoadjuvant 23 9.6% 
Palliative 45 5.4% 
Adjuvant 21 4.6% 
Total   89   
Pearson’s χ2=7.92 (p=0.02) 
 
When intent of treatment was explored, neoadjuvant patients had the highest 
rate of vomiting and the lowest rate was seen in patients receiving adjuvant 
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treatment. The differences were not large but were statistically significant 
(p>0.1).  
 
Table 67. Disease in Patients Reporting Vomiting 
    
Number 
Experiencing 
Vomiting 
% Patients in 
Disease Group 
Disease 
CNS 6 15.4% 
Upper GI 16 9.5% 
Breast 35 8.0% 
Gynaecology 7 
4.6% 
Head&Neck 2 4.3% 
Colorectal 11 3.4% 
Lung 7 2.9% 
Urology 3 2.8% 
Missing 2   
Total   89   
Pearson’s χ2=24.63 (p<0.01) 
 
The rate of vomiting was significantly higher in the breast and CNS groups. The 
differences between the groups appeared to be statistically significant (p<0.01).  
 
The rate of vomiting by treatment grouped according to cytotoxicity showed 
that there was a wide variance in the size of the groups, making comparison 
difficult.  
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Table 68. Treatment Grouped According to Number of Drugs in Patients 
Reporting Vomiting 
    
Number 
Experiencing 
Vomiting 
% Patients in 
Treatment 
Group 
Number of Drugs 
3 51 12.2% 
2 28 5.3% 
1 9 1.6% 
Missing 1   
Total   89   
Pearson’s χ2=49.6 (p<0.01) 
 
It appeared that the more drugs given, the higher the rate of vomiting. 
Pearson’s correlation coefficient was 0.184 (p<0.01) suggesting a positive 
correlation.  
 
The rate of vomiting by treatment grouped according to commissioning status 
showed that there was a large variance in the size of the groups making 
comparison difficult.   
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Table 69. Treatment Grouped According to Emetogenicity in Patients 
Reporting Vomiting 
    
Number 
Experiencing 
Vomiting 
%  Patients in 
Treatment Group 
Emetogenicity 
High 48 10.4% 
Moderate 29 5.4% 
Low 7 1.70% 
Minimal 0 0% 
Missing 5   
Total   89   
Pearson’s χ2=32.51 (p<0.01) 
 
As with nausea, the data in Table 69 suggested that the more emetogenic a 
treatment, the higher the rate of vomiting. 
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Table 70. Multivariable Logistic Regression Analysis for Vomiting 
  
  
B S.E. Sig. 
Exp(
B) 
95% C.I.for 
EXP(B) 
    Lower Upper 
Age 
(continuous)  
-0.01 0.011 0.335 0.99 0.969 1.011 
Treatment Intent 
 
    0.02       
  
Palliative 0.501 0.36 0.164 
1.65
1 
0.815 3.346 
  
Adjuvant -0.447 0.349 0.2 
0.63
9 
0.323 1.268 
Disease 
 
    0.123       
  
CNS 1.832 1.192 0.124 
6.24
5 
0.604 64.582 
  
Breast 0.923 1.094 0.399 
2.51
6 
0.295 21.481 
  
Colorectal 0.44 1.075 0.682 
1.55
3 
0.189 12.773 
  
Gynaecology 0.724 1.097 0.51 
2.06
2 
0.24 17.702 
  
Head & Neck 1.452 1.356 0.284 
4.27
2 
0.3 60.88 
  
Upper GI 1.06 1.083 0.327 
2.88
7 
0.346 24.09 
  
Lung -0.52 1.124 0.644 
0.59
5 
0.066 5.382 
Number of 
Drugs  
    0.034       
  
1 -1.384 0.542 0.011 
0.25
1 
0.087 0.726 
  
2 -0.207 0.409 0.613 
0.81
3 
0.365 1.814 
Emetogenicity 
 
    0.235       
  
High 17.498 
7103.91
6 
0.998 
3975
1906 
0 . 
  
Moderate 17.04 
7103.91
6 
0.998 
2513
9573 
0 . 
  
Low 16.229 
7103.91
6 
0.998 
1117
1231 
0 . 
Constant   -19.705 
7103.91
6 
0.998 0     
Pseudo R2=0.05 
 
A logistic regression analysis for vomiting, using predictors shown to have a 
relationship by descriptive statistics, controlled for age showed that the only 
statistically significant prediction is with the number of drugs. The analysis 
suggested that patients who received 1 drug were 75% less likely to 
experience vomiting than those on 3 drugs (p=0.01).  
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4.4.2.1 Grade of Vomiting 
The only statistically significant relationship shown by the descriptive statistics 
was that between age and grade of vomiting (p<0.01), however this did not 
yield a statistically significant correlation coefficient (p>0.1). Regression 
analysis was therefore not undertaken.  
 
4.4.2.2 Vomiting and Admission Within 30 Days of Chemotherapy 
Of the patients who reported vomiting, 14 (15.7%), were admitted within 30 
days of chemotherapy, which was slightly higher than the rate for the whole 
study population. The patients who did not report vomiting had an admission 
rate of 13%. Pearson’s χ2 did not show this difference to be statistically 
significant (p>0.1).  The median length of stay in patients reporting vomiting 
was 1.5 days (1-8), compared to 3 days (1-28) in those not reporting vomiting. 
No statistically significant predictions were found in a logistic regression 
analysis (p>0.1).  
 
4.4.3 Fatigue 
Fatigue was explored in a similar way to nausea and vomiting. Fatigue was the 
third most reported toxicity and was reported by 159 (10.3%) of patients. 
 
Table 71.  Grade of Fatigue 
    n Valid % 
Grade of Fatigue 
0 1375 89.6 
1 151 9.8 
2 8 0.5 
Total 1534 100 
Missing 5   
Total   1539   
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The mean age of patients reporting fatigue was 63.1 years (SD=10.4), with a 
range of 38 to 82 and quartiles of 53.25 and 73.5. This compared to a mean of 
63.2 years (SD= 11.5) for patients not reporting fatigue and the same for the 
population as a whole. Clearly there was no difference in these values.  
 
 
Figure 13.  Distribution of Age in Patients Reporting Fatigue 
 
The distribution of age in patients reporting fatigue followed a similar pattern to 
that of the whole population and the other toxicities. There was a peak 
incidence at 61-70 years.  
 
When treated as a categorical variable, the differences between the age 
groups was shown to be not statistically significant (p>0.1). Performance status 
and treatment intent appeared to have no relationship with fatigue either.  
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Table 72. Disease in Patients Reporting Fatigue 
    
Number 
Reporting 
Fatigue 
% Patients in 
Disease Group 
Disease 
Breast 62 14.2% 
Gynaecology 18 11.9% 
Upper GI 20 11.8% 
Urology 11 10.3% 
Head&Neck 4 8.5% 
CNS 3 7.7% 
Colorectal 24 7.4% 
Lung 17 7.0% 
Total   159   
Pearson’s χ2=14.05 (p=0.05) 
 
Breast cancer patients reported the highest rate of fatigue, closely followed by 
gynaecology and Upper GI cancer patients with lung cancer patients reporting 
the lowest rate. 
 
Table 73. Treatment Grouped According to Cytotoxicity in Patients Reporting 
Fatigue. 
    
Number 
Reporting 
Fatigue 
% Patients in 
Treatment 
Group 
Cytotoxicity 
Mixed 18 27.3% 
Cytotoxic 138 9.7% 
Non-cytotoxic 3 5.9% 
Total   159   
Pearson’s χ2= 22  (p<0.01) 
 
Those receiving a mixed regimen of a cytotoxic and non-cytotoxic drug had a 
much higher rate of fatigue. Although this appeared to be statistically significant 
(p<0.01), the sizes of the groups was very uneven, making comparison difficult.  
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Table 74. Treatment Grouped According to the Number of Drugs in Patients 
Reporting Fatigue 
    
Number 
Reporting 
Fatigue 
% Patients in 
Treatment 
Group 
Number of Drugs 
3 62 14.8% 
1 48 8.6% 
2 46 8.6% 
Missing 3   
Total   159   
Pearson’s χ2=11.56 (p<0.01) 
 
Those receiving 3 drugs had a much higher rate of reporting than the other two 
groups, which had the same rate of fatigue. This difference was statistically 
significant (p<0.01).  
 
Table 75. Treatment Grouped According to Commissioning Status in Patients 
Reporting Fatigue 
    
Number 
Reporting 
Fatigue 
% Patients in 
Treatment 
Group 
Commissioning Status 
CDF 21 19.8% 
Baseline 138 9.7% 
Total   159   
Pearson’s χ2=10.92 (p<0.01) 
 
Those on CDF drugs had a significantly higher rate of fatigue than those on 
baseline commissioned drugs. It should be noted that the baseline group was 
significantly larger than the CDF group, which made comparisons less reliable.  
 
No statistically significant difference between the groups was found, when 
treatments were grouped according to emetogenicity (p>0.1).  
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Table 76. Multivariable Logistic Regression for Fatigue 
  
B S.E. Sig. Exp(B) 
95% C.I.for 
EXP(B) 
Lower Upper 
Age 
(continuous)  
0.008 0.008 0.33 1.008 0.992 1.024 
Number of 
Drugs  
    0.098       
  1 -0.522 0.242 0.031 0.593 0.369 0.954 
  2 -0.325 0.273 0.233 0.723 0.423 1.233 
Disease 
 
    0.336       
  CNS -0.307 0.7 0.661 0.735 0.187 2.899 
  Breast 0.164 0.387 0.671 1.178 0.552 2.514 
  Colorectal -0.468 0.394 0.236 0.626 0.289 1.357 
  Gynaecology 0.179 0.408 0.661 1.196 0.537 2.663 
  Head&Neck -0.07 0.626 0.911 0.932 0.273 3.179 
  Upper GI -0.043 0.416 0.917 0.958 0.424 2.164 
  Lung -0.509 0.422 0.228 0.601 0.263 1.375 
Constant   -2.272 0.663 0.001 0.103     
Pseudo-R2=0.01 
 
The analysis in Table 76 omitted treatment grouped according to 
commissioning status and cytotoxicity due to the uneven sizes, meaning that 
reliable conclusions were unlikely to be drawn. The analysis had a very small 
pseudo-R2 value, suggesting that it only explained a very small amount of the 
variance in fatigue. It suggested that those patients who received 1 drug were 
41% less likely to experience fatigue, compared to those who received 3 drugs 
(p=0.03). No other statistically significant relationships were shown in the 
analysis (p>0.1). This could suggest type 1 error with the descriptive statistics.   
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4.4.3.1 Grade of Fatigue 
Descriptive statistics suggested that age group, performance status, treatment 
intent and treatment grouped according to commissioning status all had 
statistically significant relationships with the severity of fatigue (p<0.05). 
However the number of patients in each group was small, due to the numbers 
of patients reporting fatigue. This made showing relationships difficult. No 
statistically significant predictions were seen in an ordinal regression analysis 
of fatigue grade using the above predictors that had shown a relationship with 
fatigue in the descriptive statistics (p>0.1).  
 
4.4.3.2 Fatigue and Admission 
Of the patients reporting fatigue, 26 (16.4%) were admitted within 30 days of 
chemotherapy. This was higher than the percentage admitted for the whole 
study population (13.1%) and higher than the rate for patients not reporting 
fatigue (12.8%). However, Pearson’s χ2 test suggested that this difference was 
not statistically significant (p>0.1).  Median length of stay in patients reporting 
fatigue was 2.5 days (1-11), which was less than the median for those patients 
not reporting fatigue of 3 days (1-28). The median length of stay for the 
population as a whole was 3 days (1-28). The length of stay of those patients 
reporting fatigue had a range of 1 to 11 and quartiles of 1 and 6. The number 
admitted was too small to perform any meaningful regression analysis.  
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5.0 Discussion 
Following a thorough literature search, which found various studies alluding to 
predictors of chemotherapy toxicity, this research set out to identify the 
predictors of chemotherapy toxicity, severity of toxicity, hospital admission due 
to toxicity and subsequent length of stay, as well as the sub-group analyses 
and secondary outcome measures alluded to in the aims and objectives in 
Section 2.0  
 
The data enabled an overall incidence of chemotherapy toxicity and admission 
to be established and the following key findings were seen as the research 
answered the questions posed by the aim and objectives described: 
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Primary Outcome Measures 
 Toxicity 
o Negative correlation between performance status and toxicity rate 
(p<0.01) and univariable analysis suggested that PS1 patients 
had a lower risk of toxicity than PS0 patients (p<0.01) 
o Breast (p=0.06) and upper GI cancer patients (p=0.02) had a 
higher risk of toxicity than urology patients  
o The higher the number of drugs, the higher the rate of toxicity 
(p<0.01) 
o In the univariable analysis, the more emetogenic a chemotherapy 
treatment, the higher the rate of toxicity ([Moderate p=0.02], [low 
p<0.01], [minimal p=0.02]) 
 Severity of Toxicity 
o In univariable analysis, as age increased, the severity of toxicity 
reduced (p=0.04) 
o Urology (p<0.01), gynaecology (p=0.04) and lung cancer patients 
(p<0.01) experienced higher grades of toxicity than breast cancer 
patients  
o Positive correlation between the number of drugs and the severity 
of toxicity but not confirmed in regression analysis (p<0.01) 
 Hospital Admission 
o Gynaecology (p=0.02), head and neck (p<0.01), upper GI 
(p<0.01) and lung cancer patients (p=0.03) had a higher risk of 
hospital admission than urology patients  
o Non-cytotoxic chemotherapy carried a lower risk of admission 
then cytotoxic in the univariable regression (p=0.02) 
o A regimen containing 2 drugs had a higher risk of admission than 
a regimen containing 1 drug (p=0.04) 
 Length of Stay 
o There was a negative correlation between age and length of stay 
(p=0.04) 
o Median length of stay reduced as the number of drugs in a 
regimen increased (p=0.05) 
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o The more emetogenic a regimen, the lower the length of stay 
(p=0.03) 
 
Breast Cancer Patients 
 Patients on 1 drug less likely to experience a toxicity than those on 3 
drugs (p=0.02) 
Colorectal Cancer Patients 
 Patients on moderately emetogenic chemotherapy more likely to 
experience toxicity than those on low emetogenic risk chemotherapy 
(p=0.08 borderline) 
Nausea 
 The higher the number of drugs, the more likely patients were to report 
nausea ([1 drug p<0.01], [2 drug p<0.01]) 
Vomiting 
 Patients on 1 drugs less likely to report vomiting than those on 3 drugs 
(p=0.01) 
Fatigue 
 Patients on 1 drug less likely to experience toxicity than those on 3 
drugs (p=0.03) 
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5.1 Population 
This study looked at the population of patients receiving chemotherapy or 
anticancer therapy in a large, UK inner city teaching hospital. Almost the entire 
population of oncology patients was included in the study, with the exclusions 
as mentioned in the methodology. Toxicity was investigated as a binary 
variable where all toxicities were combined, along with severity of toxicity, 
admissions and length of stay. No other study was found that involved a similar 
population, investigating similar outcomes.  National data was available on the 
administration of SACT, but patient level detail was not published, nor was 
analysis of the population receiving the chemotherapy, although this data was 
submitted on a monthly basis as mandated by NHS England (Public Health 
England, 2018). As such, comparison of the entire dataset was not possible, 
however when individual outcomes were considered, it was possible to 
compare these to published studies in some cases.  
 
With incomplete entries being excluded, 1539 patients were included in the 
study population. This was a large population that allowed for robust data 
analysis. The population was heterogeneous in terms of age, diagnosis, 
performance status and treatment received. The age of the population had a 
negatively skewed distribution that would be expected of a large population and 
the average age was 65 years old.  Cancer Research UK statistics suggested 
that the highest incidence of cancer was in patients over 75 years old (Cancer 
Research UK, 2015e). The number of new cases peaks in the 65-70 year old 
patients. Cancer incidence and number of patients receiving chemotherapy 
does not necessarily correlate as many people with cancer do not receive 
chemotherapy. There was no national data available on the average age of 
people receiving chemotherapy. The distribution of age, did however, relate to 
the known incidence of cancer nationally.  
 
The majority of patients were performance status 0 or 1. Only 92 (6%) of the 
patients receiving chemotherapy had a performance status of 2 or above and 3 
was the highest performance status recorded for the population. This was as 
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would be expected, as national recommendations suggest that chemotherapy 
should only be used in patients with performance status 3 or 4 with caution and 
after discussion with the MDT (Mort et al., 2008). The rationale for this is that 
chemotherapy carries risk and is associated with significant morbidity and 
giving chemotherapy to less fit patients can result in higher rates of mortality. 
No similar studies were found that reported distribution of performance status 
in a chemotherapy population.  
 
A wide variety of cancer diagnoses were included in the population. Breast, 
colorectal and lung cancers accounted for the largest groups of patients, which 
related to UK cancer statistics that suggested that breast, prostate, lung and 
bowel cancers accounted for over half of cancers diagnosed in the UK in 2015 
(Cancer Research UK, 2015e). Prostate cancer patients only made up 3.6% 
(55 patients) of the study population, however, at the time of writing,  SACT 
was only used in metastatic prostate cancer at NUH, in line with international 
guidance (Horwich et al., 2010). Advanced prostate cancer accounted for 40% 
of prostate cancer diagnoses in England in 2015, and not all of these patients 
would receive treatment, hence the lower numbers of prostate cancer patients 
in the study population (Cancer Research UK. 2015e). Central nervous system, 
cancer of unknown primary, primary peritoneum, vaginal, nasopharynx, tongue, 
hypopharynx, larynx, floor of mouth, hepatocellular, and gastro-oesophageal 
junction cancers had very low numbers and this reflected the rarity of the 
diseases and potential for other treatment modalities. Sarcomas and germ cell 
tumours had low numbers as there was a high likelihood that these patients 
received their chemotherapy on an inpatient basis and were excluded from the 
call back service. Renal cell and melanoma also had small numbers as these 
patients received their call back from a clinical nurse specialist who did not 
record the toxicity assessment in the database. In order to facilitate meaningful 
data analysis, the diseases were grouped according to the multi-disciplinary 
team to which they pertained. This mirrored clinical practice, as at NUH, as in 
most centres, clinicians tended to specialise in treating cancers of one of two 
types, usually grouped by body systems. This was the practice nationally 
(Department of Health, 2011), with peer review being centred around the 
specialist MDT.   
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Just over half of the treatments given had a palliative intent. According to 
cancer research UK, 28% of patients with cancer in the UK in 2013/14, 
received chemotherapy with a curative or palliative intent (Cancer Research 
UK, 2015d). Little data could be found on national trends in intent of treatment, 
so comparison of these figures was not possible. The SACT website did give a 
report on the top regimens by diagnostic groups. For breast cancer, the 
regimens were broken up into treatment intent, where slightly more cycles of 
chemotherapy were of palliative intent than of curative intent (Chemotherapy 
Intelligence Unit, 2015). In the national data in colorectal cancer patients, over 
four times as many palliative cycles of chemotherapy were given compared to 
curative. The other tumour sites were not broken down into intent of 
chemotherapy, however breast and colorectal were probably the two largest 
groups where chemotherapy of adjuvant or neoadjuvant intent was used. It was 
likely that treatment intent was affected by a number of other variables such as 
age, treatment and performance status. Age and performance status were 
likely to be taken into consideration when deciding  if a patient was fit enough 
for chemotherapy and adjuvant and neoadjuvant treatments were likely to be 
more intensive, so these variables would play an important role in the decision 
process. Treatment was interlinked with intent as treatments were often only 
used for one treatment intent in a particular disease, however there could have 
been overlaps such as FEC, which was used in palliative, neoadjuvant and 
adjuvant settings at NUH. Doses of drugs used across differing treatment 
intents may have been different. 
 
A significantly higher percentage of adjuvant and neoadjuvant patients were 
performance status 0 than in the palliative group, which suggested that these 
patients were fitter. This could potentially have a significant impact on the 
occurrence and severity of toxicity, and highlighted the interaction between 
treatment intent and performance status.  
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A wide variety of different treatments were used in the study population. The 
number of patients receiving each type of treatment reflected the numbers of 
patients with each cancer diagnosis. For example, breast cancer was the 
largest disease group accounting for 28.5% (439 patients) of the study 
population and the most commonly used regimen was FEC75 used in 242 
(15.7%) patients. This mirrored the national picture of FEC being the most 
commonly used chemotherapy regimen (Chemotherapy Intelligence Unit, 
2015).  It was necessary to group the treatments in order to produce 
meaningful data analysis. Several methods of grouping were explored that 
reflected the clinical relevance of the treatments. Targeted treatments account 
for an increasing number of anticancer agents and as such, treatments were 
grouped according to cytotoxicity, as most targeted therapies are not 
considered cytotoxic. A significantly higher proportion of patients received 
cytotoxic chemotherapy (92.4% [1422 patients]) compared to those who 
received non-cytotoxic or mixed treatment. This made comparison of the 
groups very difficult, as the numbers in the smaller groups were very small and 
it was not possible to rule out size effect. This method of categorisation had 
little meaning for clinical practice, as it was too broad to make any meaningful 
conclusions.  
 
Treatment was also grouped according to the number of drugs in the regimen, 
which ranged between one and three and the spread amongst the groups was 
fairly even. This method of grouping was employed as it was suspected that 
the more drugs used, the higher the level of toxicity due to the potential additive 
effects of different agents. 
 
Commissioning of chemotherapy was highly relevant to current clinical practice 
and as such treatments were grouped according to commissioning status. The 
cancer drugs fund remains a controversial means of funding chemotherapy, 
with much focus on the outcomes of treatments. Indeed in 2017, an analysis of 
outcomes of patients who received drugs funded by the cancer drugs fund, 
found that only 18 (38%) of treatments reported a statistically significant overall 
survival advantage with a median of 3.1 months (1.4-15.7) (Aggarwal et al., 
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2017). An expenditure of £1.3billon was seen from the launch of the cancer 
drugs fund until it was rationalised back into NICE in 2016. The authors 
concluded that the cancer drugs fund was not an effective use of money and 
that there was no evidence found to support a drug only ring-fenced fund. No 
reports of toxicity of drugs funded by the cancer drugs fund have been 
published and as such, toxicity may be a factor of interest when discussing the 
benefits of the cancer drugs fund. No hypothesis could be formed on the 
occurrence of toxicity in these groups and it was accepted that commissioning 
status could not have an effect on toxicity and this method of grouping was 
merely observational. Unfortunately the size of the groups was very uneven 
with 1431 (93%) of patients receiving baseline commissioned chemotherapy. 
This made comparison between the groups very difficult as size effect was very 
likely. 
 
Drugs are organised by class in the BNF (Baxter, 2018). Different drug classes 
are often associated with different toxicities and so it was decided to group 
treatments according to drug class. There are 10 classes in the BNF and these 
were employed for the grouping, however this produced groups of very uneven 
size, with the most common group accounting for 526 (34.2%) of patients with 
the smallest accounting for just 2 patients (0.1%). When dividing the treatment 
regimens into drug class, it was not possible to encompass all of the drug 
classes in the combination regimens as this would have resulted in too many 
variables to allow for robust data analysis. As such, only the first category into 
which a combination regimen falls was used. Drug class showed signs of 
having some effect on the prediction of toxicity, but to fully and accurately 
explore this effect, it would be necessary to use a much larger population to 
allow for more groups in data analysis and a robust means of classifying the 
treatments would be imperative. Drug class was omitted from further analysis.  
 
The emetogenic potential of chemotherapy agents is highly relevant in clinical 
practice. Local, national and international guidelines exist and guide antiemetic 
therapy for both treatment and prevention of chemotherapy induced nausea 
and vomiting (Hesketh et al.,  2017a). Given the relevance and potential impact 
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on practice, treatments were grouped according to emetogenicity, in 
accordance with American Society of Clinical Oncology (ASCO) guidelines. 
Similar numbers of patients were seen in the high, moderate and low groups, 
with the minimal group only accounting for 2.1% (32 patients) of the population. 
This meant that meaningful conclusions were unlikely to be drawn from the 
data. 
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5.2 Toxicity Incidence 
One of the main aims of this research was to establish an overall incidence of 
toxicity for a chemotherapy population. In the study, 542 (35.6%) of patients 
experienced a toxicity of any grade. No data reporting overall incidence of 
toxicity in a similar population was found. It is common for clinical trials to 
report toxicity rates by grade, but this is for specific drugs in specific indications 
so comparison to this population could not be made. This was, of course, a 
crude measure and could be used for descriptive purposes only as the effect or 
severity of those toxicities was not explained by this figure.  
 
Only one grade 4 toxicity was reported, and the most common grade of toxicity 
was grade 1. Nausea, vomiting and fatigue were the most commonly reported 
toxicities and nausea had the highest mean grade. These individual toxicities 
were explored later in the sub-group analyses. Fever was reported by a low 
percentage of patients but was not included in this analysis as it was not 
recorded as a graded toxicity. For the majority of regimens, the neutrophil 
count was unlikely to drop until at least a week after chemotherapy and as such 
it would not be anticipated that any chemotherapy-associated fevers would be 
seen so soon after chemotherapy as when the toxicity assessment took place 
(Brooks et al., 2012).  
 
Extravasation was reported by only three people. It was decided not to explore 
this within this study as extravasation was usually reported and managed whilst 
undergoing chemotherapy. It is likely that these three patients had an 
extravasation whilst undergoing chemotherapy and this was managed by the 
nursing staff in line with local policy and guidelines. Grade of extravasation was 
not reported and so comparison to other toxicities would not be possible. In 
order to explore extravasation further, a different data collection method would 
be required, which was beyond the remit of this study.  
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5.3 Primary Outcome Measures 
5.3.1 Toxicity 
The first primary outcome to be explored was the occurrence of toxicity as a 
binary variable. This variable was used to give an overall incidence of toxicity 
for the whole population as described above. The various predictors were 
explored to identify any effect on the occurrence of toxicity.  
 
5.3.1.1 Toxicity and Age 
There was no difference in the mean age of those patients experiencing toxicity 
and those who did not experience toxicity. When age was grouped into a 
categorical variable, there was no apparent difference between the groups. The 
age group 51-60 year olds reported the most toxicities, and the over 80 years 
old group reported the least, however these differences were not statistically 
significant (p>0.1). From a logistical regression analysis, it appeared that age 
was not associated with the occurrence of toxicity. No literature was found to 
associate age with the overall occurrence of toxicity, however Balducci and 
Extermann suggested a number of toxicities that increase with age (Balducci 
and Extermann, 2000), however much of this was based upon theory of the 
mechanisms that cause toxicity, rather than data from large scale clinical 
studies. The findings of this study were not able to draw any conclusions 
around the association of age with toxicity occurrence and certainly could not 
suggest that age is a predictor of toxicity.  
 
Hurria et al. claimed that the risk of toxicity increases with age (Hurria et al., 
2011). This was a large study with a heterogeneous population of older adults 
in several centres with several different types of cancer.  It identified being 
aged over 72 years as a risk factor for chemotherapy toxicity. It was not 
possible to corroborate this claim with the data from this study. Similarly 
Balducci and Extermann’s claimed that increasing age increases the incidence 
of toxicity could not be confirmed by this study (Balducci and Extermann, 
2000).  
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It was expected that as co-morbidity tends to increase with age, that toxicity 
may also increase, but this was not the case. The toxicities recorded in this 
study relied on patient reporting during a telephone consultation and so there 
could have been a number of other factors that influenced this, of which age 
may have been a part, but elucidating these factors was beyond the remit of 
this study.   
 
5.3.1.2 Toxicity and Performance Status 
Performance status is an important tool used regularly in clinical practice and 
can be used to influence the decision of whether or not to treat a patient with 
chemotherapy (Mort et al., 2008). It was therefore important to ascertain any 
effect of performance status on the occurrence of toxicity. The rate of toxicity 
reporting appeared to reduce as performance status increased. Only 6% (90 
patients) of the population were performance status 2 or 3 and as such it was 
difficult to draw any conclusions for these groups. However the correlation 
coefficient of -0.082 (p<0.01) between rate of toxicity and performance status 
suggested a slight inverse correlation.  
 
Logistic regression analysis showed that performance status did appear to be a 
significant predictor of toxicity when treated as an independent variable. The 
analysis produced had a low pseudo R2 value suggesting that it explained only 
a minimal amount of variance in toxicity, however there were some statistically 
significant predictions. The analysis suggested that patients with performance 
status 1 were 26% less likely to experience a toxicity than those who were 
performance status 0 (p<0.01). There was a similar effect seen in performance 
status 2 patients but this was of borderline significance (p=0.06). In the study 
population, the majority of patients were performance status 0 or 1 and only 86 
(5.6%) were performance status 2, giving a selection bias and making drawing 
conclusions around differences in patients who were performance status >2 
difficult. Performance status did not yield any statistically significant results in 
the multivariable analysis (p>0.1), however it was left in the analysis as it was 
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felt that it could have been a confounder. Performance status had likely 
relationships with other variables, for example, it may have influenced 
treatment intent or the treatment given.  
 
The findings of this study contradicted the large study by Sargent et al., which 
suggested that higher performance status patients experienced higher levels of 
toxicity (Sargent et al., 2009). Despite being a large meta-analysis, Sargent et 
al. only looked at metastatic colorectal cancer and only found specific toxicities 
that this applied to. The population in this study was much more heterogeneous 
in terms of disease compared to Sargent et al.’s review, but also in terms of 
treatment intent and treatment used. Sargent et al. found that higher 
performance status patients had a higher all-cause mortality. This could also 
have been true for the population in this study, but such outcomes were 
beyond the reach of this research. The data used in Sargent et al.’s study 
would also include toxicity over a much greater period than the acute toxicity 
included in this research, so it was possible that if the population in this study 
were followed up over a longer period of time, the findings may have changed.  
 
Performance status is a crude measure of functionality, yet remains a widely 
used clinical tool. A large number of factors could affect performance status, 
which extend far beyond any disability that may have occurred from cancer or 
chemotherapy. It is also possible that a patient could have several co-
morbidities and still remain a low performance status and this highlights the 
limitations of such a measure. The literature may have led to the hypothesis 
that toxicity would increase with performance status, but the opposite was 
found. One theory to explain this was that patients of a lower performance 
status had fewer symptoms from their cancer or other diseases and so when a 
toxicity occurred, it was more noticeable and was thus reported. Many of the 
toxicities explored were very subjective and so inter-patient variability could 
have played a large role in explaining the differences in reporting of toxicity. 
Although it did appear that performance status influenced the occurrence of 
toxicity, further research would be required to elucidate the exact effects and to 
explore and control for, the other factors affecting performance status.  
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5.3.1.3 Toxicity and Disease 
Different diseases affect patients in different ways and are associated with 
different symptoms (Neal and Hoskin, 2009). It was therefore theorised that the 
disease being treated could have an effect on toxicity.  
 
Different diseases were associated with different rates of toxicity and initial 
descriptive statistics suggested that the differences between the groups was 
statistically significant (p<0.05). CUP, skin and sarcoma cancer patients were 
excluded from analysis due to the small numbers of patients, as it was felt that 
no meaningful conclusions could be drawn regarding this group of patients. 
Upper GI cancer patients had the highest rate of toxicity reporting, followed by 
breast cancer patients. Klute et al. found that malnutrition was predictive of 
toxicity in upper GI cancers, but no literature was found that reported an overall 
rate of toxicity (Klute et al., 2015).  Similarly in breast cancer, no literature could 
be found that showed a study reporting the overall rate of toxicity, however 
Friese et al. did show that when surveyed, 872 (45%) of American women 
treated with chemotherapy for breast cancer reported a severe toxicity (Friese 
et al., 2017). This was severe according to the patient, so was of course a 
subjective measure, however an overall toxicity rate of 42.9% (186 patients) in 
breast cancer patients in this study was fairly similar, although many of those 
would have been grade 1 and not classified as severe by CTCAE criteria 
(National Cancer Institute, 2010).  
 
A multivariable logistic regression analysis suggested that breast and upper GI 
cancer patients were significantly more likely to experience a toxicity than 
urology cancer patients (p<0.05), with a Pseudo-R2=0.03, suggesting that the 
analysis explained a small amount of the variance in toxicity. No similar 
literature was found that compared toxicity rates amongst different diseases. 
Disease also appeared to have a significant effect on toxicity when included in 
multivariable regression analysis.  
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The disease being treated will dictate the regimen used and the treatment 
intent and so these variables must be considered when thinking about the 
effect of disease on toxicity. For example, adjuvant chemotherapy was not 
used in prostate cancer at the time of writing, but adjuvant chemotherapy 
accounted for 192 (43.8%) of the chemotherapy used in breast cancer. 
Different drugs were used in different diseases and as explored later in this 
study, the treatment used could have a significant effect on toxicity. Further 
research could include larger sample sizes for each disease and control for 
treatment and treatment intent. 
 
5.3.1.4 Toxicity and Treatment Intent 
Treatment intent can affect the regimen used to treat a cancer and the dose 
used. As such it was logical that it would affect toxicity. The three treatment 
intents had quite different numbers of patients, with over half of patients 
receiving treatment of palliative intent.  Logistic regression analysis revealed an 
analysis with a very small pseudo-R2 value of 0.003. This suggested that only a 
very small amount of the variance in toxicity could be explained by treatment 
intent alone. Neoadjuvant and adjuvant chemotherapy had higher rates of 
toxicity than palliative, and the regression analysis suggested that adjuvant 
chemotherapy carried a 21% higher risk of toxicity and neoadjuvant a 29% 
higher chance of toxicity than palliative chemotherapy. These predictions were 
not statistically significant, but could be considered of borderline significance as 
p<0.1 for each. Due to the differing sizes of the groups, it was possible that a 
larger sample size may have been required in order to produce statistically 
significant predictions. No literature was found that explored the effect of 
treatment intent on chemotherapy toxicity.  
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5.3.1.5 Toxicity and Treatment 
Grouping treatments according to cytotoxicity yielded very unevenly sized 
groups, with 1416 (92%) of patients receiving a cytotoxic treatment. This made 
analysis difficult as a size effect could not be ruled out. Although the highest 
rate of toxicity was seen in patients who received a mixed treatment containing 
a cytotoxic and non-cytotoxic, this was not statistically significant (p>0.1). Other 
methods of grouping the treatments may have impacted on the number in the 
cytotoxicity groups. For example, all of the patients in the mixed group would 
have received a regimen with two or more drugs. It may have been possible 
with a larger sample to elucidate some predictions of statistical significance, 
however given the overlap of cytotoxicity with other groupings of treatments, 
this may not have been necessary.  
 
The rate of toxicity increased as the number of drugs used increased and just 
under half of the patients who received 3 drugs experienced a toxicity. 
Spearman’s correlation coefficient was 0.163 (p<0.01), suggesting a fairly 
strong correlation. The logistical regression analysis confirmed the relationship 
between the number of drugs and toxicity, with patients on 2 drugs being 50% 
less likely to experience a toxicity than those on 3 drugs (p<0.01) and those on 
one drug being 59% (p<0.01) less likely to experience a toxicity than those on a 
single agent. Little data was found on the number of drugs and the occurrence 
of toxicity, however Hurria et al. suggested that the number of drugs was a 
significant predictor of toxicity in older adults receiving chemotherapy (Hurria et 
al., 2011). Hurria et al.’s study included a variety of cancer diagnoses and 
treatment intents, but was confined to patients over 65 years of age. Each 
individual drug will be associated with a number of individual toxicities as 
reported in the summary of product characteristics and clinical trials. The 
addition of another drug will also result in a new group of adverse effects and 
as such there may be an increased risk of toxicity. It was possible that certain 
drugs may have potentiated the effects of others through pharmacodynamic 
and pharmacokinetic interactions, but these were not explored in detail in this 
study.  
 
 165
As mentioned above, the commissioning status of a treatment was felt to be of 
clinical significance. The main issue with this grouping was the inequality in 
size of the groups, with 1431 (93%) of patients falling in to the baseline-
commissioning group. This meant that there was a large size effect and as 
such conclusions could not be drawn around the effect of commissioning on 
toxicity. A much larger sample size would be required to explore if 
commissioning status does have a relationship with toxicity, although clinically 
this is unlikely. 
 
Emetogenicity is highly clinically significant. It was expected that the higher the 
emetogenicity of a regimen, the more toxicities would be seen, as more 
patients would be reporting nausea or vomiting. The data confirmed this 
suspicion. The highly emetogenic group had a higher rate of toxicity than the 
other groups and the higher the emetogenic potential, the higher the rate of 
toxicity. This was confirmed by logistic regression analysis, which suggested 
that moderate emetogenic drugs had a 29% (p=0.01) lower chance of toxicity 
than those on highly emetogenic treatments. The risk reduced further to 42% 
(p<0.01) for low emetogenic and 64% (p=0.02) for minimally emetogenic 
treatments. These predictions were statistically significant. It should be noted 
that the minimally emetogenic group only had 7 patients who reported a toxicity 
and so the group was significantly smaller than the others.  A larger sample 
size would be required to confirm the findings for the minimally emetogenic 
group as when combined with other variables in the multivariable regression 
analysis, emetogenicity did not have a significant effect on toxicity (p>0.1).  
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5.3.1.6 Multivariable Logistic Regression for toxicity 
This was performed using the predictors that had been shown independently to 
have an effect on toxicity. The sample was controlled for age and confirmed 
that a number of predictors had a statistically significant relationship with 
toxicity. The pseudo R2 = 0.04, which, although still small, was higher than 
those of the individual values. Once other variables were included, 
performance status did not yield any statistically significant predictions (p>0.1).  
 
Treatment intent was not included in the analysis as the univariate analysis 
explained such a small amount of the variance.  It was, however, suspected 
that it could have an effect, but would interact with other variables. Only certain 
regimens were given within each intent, so it is likely that if a treatment was 
having an effect on toxicity, then treatment intent would be considered within 
that treatment type. Disease may have also played a role in the treatment 
intent. Adjuvant or neoadjuvant chemotherapy is only used in certain diseases 
and as such the variables of treatment intent and disease interact. Treatment 
intent could also be related to performance status. Patients with a higher 
performance status may have been less likely to receive chemotherapy of 
curative intent as they may have been deemed unable to tolerate a rigorous 
treatment of curative intent.  
 
Cytotoxicity of treatment and commissioning status were not included in the 
multivariable analysis as they had not been shown to have a relationship 
independently with toxicity. Also, as described above, these variables had a 
degree of overlap with other methods of grouping treatments.  
 
The multivariable analysis confirmed that as the number of drugs increased, so 
did toxicity. Those patients who received a single agent treatment were 54% 
less likely to report a toxicity than those on 3 drugs (p<0.01) and those on 2 
drugs 35% less likely (p=0.05). Disease played a significant role in predicting 
toxicity with an overall p=0.01. Breast and upper GI cancer patients had higher 
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toxicity rates than urological and other diseases, which were statistically 
significant (p<0.05). Many factors could have been at play here. The disease 
would dictate the treatment used and possibly the intent of treatment. Some 
patients may have recently had surgery, especially in the adjuvant treatment 
intent and as such may have been predisposed to toxicity or already 
experiencing the symptoms covered by the toxicity assessments before 
chemotherapy was given. Disease itself could have been responsible for 
certain toxicity symptoms. For example, in upper GI malignancy, nausea or 
vomiting could be caused by disease rather than treatment. In order to further 
explore the true relationship of these symptoms with chemotherapy, further 
research would be needed to assess symptoms at baseline and then following 
chemotherapy, to allow for comparison.  
 
5.3.2 Grade of Toxicity  
The grade of toxicity according to CTCAE criteria (National Cancer Institute, 
2010) is a measure of the severity of a toxicity. The majority of toxicities were 
grade 1 with grade 3 and 4 toxicities only accounting for 7 (1.3%) of toxicities 
reported. The numbers of patients reporting a grade 3 or 4 toxicity was too 
small for any meaningful analysis, but it should be remembered that this study 
only included acute toxicity within the first 24 hours following chemotherapy. It 
was possible that higher grade toxicities may have occurred later after 
chemotherapy, indeed this could have been true for all grades of toxicity. The 
hypothesis that more low grade toxicities would be seen than high grade was 
proved correct, with low grade accounting for 523 (99%) of toxicities reported. It 
was theorised that the severity of toxicity would follow the areas in which higher 
rates of toxicity were reported. Although true in some instances, this did not 
always follow for all predictors.  
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5.3.2.1 Grade of Toxicity and Age 
Age was analysed in two ways. Firstly as a continuous variable where the 
mean was compared, but this treated age as an outcome rather than a 
predictor. The second method was to group age and treat it as a categorical 
variable. The data gave contradictory conclusions about the relationship of age 
and toxicity. It appeared that the mean age of patients experiencing each grade 
of toxicity was fairly similar, although there were subtle differences. Ordinal 
logistic regression analysis of age as a continuous variable did produce a 
statistically significant odds ratio, suggesting that for every year of age 
increase, there was a 2% decrease in the grade of toxicity (p=0.04). This was a 
small effect but over large differences in age was likely to have an effect 
clinically.  
 
When categorising age into groups, it was difficult to pick up any pattern from 
the data. For grade 1 toxicities, the rate appeared to increase with age up to 
the 71-80 year old group. The same was not true for grade 2 toxicity, which did 
not seem to follow a pattern in terms of differences between the age groups. 
Ordinal logistic regression analysis did not produce any statistically significant 
predictions of grade of toxicity (p>0.1).  
 
In a review of 242 prescriptions for chemotherapy in phase I clinical trials, 
LoConte et al. found that age was not predictive of the severity of toxicity 
(LoConte et al., 2009). The results of this study would agree, however true 
comparison could not be made as LoConte et al. only looked at phase I trials, 
which would have introduced a selection bias into the population as all patients 
would have had to fulfil the trial entry criteria, which was likely to require a good 
performance status and exclude many co-morbidities, disease states and other 
variables.  
 
It was possible that age did affect the grade of toxicity, but this study did not 
produce robust enough data to conclude that age had an effect on the severity 
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of toxicity. Indeed, the data did not reveal that age influenced the occurrence of 
toxicity, but it was possible it affected severity. There was little available 
literature to suggest that age affected the severity of toxicity and the literature 
was contradictory as to the effect of age on the occurrence of toxicity.  
 
5.3.2.2 Grade of Toxicity and Performance Status 
This study has seen that performance status alone seemed to affect the 
occurrence of toxicity but when other variables were taken into account, no 
statistically significant predictions were seen (p>0.1). The data suggested that 
for grade 1 toxicities, the higher the performance status, the less grade 1 
toxicities were seen. This was not true for grade 2 toxicities and regression 
analysis could not produce any statistically meaningful predictions. It was 
possible that performance status influenced grade of toxicity, but a larger 
sample size would be required to prove this, as more performance status >1 
patients would be needed in order to prove any relationship. Again, the small 
number of grade 3 and 4 toxicities made it impossible to draw any conclusions.  
 
The only study found in the literature regarding performance status and grade 
of toxicity was Sargent et al., who studied patients with metastatic colorectal 
cancer and found higher rates of grade ≥3 nausea and vomiting in patients who 
were performance status 2 or above (Sargent et al., 2009). It was very difficult 
to find comparisons with this study as it only included colorectal cancer patients 
who underwent chemotherapy of palliative intent. Another study found that 
malnutrition was predictive of patients with a GI malignancy receiving lower 
doses of chemotherapy due to toxicity, but the grades of toxicity were not 
explored and so it was difficult to extrapolate the findings regarding co-
morbidity to this research (Klute et al., 2015).  
 
From the literature and the findings from the data in this study, it was not 
possible to associate performance status with grade of toxicity.  
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5.3.2.3 Grade of Toxicity and Disease 
Disease was found to be predictive of the occurrence of toxicity, so the 
potential relationship between disease and grade of toxicity was explored. The 
different diseases showed significantly different rates of each grade of toxicity, 
however univariate ordinal logistic regression analysis failed to show any 
statistically significant predictions (p>0.1). When entered into a multivariable 
ordinal logistic regression analysis, the disease was shown to be a predictor of 
grade of toxicity. This would suggest that other variables needed to be 
controlled, in order to illicit the effect of disease on grade of toxicity. Urology, 
gynaecology and lung cancer patients were all shown to report a higher grade 
of toxicity than breast cancer patients. It was decided to use breast as the 
reference group, as this was the largest group and a group in which a good 
number of toxicities was reported and so was felt to be an appropriate 
comparator. As described above, disease was linked to a number of other 
factors including performance status, age, treatment used and treatment intent. 
It was clear from the data that lung cancer patients tended to have a higher 
performance status than other tumour sites, which may have contributed to the 
severity of toxicity, however the same was not true for urology or gynaecology 
cancer patients. It was possible that the treatments used in the diseases may 
have played a major role in the severity of toxicity experienced.  No specific 
data in the literature, concerning the link between disease and toxicity was 
found, as many studies focused on one particular disease or treatment. 
Disease was a particularly wide variable and within each disease there was a 
wide variety of patients with different problems, symptoms and co-morbidities. 
For example in breast cancer there may have been some relatively healthy 
patients undergoing adjuvant chemotherapy, with no co-morbidities or patients 
with very advanced cancer who had a number of symptoms from their cancer 
and a poorer performance status. All of these factors may have influenced 
toxicity and its severity.  It was also impossible from this data to distinguish 
symptoms arising due to chemotherapy toxicity or from other causes such as 
disease or co-morbidities. Only a toxicity assessment at baseline would have 
helped to differentiate this.  
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5.3.2.4 Grade of Toxicity and Treatment Intent 
The research revealed no significant link between toxicity and treatment intent 
and did not reveal any statistically significant relationship between the severity 
of toxicity and treatment intent (p>0.1). No obvious differences were seen in the 
rates of each grade of toxicity. It could be theorised that adjuvant and 
neoadjuvant treatments were more likely to produce a higher grade of toxicity, 
as higher doses of more intensive treatments tended to be used. There was a 
large body of evidence suggesting that toxicity is closely related to dose (Frei 
and Canellos, 1980) and so it would follow that the higher the dose, the more 
likely and more severe toxicity was. Adjuvant and neoadjuvant chemotherapy 
patients were also more likely to be fitter as seen with the distribution of 
performance status, which could affect the severity of toxicity. As cure or 
prevention of recurrence is the aim of neoadjuvant or adjuvant chemotherapy, 
more toxicity may be tolerated than in palliative treatment where quality of life is 
a more significant goal (Neal and Hoskin 2009). However this was not evident 
from the data. It was possible that higher grade toxicities may have occurred 
later than the 24 hour period which was included in this research. Further 
research would need to follow patients up over a longer period of time. It was 
also possible that higher grade toxicities may have occurred in subsequent 
cycles, rather than the first, which were not captured by the data in this study.  
 
5.3.2.5 Grade of Toxicity and Treatment 
As with toxicity, the cytotoxicity of treatment did not reveal any significant 
differences in the grade of toxicity (p>0.1), probably because of the uneven 
spread across the groups. It was not possible to draw any conclusions 
regarding this and no literature was found that explored the cytotoxicity of 
treatment and toxicity.  
 
The number of drugs had a significant impact on the occurrence of toxicity, but 
ordinal logistic regression was not able to show any statistically significant 
relationship between the number of drugs and the grade of toxicity (p>0.1). A 
Spearman’s correlation coefficient of 0.168 (p<0.01) was found, which did 
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suggest that as the number of drugs increased, so did the grade of toxicity, 
however this was the only statistically significant relationship found. This was 
probably due to the low numbers of grade 3 and 4 toxicities and as such a 
larger sample size would be required to further explore the relationship and 
prove that there was no type 1 error. It may be that if a longer follow up time of 
toxicity was undertaken, then more grade 3 and 4 toxicities would occur and 
analysis would be more feasible. The higher likelihood of toxicity with the more 
drugs used was clear, so it would follow that the more drugs used, the more 
severe a toxicity is likely to be. If two drugs cause the same toxicity then it may 
be that an additive effect is seen, however evidence for this is beyond the 
reach of this research.  
 
As with the occurrence of toxicity, it was not possible to find any link between 
commissioning status of chemotherapy and severity of toxicity and this was 
also something for which no literature was found. 
 
There was a strong relationship between toxicity and emetogenicity, as 
predicted. It was expected that this would also have a significant effect on the 
severity of toxicity, however the data was unable to prove such a relationship 
(p>0.1). The method for classifying regimens according to emetogenicity is 
based on risk and the international guidelines used are designed to prevent the 
degree of vomiting, which would suggest that emetogenic potential is related to 
the severity of nausea and vomiting (Basch  et al., 2011). The small numbers of 
grade 3 and 4 toxicities reported, made it difficult to identify any differences 
between the emetogenic groups. A larger sample size or a longer follow up 
would be required to elucidate this. This research only considered acute 
emesis, within 24 hours of chemotherapy and delayed emesis is a well-
documented sequala of chemotherapy (Hesketh, 2008), meaning that there 
would have been a number of instances of toxicity which were not recorded in 
this data. The effect of other toxicities on the data should also be considered. 
Non-nausea or vomiting toxicities were included in the data, which would have 
been unlikely to have been affected by the emetogenicity of a chemotherapy 
regimen, which will have had a significant effect on the data. Nausea and 
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vomiting accounted for 230 (43.4%) of the toxicities reported, meaning that the 
majority of toxicities would be unrelated to the emetogenicity of chemotherapy. 
However it was possible that if nausea or vomiting was present, it could lead to 
other toxicities such as pain or fatigue, but no data was seen to support this 
theory. The specific data regarding nausea and vomiting was explored later on.  
 
5.3.2.6 Multivariable Ordinal Logistic Regression of Grade of Toxicity 
As grade of toxicity was an ordinal variable, ordinal logistic regression was 
employed. Other than for age, no statistically significant predictions were seen 
in the independent regression analyses (p>0.1). When all factors were 
considered together, the analysis did suggest some statistically significant 
relationships (p<0.05). The pseudo-R2=0.02, suggested that the analysis still 
left a large amount of variance in the data unaccounted for. The disease 
seemed to have an effect on the grade of toxicity as discussed above. This was 
as expected and could have been due to a variety of reasons. The literature 
has suggested that higher performance status is associated with more toxicity 
of severe grades in some cancers, but this research was unable to corroborate 
this (Phaibulvatanapong et al., 2018). Disease also appeared to have an effect 
on the severity of toxicity. Breast cancer patients was the biggest group, 
meaning that there may have been a size-effect, however breast cancer 
patients had a higher percentage of patients who were performance status 0 
than any other group. Breast cancer patients also received more adjuvant or 
neoadjuvant chemotherapy than any other group, which could have had an 
effect on grade of toxicity, although this research was unable to prove this. FEC 
was the most frequently used regimen in the population and this was 
exclusively a breast regimen. FEC is highly emetogenic and so this could have 
had an effect on the grade of toxicity reported if nausea or vomiting were 
experienced, but again, it was not possible to prove this statistically using this 
research.  
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5.3.3 Hospital Admission within 30 days of Chemotherapy 
As described earlier, hospital admission is a possible consequence of 
chemotherapy toxicity, which can have implications for the patient but also the 
wider healthcare system.  Hospital admissions were identified through the 
patient management system at NUH and only admission due to toxicity type 
symptoms were included. As with toxicity, it was not possible to differentiate 
between admissions due to symptoms of toxicity and those due to symptoms 
similar to toxicity but due to another cause such as disease.  
 
There was a significant number of hospital admissions, with 203 (13.1%) of 
patients being admitted. This accounted for a significant proportion of inpatient 
capacity within the oncology department at NUH and as such was a necessary 
area to research given the financial and operational implications. The effect of 
hospital admission on patients was not readily described in the literature in 
terms of comparisons of outcomes with patients not admitted. The reasons for 
hospital admission were fairly varied with 37 different reasons. Some of these 
reasons had overlap and so were consolidated for presentation in Table 32. 
Many of the reasons for admission only applied to a single patient, making 
comparison very difficult.  
 
For the purposes of analysis, hospital admission was treated as a binary 
variable. This showed the patients who were admitted within 30 days of the first 
cycle of chemotherapy. Thirty days may have been an arbitrary number, but 
was based on the 2008 report of mortality within 30 days of chemotherapy 
(Mort et al., 2008). It was also a measure used in clinical practice, both 
nationally and locally. At NUH all patients who die or have a critical care 
admission within 30 days of a cycle of chemotherapy, have their case 
discussed at a monthly morbidity and mortality meeting and the measure is felt 
to be highly relevant to clinical practice. The mean number of days that patients 
were admitted following the first cycle of chemotherapy was 8.2 (SD= 5.6), 
which suggested that the admissions seen may not have been due to the 
toxicities reported in this dataset as they only covered the first 24 hours after 
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chemotherapy. Only 9 patients were admitted within the first 24 hours of 
chemotherapy.  It could have been the case in some instances that admissions 
were due to the acute toxicities reported, that worsened in the period after 
chemotherapy, necessitating admission.  
 
Very little literature was found regarding hospital admission due to 
chemotherapy toxicity and so making comparisons to this data was not 
possible in many instances.  
 
5.3.3.1 Hospital Admission and Age  
As with toxicity, age was analysed as a continuous variable and also as a 
categorical variable.  There was no difference in the mean age of those 
patients who were admitted, compared to those who were not. The rate of 
admission was highest in the 51-60 year old age group and lowest in the 41-50 
year old age group, but a logistical regression analysis was not able to prove a 
statistically significant relationship between age and admission (p>0.1). 
Benard-Laribiere et al. found that patients admitted with an adverse drug 
reaction were significantly older than those admitted for other reasons (Bénard-
Laribière et al., 2015), however this study was over a small period of time and 
was not specific to chemotherapy, so true comparison was not possible. A 
larger sample size would be required in order to further explore the effect of 
age on hospital admission within 30 days of chemotherapy. Not all toxicity 
requires admission. It may have been that higher grades of certain toxicities 
could be managed at home, whereas lower grades of other toxicities 
necessitated hospital treatment.  
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5.3.3.2 Hospital Admission and Performance Status 
No statistically significant differences were seen in admission rates between 
the performance status groups (p>0.1). The higher performance status groups 
had small numbers of patients and so a larger sample size would be required 
to establish any effects of performance status on admission. Aliyu et al. 
suggested that in a general population that included people without a cancer 
diagnosis, people with an impairment of functional state had a higher risk of 
hospital admission (Aliyu et al., 2003). It could not be taken from this that 
patients with a poorer performance status had a higher risk of admission due to 
chemotherapy toxicity, as there were many other variables not included in the 
research that would apply to patients on chemotherapy. Aliyu et al. also only 
looked at elderly patients, so the population was not comparable to the 
population in this research. It was therefore not possible to make any 
judgement on the effect of performance status on hospital admission.  
 
5.3.3.3 Hospital Admission and Disease 
Admission rates were different amongst the different disease groups with upper 
GI and lung cancer patients having the highest rates of admission. As with 
toxicity, CUP, skin and sarcoma were omitted from analysis due to the very low 
numbers. Pearson’s Χ2 test showed that the differences between the groups 
were statistically significant (p<0.01). The lowest rate of admission was seen in 
the urology cancer patients. A univariate logistic regression analysis produced 
significant predictions, confirming that gynaecology (p=0.02), head and neck 
(p<0.01), upper GI (p<0.01) and lung cancer patients (p<0.01) were all more 
likely to be admitted than the reference group, which was urology cancer 
patients. Pseudo-R2 = 0.02, suggesting that the analysis only explained a small 
amount of the variance in admission rates. These effects continued to be seen 
in a multivariable regression analysis, suggesting that disease was a predictor 
of hospital admission. As stated previously, it was not possible to distinguish 
between admission for true chemotherapy toxicity and admission due to 
symptoms from another cause such as disease. There was also the possibility 
that patients had undergone another modality of treatment such as surgery or 
radiotherapy that could account for the symptoms. The four diseases that were 
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associated with a higher risk of admission, are associated with a wide variety of 
symptoms which could overlap with the symptoms of toxicity (Neal and Hoskin, 
2009). As with the other outcomes, disease will dictate a number of other 
variables such as treatment intent and the treatment used. In order to explore 
the relationship between disease and hospital admission further, it would be 
necessary to measure baseline toxicities then measure again after 
chemotherapy to identify those symptoms arising from toxicity.  
 
5.3.3.4 Hospital Admission and Intent of Chemotherapy 
There did not appear to be significant differences in the admission rate 
between the different intents of treatment and a logistic regression analysis 
confirmed this (p>0.1). This was not unexpected as it was not possible to prove 
a link between treatment intent and toxicity or severity of toxicity. With a larger 
sample size, wider variances may have been seen and as described previously 
there was a likely interaction of treatment intent with other variables.  
 
5.3.3.5 Hospital Admission and Treatment 
The effect of treatment on admission was explored. As it was expected that 
toxicity would differ between different treatments, it was also anticipated that 
this would be true for admission.  
 
Again the wide variance in the sizes of the groups when treatment was 
grouped according to cytotoxicity, meant that comparing the groups was 
difficult, with only one admission in the non-cytotoxic group. However, logistic 
regression analysis gave a pseudo-R2 = 0.06, suggesting that the analysis did 
go some way to explaining some of the variation between admission rates but 
left a large amount of the variance unexplained. Patients on non-cytotoxic 
chemotherapy appeared 10% less likely to be admitted than those on a mixed 
regimen. Although this difference was statistically significant (p=0.02), it was 
difficult to ascertain how this would be useful to clinical practice as the groups 
were very broad.  
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As toxicity increased with the number of drugs used, it was anticipated that 
admission rates would be higher with the more drugs used. This was shown 
not to be the case, with patients who received two drugs having the highest 
admission rate. Logistic regression analysis showed that those on 2 drugs were 
63% more likely to be admitted than those on 3 drugs (p<0.01), which did not 
follow the same pattern as toxicity. It may have been that delayed toxicities 
were higher in these patients, but this was not recorded in this research. It was 
also possible that the patients admitted in the 2 drug group were admitted for 
symptoms not due to toxicity, but without a baseline toxicity assessment, it was 
not possible to establish this. Another possibility was that the 2 drug regimens 
contained more toxic agents or agents associated with symptoms requiring 
hospital admission.  
 
As with toxicity, no statistically significant relationship was seen with hospital 
admission and commissioning status of chemotherapy (p>0.1). As the cancer 
drugs fund is costly and the benefits of its use have been under question 
(Aggarwal et al., 2017), establishing the additional costs and burden of 
resources associated with it, such as admission due to toxicity, was important. 
Unfortunately this research was not able to establish any conclusions regarding 
this.  
 
As emetogenicity was associated with toxicity, it was expected that it would 
have an effect on hospital admission. However, nausea and vomiting was the 
reason for admission in 20 cases with diarrhoea and vomiting being cited as 
the reason for another 5 admissions. It was therefore not unexpected that a 
statistically significant relationship could not be identified between 
emetogenicity and hospital admission (p>0.1). Patients on moderately 
emetogenic drugs had a higher rate of admission than the other groups, but 
logistic regression did not reveal any statistically significant predictions (p>0.1).  
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5.3.3.6 Multivariable Logistic Regression of Hospital Admission 
The factors that had shown relationships with hospital admission were included 
in a logistic regression analysis controlled for age. The analysis had pseudo-R2 
= 0.02, suggesting that a small amount of variance was explained by the 
analysis. The number of drugs had an overall significant p-value (p=0.04), with 
patients on 2 drugs being more likely to be admitted to hospital than those on 3 
drugs. This was contradictory to the findings for toxicity, where the more drugs 
used, the more toxicity was seen. It could be that with a larger sample size, the 
effect of number of drugs on hospital admission would become clearer.  
 
Disease was the only other factor that had a significant impact on hospital 
admission. As in the individual analyses, patients with gynaecological (p=0.02), 
head and neck (p<0.01), upper GI (p<0.01) and lung cancers (p<0.03) had 
significantly higher rates of admission than the reference group, which was 
urology. The size of the effects were also large, suggesting that disease had a 
significant impact on the risk of admission. As explained earlier, it was not 
possible to distinguish between admissions truly due to chemotherapy toxicity 
and those due to symptoms from other causes. The analysis controlled for age 
and treatment by the number of drugs, but it did not include any other 
variables, which may have had an effect on admission. Other variables could 
have an effect within disease such as intent of treatment and treatment used (if 
grouped in alternative ways). A larger sample size or investigating admission 
over a prolonged period may yield more robust data that could confirm the true 
effect of the other variables on admission. The disease sites that had higher 
admission rates, were those sites associated with higher grades of toxicity, 
which agreed with the initial hypothesis.  
 
5.3.3.7 Toxicity and Hospital Admission 
In order to assess the effect of the toxicities reported on hospital admission, the 
patients experiencing a toxicity were separated from the rest of the population. 
Of those patients who reported a toxicity, 77 (14.2%) were admitted. This was 
in comparison to a rate of 13.1% (203 patients) for the entire population and 
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12.8% (125 patients) for those patients who did not experience a toxicity. A 
logistic regression analysis did not yield any statistically significant prediction 
around admission and toxicity (p>0.1). It may have been that delayed toxicity 
played more of a role in predicting the risk of admission, but this was not 
included in this research.  
 
The grade of toxicity seemed to have an effect on hospital admission with 
higher rates of admission seen in the higher grades of toxicity, however the 
size of the groups did not allow for any reliable assumptions to be made. It may 
have followed that the more severe a toxicity, the more likely a hospital 
admission was, as it could require more intensive intervention.  By definition, a 
grade 3 toxicity is severe or medically significant and indicates hospitalisation 
or prolongation of hospitalisation and grade 4 toxicity is life threatening 
(National Cancer Institute, 2010). 
 
It was seen that upper GI cancer increased the risk of experiencing a toxicity, 
the upper GI group also had higher risk of admission in regression analysis. 
This was not true for other diseases. Gynaecology and lung cancer patients 
were more likely to report a higher grade of toxicity according to the ordinal 
regression analysis in Table 31. These disease groups were also shown to 
have a higher rate of admission in the analysis in Table 35. It may have been 
that the original hypothesis of higher rates of hospital admission being seen 
where higher grades of toxicity were seen was correct, however beyond the 
parameter of disease, this research was not able to demonstrate any further 
relationships. A larger sample size with more patients experiencing grade 3 or 
4 toxicity would allow further elucidation of this.  
 
5.3.4 Length of Stay 
The length of stay was investigated for all patients who were admitted. In order 
to do this, patients who were admitted were separated from the rest of the 
population. The median length of stay was 3 days for the entire population. No 
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data was found in the literature, which reported a length of stay following 
admission for a chemotherapy related toxicity in a general population. Cuppens 
et al. reported a mean length of stay of 9.5 days for lung cancer patients 
admitted to hospital, but this was only a single disease and included admission 
for disease related effects as well as toxicity so could not be compared 
(Cuppens et al., 2016). It was seen that some of the factors explored had an 
effect on the risk of hospital admission, so it was suspected that length of stay 
would also be affected. Due to time constraints, and given that there were not a 
large number of hospital admissions, only descriptive statistics were employed 
in order to explore length of stay. Regression analysis did not prove possible 
for this research, but may be an area for future research to focus on. Length of 
stay has clear implications for both patients and the health economy and so is 
an important area for research to focus on.  
 
Many factors may affect length of stay as described by Clarke (Clarke, 1996). 
There are obvious implications on the health economy and the patient. Patient 
factors such as co-morbidity and disease severity affect length of stay, as do 
healthcare system factors such as geographical location, physician practice 
style and method of payment. When considering length of stay in a wider 
context than the NHS, it is important to consider these factors.  
 
5.3.4.1 Length of Stay and Age 
As previously, age was analysed as a continuous variable and also as a 
categorical variable. Median length of stay was highest in the 21-40 year old 
age group and lowest in the over 70 year olds, but both of these groups had far 
fewer admissions than the other groups, so this may have affected the data 
validity. For the rest of the groups, the median length of stay was fairly similar 
and was close to the median for the population. Kruskall-Wallis test gave 
p=0.29, confirming that the differences between the groups was not statistically 
significant. 
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When treating age as a continuous variable, a statistically significant 
Spearman’s correlation coefficient of -0.146 was seen (p=0.04), suggesting that 
as age increased, length of stay decreased slightly. This was unexpected as it 
was known that older patients were more likely to have co-morbidities and be 
potentially more frail and less able to tolerate chemotherapy (Hurria, 2014). 
The literature was contradictory around age and toxicity, although several 
sources suggested that older patients were more vulnerable to toxicity. It could 
therefore have been theorised that admission could have been more likely and 
length of stay longer in older patients as they were less able to tolerate toxicity 
than younger patients. However the data in this research was not able to draw 
conclusions around the relationship of age and length of hospital stay.  
 
5.3.4.2 Length of Stay and Performance Status 
Performance status did not appear to affect length of stay with no statistically 
significant differences seen between the groups (p>0.1). The low numbers of 
patients in the performance status >1 groups meant that there was not enough 
data to reliably identify any relationships. Co-morbidity was suggested as a 
factor that affects length of stay by Clarke (Clarke, 1996), but this research was 
unable to reach any conclusions regarding this.  
 
5.3.4.3 Length of Stay and Treatment Intent 
It was not possible to show a link between toxicity, severity of toxicity or 
admission and treatment intent. The distribution of patients in each group was 
varied and as such made comparison difficult. The median length of stay did 
appear significantly shorter in the neoadjuvant group and this group had a 
much smaller standard deviation than the other groups, so it may have been 
that patients receiving neoadjuvant chemotherapy had a shorter length of stay 
than other patients. This was of borderline statistical significance (p=0.09). As 
discussed previously, intent of treatment was linked to a number of other 
variables. The neoadjuvant group had the highest proportion of performance 
status 0 patients, suggesting that patients in this group were generally fitter 
than patients who received palliative or adjuvant chemotherapy. Neoadjuvant 
 183
chemotherapy was used in only a few of the diseases and so disease may 
have had an effect within these groups.  A larger sample size obtained by 
looking at admissions in another centre or over a longer period of time would 
be required to confirm this suspicion.  
 
5.3.4.4 Length of Stay and Disease 
The length of stay was quite different among the different disease groups, but 
these differences were not statistically significant (p>0.1). Again the numbers in 
each group was low and the variance in each group fairly wide. There was little 
available literature for comparisons, although interestingly, median length of 
stay in the lung cancer patients was 2 days, which was significantly lower than 
the 9.5 days reported by Cuppens et al., however that study included 
admissions for reasons other than chemotherapy toxicity, so direct 
comparisons could not be made (Cuppens et al., 2016). Clarke suggested that 
severity of disease was a factor that affected length of stay, however this was 
not recorded in the data in this research and so could not be commented upon 
(Clarke, 1996). Clarke’s review was also of a much more general population 
and not restricted to chemotherapy toxicity as this research was. Further data, 
possibly from additional centres would be needed to further assess the effect of 
disease on length of stay. Data from other centres would allow a control for 
variance in local practice to be introduced and a national database would allow 
for trends be monitored across multiple localities.  
 
5.3.4.5 Length of Stay and Treatment 
When grouped according to cytotoxicity, drug class and commissioning status, 
there were no statistically significant variations in length of stay (p>0.1).  
 
When grouped according to number of drugs, length of stay was significantly 
shorter, the higher the number of drugs used. There were a larger number of 
patients in the group who received 2 drugs, but the other two groups had 
similar numbers of patients. Spearman’s correlation coefficient gave a 
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statistically significant correlation coefficient of -0.149 (p=0.04), which 
suggested that there was an inverse correlation between the number of drugs 
and length of stay. This was an unexpected finding, as toxicity and severity of 
toxicity both increased with the number of drugs used it was anticipated that 
admission rate and length of stay would also increase, however the opposite 
was true. It may have been that the toxicities seen in the patients receiving 
higher numbers of drugs were self-limiting or managed at home, rather than 
necessitating admission. It could also have been that the toxicities that did 
result in hospital admission, were more easily and quickly managed in the 
patients receiving a higher number of drugs than those who received fewer 
drugs. The groups in the number of drugs all had wide variances but had 
similar standard deviations, so it was likely that they were comparable.  
 
When grouped according to emetogenicity, length of stay was significantly 
different between the groups (p=0.03). Length of stay appeared to reduce the 
higher the emetogenicity of a regimen. The minimally emetogenic group could 
not be considered in the analysis as it contained only one patient. Each group 
had a wide variance. All toxicities were included in this analysis and as pointed 
out previously, admissions for reasons other than nausea or vomiting were 
included, which may have skewed the data. Also the toxicity reported in this 
study would only include acute nausea or vomiting and so it was probable that 
many of these admissions were for delayed nausea or vomiting. No data was 
available in the literature for comparison of admission or length of stay in 
chemotherapy induced nausea and vomiting.  
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5.4 Sub-group Analyses 
Following on from the primary outcome measures, sub-group analyses were 
undertaken to further explore the data according to the three largest tumour 
groups and the three most frequently reported toxicities.  
 
5.4.1 Breast Cancer 
Breast cancer patients were the largest group of the study population and 
national data suggested that high levels of chemotherapy are used in breast 
cancer patients (Chemotherapy Intelligence Unit, 2014). Breast cancer is also 
known to be the most common cancer in females in the UK (Cancer Research 
UK, 2014). This means that toxicity could have wide implications for the 
healthcare provider and the health economy.  
 
The age distribution was not too dissimilar from the whole population with a 
peak incidence between 51 and 70 years old. This was as expected, as the UK 
has a national breast screening programme between the ages of 50 and 70 for 
all women (England, 2018) and these age groups see the highest number of 
cases, despite incidence of breast cancer increasing with age (Cancer 
Research UK, 2015c). The mean age of the breast cancer patients was 59.1 
years (SD= 11.5), which was slightly younger than the mean for the entire 
population of 63.2 (SD=11.4) years. Nearly three-quarters of patients were 
performance status 0, which was higher than the 50% for the whole population, 
suggesting that breast cancer patients were perhaps fitter then the rest of the 
population. This could have been explained by the fact that the majority of 
patients in the breast group received adjuvant or neoadjuvant chemotherapy. 
This would mean that they had localised disease, which was unlikely to impair 
function, as perhaps a localised lung cancer might. It was probable that this 
group of patients had fewer co-morbidities than other disease groups, such as 
in lung cancer where smoking is prominent (Cancer Research UK 2015f). 
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Breast cancer patients received a wide variety of different regimens, which 
introduced a variable that may have had a significant effect on the outcomes 
for breast cancer patients, but which also created a large number of groups, 
making comparison difficult. Treatments were grouped according to the 
methods that the whole population was subjected to. Over 60% (278 patients) 
of breast cancer patients received a regimen containing 3 drugs. This was as 
expected as it was seen that FEC was the most common regimen used and 
this was solely used in breast cancer. This was a contrast to the whole study 
population where the majority of patients received a 2-drug regimen. The 
breast cancer patients received a significantly higher percentage of highly 
emetogenic chemotherapy than the whole population and this was largely due 
to the high usage of FEC, which as an anthracycline/cyclophosphamide 
combination, is classed as highly emetogenic (Basch  et al., 2011).  
 
5.4.1.1 Toxicity in Breast Cancer 
Toxicity of any grade was reported by 180 (42%) of breast cancer patients, 
which was slightly higher than 530 (35.6%) for the general population. As with 
the whole population, the breast cancer patients reported nausea, vomiting and 
fatigue most frequently. There was little comparable literature found that 
evaluated the overall incidence of toxicity. Friese et al. stated that when 1945 
American patients with breast cancer treated with chemotherapy were 
surveyed, 875 (45%) reported a toxicity that they considered severe (Friese et 
al., 2017). This included delayed toxicity and toxicity beyond the first cycle of 
chemotherapy, neither of which this study recorded. Friese et al. used a 
questionnaire completed by patients, which could also have had an effect on 
the results when compared to this study, where nurses completed a telephone 
assessment of toxicity. There may have been differences in rates of reporting 
depending on the method of reporting. No literature was found to support this 
theory. Schonerr et al. found that only 7 (0.9%) of patients had an absence of 
toxicity, however this included delayed toxicity, which was beyond the scope of 
this research (Schönherr et al., 2012).  
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Multivariable logistic regression was undertaken based on the factors shown to 
affect toxicity in the whole population. The analysis yielded pseudo-R2=0.06, 
suggesting it explained some of the variance in toxicity, whilst leaving a large 
amount of variance unexplained. The only statistically significant prediction 
from the analysis was around the number of drugs given. Patients on one drug 
were significantly less likely to experience a toxicity than those on three drugs 
(p=0.02). This was the same as for the whole population. The most commonly 
used three -drug regimen used in breast cancer patients was FEC, which 
accounted for 58.7% (257 patients) of all chemotherapy given to breast cancer 
patients. This suggested a large size effect, meaning that true comparison may 
not have been possible. However FEC is known to be highly emetogenic and 
associated with a high incidence of toxicity, so it was not unexpected that FEC 
produced higher levels of toxicity (Hesketh et al., 2017a). The vast majority of 
FEC treatments were of adjuvant or neoadjuvant intent, which may have 
affected the levels of toxicity reported. It is known that dose has a significant 
impact on the occurrence of toxicity (Frei and Canellos, 1980), but this was not 
recorded in the research. It may have been that different doses were used for 
different treatment intents. Booth et al. suggested that age younger than 40 
years, nausea expectation, not eating before treatment and low alcohol use 
were risk factors for nausea and vomiting in 143 patients treated with 
chemotherapy for breast cancer (Booth et al., 2007). This was a small study 
and included delayed toxicity and factors not recorded in this research, so 
direct comparison of results was not possible.  
 
No other factors were shown to have a statistically significant effect on toxicity 
in the breast cancer patients (p>0.1). In order to explore this further, a larger 
sample size would be required, or recording of toxicity for a longer period in 
order to obtain information on delayed toxicity.  
 
5.4.1.2 Grade of Toxicity in Breast cancer patients 
Reporting rates for each grade of toxicity were similar in the breast cancer 
patients to those for the whole population. No grade 3 or 4 toxicities were 
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reported. Some of the regimens used in breast cancer are known to be 
associated with high levels of nausea and vomiting and this can be in the form 
of acute emesis (Hesketh, 2008), so it was expected that some higher grade 
toxicities would have been seen, but this was not the case. It could be that 
higher grade toxicities were seen beyond the first 24 hours after chemotherapy 
when the nurse assessment of toxicity took place. This finding concurred with 
the study by Schonherr et al., which reported low rates of grade 3 or 4 toxicities 
in patients on FEC chemotherapy, which made up the majority of the breast 
cancer patients in this study (Schönherr et al., 2012).  
 
Ordinal logistic regression analysis was undertaken to explore the relationship 
between the predictors and the grade of toxicity seen in breast cancer patients. 
The same factors were included in the analysis that were used in the analysis 
when looking at toxicity severity in the whole population. As with toxicity, the 
only statistically significant prediction was with the number of drugs. It was 
seen in the previous analysis that the more drugs given, the higher the rate of 
toxicity reporting (p<0.01). It also appeared that the higher the number of drugs 
given, the more severe a toxicity was likely to be, although this was not 
statistically significant (p>0.1). This was as expected, and FEC account for 
nearly all of the 3 drug regimens in breast cancer patients (East Midlands 
Cancer Alliance 2018). The Friese et al. study reported that 872 (45%) of 
women receiving chemotherapy for breast cancer reported a toxicity as severe 
(Friese et al., 2017), but it was not possible to make a direct comparison to this 
research, as in the Friese et al. study, toxicity was not reported in terms of 
CTCAE criteria as it was in this study (National Cancer Institute, 2010), so what 
was severe in one study, may not have been classed as severe in another. No 
other data pertaining to the grade of toxicity in breast cancer patients was 
found. 
 
5.4.1.3 Hospital Admission and Length of Stay in Breast cancer patients 
Breast cancer patients had a slightly lower admission rate than the general 
population, and median length of stay was the same. No significant predictors 
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of admission were found (p>0.1). The only data found in the literature, 
pertaining to admission in breast cancer patients, was by Pittman et al. and 
was a small single-centre study that reported an admission rate of 13% (19 
patients) (Pittman et al., 2015). This was slightly higher than the 10.3% 
reported in this study, but Pittman only included those patients treated with 
curative intent, whereas this study included those who received palliative 
chemotherapy, which was likely to impact the data for reasons discussed 
previously. None of the data suggested that admission rate or length of stay 
was particularly different in the breast cancer patient group compared to the 
whole population and no literature around general admission rate and length of 
stay was found for breast cancer patients. The studies reporting toxicity in 
breast cancer patients did not report any admission or length of stay data.  
 
5.4.2 Colorectal 
Colorectal cancer patients were the second biggest disease group, accounting 
for a fifth of the study population. Within this group there were several 
diagnoses including colorectal and anal cancer. The number of patients seen in 
this group compared with cancer incidence data with colorectal cancer being 
the third most common cancer in men and women in the UK (Cancer Research 
UK, 2014). According to national data, colorectal cancer was the second 
largest group of patients who received chemotherapy in the UK in 2014 
(Chemotherapy Intelligence Unit, 2015) 
 
Toxicity was reported by 116 (35.5%) of colorectal cancer patients, which was 
very similar to the reporting rate of 530 (35.6%) for the entire population. The 
mean age of the colorectal cancer patients was 64.5 years (SD=10.6), which 
was marginally older than that of the whole population of 63.2 years (SD= 
11.4). The incidence of colorectal cancer peaks at age 65-80 years (Cancer 
Research UK, 2015b), so the mean age of the bowel patients in this population 
was slightly lower. In 2013-14 31% of patients with colon cancer and 42% of 
patients with rectal cancer had chemotherapy in the UK, which explains why 
the mean age in this population was slightly lower than the age where bowel 
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cancer incidence is the highest (Cancer Research UK, 2015a), with Cancer 
Research UK suggesting that the proportion of patients having chemotherapy 
is strongly influenced by stage of disease at diagnosis, but age also plays a 
role in the likelihood of receiving chemotherapy. 
 
The distribution of performance status was similar to the whole population with 
only one patient performance status 3. This may have been reflective of 
patients with colorectal cancer or may have been reflective of those patients 
with colorectal cancer who were considered fit enough candidates for 
chemotherapy.  
 
The distribution of the intent of chemotherapy in the colorectal cancer patients 
was similar to that in the whole population and this was as expected from 
clinical practice where the largest proportion of patients receive palliative 
chemotherapy compared to adjuvant and neoadjuvant regimens.  
 
As in breast cancer patients, a wide variety of different treatments was used in 
the colorectal cancer patient group. Only 5 drug classes were seen in the 
colorectal cancer patients and despite the difficulties with the accuracy of 
recording, this did probably reflect clinical practice at the time. The grouping of 
regimens by the number of drugs used, was similar to the whole population, 
with most patients receiving one or two drugs. This was in contrast to the 
breast cancer patient group, where significantly more patients received three 
drugs.  The chemotherapy used in the colorectal cancer patients appeared to 
be much less emetogenic than that given to the whole population and certainly 
much less than in the breast cancer patients. Again, this reflected what was 
seen in clinical practice with few highly emetogenic regimens seen and means 
that treatment was likely to be having a larger effect on toxicity than disease 
and other variables.  
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5.4.2.1 Toxicity and Colorectal cancer patients 
Multivariable logistic regression analysis of the factors known to affect toxicity 
in the general population, was applied to the colorectal cancer patients. It 
yielded pseudo-R2=0.08, which was actually higher than seen in previous 
similar analyses for breast cancer patients and the population as a whole, 
suggesting that for colorectal cancer patients, the analysis explained slightly 
more of the variance in toxicity, however, it did still leave a significant amount 
of variance unexplained. Emetogenicity produced a borderline statistically 
significant prediction (p=0.08), suggesting that those on a moderately 
emetogenic treatment were significantly more likely to experience a toxicity 
than those on a low emetogenic treatment. This mirrored what was seen 
previously in the whole population and the breast cancer patient group. Only 11 
(3.3%) patients reported vomiting in the colorectal cancer patient group which 
was lower than the entire population which had a rate of 89 (5.8%) and nausea 
was reported by 40 (12.2%) of patients, which is lower than that of the whole 
population which was 245 (15.9%). It was possible that those in the moderately 
emetogenic group reported toxicities other than nausea and vomiting, but 
emetogenicity still appeared to affect the occurrence of toxicity. Further 
research would be needed to explore this. Chua et al. suggested that 
increasing age increases the risk of grade 3 or higher haematological toxicities 
(Chua et al., 2011) .The review also stated that several trials found that higher 
performance status increased the incidence of non-haematological toxicity, but 
this study was unable to prove this. Chua et al. also explored the effect of race 
on toxicity. This was not recorded in this research. No other literature was 
found that explored toxicity in colorectal cancer patients receiving 
chemotherapy.  
 
5.4.2.2 Grade of Toxicity in Colorectal cancer patients 
The rates of each grade of toxicity reported in the colorectal cancer patients 
was similar to the rates for the entire study population. A multivariable ordinal 
regression analysis of the factors shown to affect grade of toxicity for the entire 
population, found that emetogenicity had a borderline statistically significant 
effect on the grade of toxicity (p=0.09), with moderately emetogenic 
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chemotherapy seemingly increasing the grade of toxicity marginally. As 
emetogenicity increased the risk of toxicity occurring, it followed that it also 
increased the severity of those toxicities. It may have been possible that the 
grade of toxicity affected how likely a patient was to report a toxicity, but this 
was a theory for which no evidence was found and would require more 
research around reporting methods in order to elucidate it further. The review 
by Chua et al. was the only literature found that looked at the grade of toxicity 
and the only link found was that increasing age was predictive of grade 3 or 
higher haematological toxicity but no data was published regarding severity of 
toxicity (Chua et al., 2011).  
 
5.4.2.3 Hospital Admission and Length of Stay in Colorectal cancer 
patients 
There were only 32 patients admitted in the colorectal cancer patient group. 
This number proved too small to identify any risk factors for admission and thus 
length of stay. Tracking these patients over a longer period of time or looking at 
patients treated in other centres would produce a larger number of patients 
admitted that may result in more meaningful analysis. No data was found in the 
literature on admission due to chemotherapy toxicity in colorectal cancer 
patients.  
 
5.4.3 Lung Cancer 
Lung cancer patients was the third largest group in the population, accounting 
for 242 (15.7%) of the population. This was almost in keeping with national 
statistics which list lung cancer as the third most common cancer in males and 
females in the UK (Cancer Research UK, 2014). According to Cancer 
Research UK, in 2013-14, 68% of patients with small cell lung cancer and 25% 
of those with non-small cell lung cancer received chemotherapy (Cancer 
Research UK, 2015f). National SACT data reported lung cancer patients as the 
third largest group of patients who received chemotherapy in 2014 in the UK 
(Chemotherapy Intelligence Unit, 2015). These would suggest that a large 
proportion of lung cancer patients do not receive chemotherapy and that is why 
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it was the third largest group in this research rather than second largest as with 
national incidence statistics.  
 
Lung cancer incidence peaks in older patients with most cases being seen in 
65-79 year olds (Cancer Research UK, 2015f). The mean age in the lung 
cancer patient group was 67.0 years (SD= 9.1), slightly higher than the mean 
for the whole population of 63.2 years (SD=11.4).  
 
The lung cancer patient group had a significantly lower proportion of patients 
who were performance status 0 than the whole population and lower when 
compared to the breast and colorectal cancer patient groups. The lung cancer 
patient group also had the highest rate of performance status 3 patients seen. 
This suggested that the lung cancer patients were less fit than the whole 
population and less fit than breast and colorectal cancer patients. Lung cancer 
is heavily associated with smoking, with 72% of cases being caused by 
smoking (Cancer Research UK, 2015f). It is known that smokers have higher 
cardiac risk factors and are at risk of a number of other co-morbidities, so it 
was likely that the lung cancer patients in this research had more co-
morbidities than other groups. This could have had an effect on the toxicity 
reporting as with more co-morbidities it was more difficult to ascertain if the 
symptoms reported were due to true chemotherapy toxicity or arising from pre-
existing conditions. A baseline toxicity assessment would have helped to clarify 
this.  
 
There was a very high proportion of chemotherapy for palliative intent in the 
lung cancer patient group than in the whole population and the other disease 
groups. This reflected the poorer prognosis and survival data associated with 
lung cancer (Cancer Research UK, 2015f). Significantly less adjuvant and 
neoadjuvant treatment was seen in the lung cancer patient group and this 
probably reflected the higher proportion of patients who present with advanced 
disease that is not curable (Cancer Research UK, 2015f). Surgery for lung 
cancer is highly invasive with a high mortality and morbidity rate and so is only 
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suitable for fitter patients (Neal and Hoskin, 2009). Given that lung cancer 
patients are less fit than others, it would follow that fewer patients received 
curative therapy.  
 
As with the other tumour sites, a wide range of regimens was used in the lung 
cancer patient group. Two-drug regimens made up the majority of treatments 
given to lung cancer patients, and this was quite different to the population as a 
whole. The majority of regimens were either highly or moderately emetogenic, 
with very small proportions of low and minimal regimens used.  
 
5.4.3.1 Toxicity in Lung Cancer 
A logistic regression analysis for toxicity using the predictors shown to effect 
toxicity in the other tumour sites yielded no statistically significant results 
(p>0.1). This was unexpected, especially given the high proportion of highly or 
moderately emetogenic chemotherapy used, which if following the patterns of 
the whole population or the breast and colorectal cancer patient groups, would 
have resulted in increased toxicity. This would suggest that either the sample 
size was not adequate to draw any conclusions from or toxicity was affected by 
some other factors.  
 
The large meta-analysis by Hardy et al. of over 70000 patients with lung 
cancer, provided a good point of reference (Hardy et al., 2010). Hardy et al. 
found that patients on chemotherapy experienced a wide range of toxicities and 
haematological toxicities were reported as well as non-haematological 
toxicities. Toxicities were usefully categorised as short term or long term, 
however short term was defined as within 3 months of chemotherapy, which 
was very different to the short term toxicities in this research. Reports of 
nausea ranged from 20.1-60%. An overall short-term adverse effect rate of 1.1-
4% was reported, which differed significantly from the 25.2% (61 patients) in 
this study. It was also significantly less than other rates of reporting, for 
example in the breast cancer patient group in this research, but also to the 
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99.1% (740 patients) rate seen in the study by Schonherr et al. looking at 
breast cancer patients receiving FEC chemotherapy. This would suggest that 
disease and possibly treatment had a big effect on toxicity. (Schönherr et al., 
2012). The method of data collection in the review by Hardy et al. was based 
around a financial database used for insurance claims, which may have had a 
large effect on the toxicity reported for economic or financial reasons and the 
method of identifying toxicity from patient records may not have been robust. 
The nausea rate reported in the lung cancer patients in this study was 9.9% (24 
patients), which was significantly lower than that reported by Hardy et al. This 
suggested that delayed emesis was seen in the studies included by Hardy et 
al. and if this study had followed up patients for longer than a higher rate of 
nausea may have been seen. It was also possible that the treatments used in 
this study resulted in less nausea than those in the review by Hardy et al., 
although this is unlikely as 14 different treatments were used. Hardy et al. were 
only concerned with patients over 65 years of age and in this study, nearly 50% 
(755) of patients were under 65 years of age, which could suggest that age had 
an effect of the occurrence of toxicity within a lung cancer patient population.  
Hardy et al. compared the occurrence of toxicity to a group who did not receive 
any chemotherapy and found a more than two-fold increase in a number of 
toxicities that were not recorded in this study. This identified a useful control 
that highlighted toxicities that were due to chemotherapy rather than another 
reason.  
 
5.4.3.2 Grade of Toxicity in Lung Cancer 
The lung cancer patients reported fewer grade 1 and slightly fewer grade 2 
toxicities than the whole population. These rates were noticeably lower than in 
the colorectal and breast cancer patient groups. The numbers of toxicities 
reported in the lung cancer patient population were too low to perform any 
meaningful analysis. The review by Hardy et al. did not focus on the severity of 
toxicity (Hardy et al., 2010), so no literature was found to explore this further.  
 
 196
5.4.3.3 Hospital Admission and Lung Cancer 
In the multivariable logistic regression of admission, no significant predictions 
were found (p>0.1), but the lung cancer patients did appear to have a higher 
admission rate than the other tumour sites and than the whole study 
population. The median length of stay for lung cancer patients was shorter than 
for the whole population, which could suggest that lung cancer patients had 
toxicities that were more easily treated as an outpatient. When looking at lung 
cancer patients independently, the sample size was too small to allow for a 
meaningful logistic regression analysis to be developed. This area would 
require more research as no literature was found regarding the risk of hospital 
admission in lung cancer patients specifically on chemotherapy, although 
Cuppens et al. looked at admissions in lung cancer patients (Cuppens et al. 
2016).  
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5.5 Individual Toxicities 
The three most commonly occurring toxicities were explored as individual 
secondary outcomes, in order to identify predictors of toxicity, severity of 
toxicity, hospital admission and length of stay. It was hypothesised that rates of 
reporting of the individual toxicities would follow the patterns of toxicity as a 
whole and this was found to be partly true. The same was partly true for grade 
of toxicity and for admission and length of stay.  
 
5.5.1 Nausea 
Nausea and vomiting are closely related and vomiting often follows nausea 
(Hesketh, 2008). They were treated as separate variables in this study in order 
to understand the factors that influenced them. 
 
Nausea was the most commonly reported chemotherapy toxicity and it is well-
known that nausea can be a troublesome side effect of chemotherapy that is 
commonly feared and experienced by patients (Janelsins et al., 2013). The 
patients who reported nausea were separated out in SPSS® and analysed as a 
sub-population.  
 
This research was concerned with only acute nausea, which was reported by 
245 (15.9%) of patients. This rate seemed lower than those reported by Ihbe-
Heffinger et al. of 32.8% (68 patients) (Ihbe-Heffinger et al., 2004), Lindley et 
al. of 56% (68 patients) (Lindley et al., 1992), Pirri et al. of 62% (123 patients) 
(Pirri et al., 2011) Escobar et al. of 42% (101 patients) (Escobar et al., 2015) 
and Kottschade et al. of 35% (145 patients) (Kottschade et al., 2016), however 
none of these studies had a similar population to this research and several of 
them reported nausea and vomiting as one entity rather than two separate 
symptoms. Many of the studies only included patients with a single diagnosis or 
age group. It should also be pointed out that most of these studies did not 
differentiate between acute and delayed CINV, which could have increased the 
percentage reported to have experienced nausea.  
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The mean age of those patients experiencing nausea was slightly lower than 
that of the entire study population, but the distribution of age in the patients 
experiencing nausea is similar to that of the whole population and the 
differences in rates of nausea between the age groups was not found to be 
significantly different. Only Hesketh and Kottschade et al. suggested that age 
was a risk factor for nausea with chemotherapy, however Kottschade et al. only 
looked at highly emetogenic chemotherapy, so could not be applied to a whole 
chemotherapy population (Kottschade et al., 2016) (Hesketh, 2008). Hesketh 
quoted three references supporting the statement that younger patients were 
more likely to experience CINV, all of which only looked at cisplatin based 
treatments, which are known to be highly emetogenic (Hesketh, Kris, Basch, 
Bohlke, Barbour, Clark-Snow, Danso, Dennis, Dupuis, Dusetzina, Eng, Feyer, 
Jordan, Noonan, Sparacio, Somerfield and Lyman, 2017a). As such no reliable 
data was found linking nausea to age, in a general population receiving a 
variety of treatments.   
 
Performance status appeared to have an effect on nausea, as a significantly 
higher proportion of patients who were performance status 0 reported nausea 
than in the other performance status groups and a Pearson’s χ2 test suggested 
that this was statistically significant (p<0.01). However in the multivariable 
logistic regression analysis, performance status did not yield any statistically 
significant predictions (p>0.1). Pirri et al. suggested functioning status as a risk 
factor for CINV (Pirri et al., 2013), but no other literature was found that linked 
performance status to nausea. It was therefore not possible to confirm if 
performance status increased the risk of nausea, despite other patient factors 
such as history of motion sickness, having been shown to be predictive of 
CINV (Kottschade et al., 2016). This suggested that patient factors can 
increase the risk of nausea but this research was not able to further explore 
this theory.  
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It was expected that the intent of treatment would have an impact on nausea, 
but as stated previously the intent of treatment may have been affected by 
other variables such as treatment used and disease treated. Neoadjuvant 
patients experienced a higher rate of nausea than the other groups, with the 
palliative group experiencing the least. This appeared significant using a Χ2 test 
(p<0.01) but did not produce any statistically significant predictions in the 
multivariable regression analysis. It may have been expected that the more 
intense a treatment, the more nausea may be seen, but no literature was found 
that explicitly described the effect of the intent of treatment.  
 
The disease being treated may have had an effect on nausea, although the 
numbers of patients in each group was not evenly distributed and so made 
comparison difficult. Breast, CNS and upper GI cancer patients reported the 
most nausea. It was possible that nausea was a symptom of some of the 
diseases and it was not possible from the research to identify what nausea was 
due to chemotherapy and what was due to other causes such as disease. Of 
course, as seen previously, the disease being treated will have involved 
interaction with a number of other variables including treatment and treatment 
intent. In the regression analysis, no statistically significant predictions were 
produced. Kottschade et al. suggested that a diagnosis of breast cancer 
increased the likelihood of CINV on day 1 but this could not be corroborated by 
this research (Kottschade et al., 2016). This research was also unable to 
identify a clear link between disease and nausea.  
 
It was expected that treatment would have a significant effect on nausea as 
trials for individual agents or regimens will all report slightly different rates of 
nausea and the fact that a classification system is in place, which describes the 
risk of nausea associated with a given treatment, confirms that treatment is 
likely to have a large effect on nausea (Hesketh et al. 2017a). Indeed the 
pathological mechanisms of CINV have been documented and the different 
mechanisms for different drugs explained. When treatment was grouped 
according to cytotoxicity (p<0.01), number of drugs (p<0.01), emetogenicity 
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(p<0.01) and commissioning status (p=0.01), the differences between the 
nausea in the groups appeared statistically significant by χ2.  
 
Multivariable logistic regression confirmed that nausea increased as the 
number of drugs increased. Surprisingly the analysis did not identify any 
statistically significant links between nausea and the emetogenicity of an agent 
(p>0.1). This highlighted a problem with the data as it was well-documented 
that the emetogenicity of a treatment affects the likelihood of nausea (Basch, 
Hesketh, et al., 2011). It was likely that the sample size of patients who 
experienced nausea was not large enough to produce reliable statistics. As 
such, patients would need to be followed up for longer to identify any delayed 
nausea and to produce a larger sample size, perhaps with patient 
demographics more controlled to allow for comparisons between groups. 
Hesketh suggested that female patients and younger patients were at a higher 
risk of CINV (Hesketh, 2008). This research was unable to confirm this, as 
gender was not recorded and the data did not support a link between age and 
nausea. Hesketh also stated that patients with a high pre-treatment expectation 
of severe nausea were more likely to experience nausea after treatment. This 
was not recorded in this research and so could not be confirmed. Hesketh also 
stated that chemotherapy dose and emetogenicity were predictive factors of 
nausea. Dose of chemotherapy was not explored in this research.  
 
5.5.1.1 Grade of Nausea 
No significant differences were found in the grade of nausea using the factors 
expected to affect severity of nausea. Ordinal logistic regression analysis did 
not show any statistically significant predictions with respect to grade of nausea 
(p>0.1). It was also difficult to find much in the literature regarding the severity 
of nausea. Nausea is a subjective symptom and so there may have been 
distinct differences in reporting between patients, however little literature was 
found that explored this.  
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5.5.1.2 Hospital Admission and Nausea 
The rate of admission in the patients who reported nausea was very similar to 
the admission rate in the population as a whole, with median length of stay 
being slightly lower. No significant data was found that linked nausea and 
admission rate or length of stay. This was also an area not covered in the 
literature as very little data was found. Only Ihbe-Heffinger et al. reported on 
hospital admission, and that study only found 1 admission (Ihbe-Heffinger et 
al., 2013). It was seen in this research that there were 20 admissions for 
nausea and vomiting, suggesting that it was an issue, but perhaps this study 
was not powered to make any predictions regarding the risk factors.  
 
5.5.2 Vomiting 
As described above, chemotherapy induced nausea and vomiting was 
frequently described in the literature as a single entity rather than two separate 
toxicities. However, vomiting was the second most reported toxicity, affecting 
89 (5.8%) of patients, so it was thought worthwhile to explore it in more depth. 
As with nausea, the rate of vomiting was significantly lower than rates quoted in 
the literature, but all of the literature reviewed included acute and delayed 
vomiting rather than just the acute that was included in this study. Escobar et 
al. quoted separate rates for nausea and vomiting and suggested a rate of 
20.8% (100 patients) for vomiting in patients receiving moderately emetogenic 
chemotherapy (Escobar et al., 2015). This included delayed and acute 
vomiting, suggesting that delayed vomiting accounted for a significant 
proportion of vomiting reported when compared to this study.  
 
The mean age of patients reporting vomiting was lower than that of the rest of 
the population. This would support the suggestion by Hesketh and Kottschade 
et al. that younger age was predictive of CINV (Hesketh, 2008; Kottschade et 
al., 2016), however those studies included delayed CINV. The distribution of 
age in patients reporting vomiting looked similar to the age distribution in the 
whole population. The rate of vomiting was highest in the youngest age group 
and the differences between the groups were significant (p<0.01), but the 
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number of patients reporting vomiting was quite low. The statistically significant 
Spearman’s correlation coefficient of -0.081 (p=0.02) suggested that as age 
reduced, vomiting rate increased, which, again, would agree with Hesketh and 
Kottschade et al.  
 
Although vomiting appeared to be higher in the lower performance status 
groups, the numbers of patients in each group was not evenly distributed 
making direct comparison difficult, with the χ2 test showing that the variance 
was not statistically significant (p>0.1).  
 
As with nausea, vomiting was highest in the neoadjuvant patients, but where 
nausea was lowest in the palliative patients, vomiting was lowest in adjuvant 
patients. The χ2 test suggested that the differences between the groups were 
significant, but the regression analysis was unable to make any statistically 
significant predictions. It was unclear why the nausea and vomiting rates were 
different in these groups and further research with a larger sample size would 
be needed to further explore this. If patients had been followed up for longer, 
and data collected on delayed nausea and vomiting, it may have been possible 
to draw further conclusions.  
 
The disease being treated seemingly affected vomiting in the same way as it 
affected nausea, with CNS, breast and upper GI cancer patients reporting the 
most. This might have suggested that these patients were pre-disposed to 
vomiting or there may have been other factors within the disease groups such 
as treatment or treatment intent that were affecting the rate of vomiting. Again, 
the multivariable logistic regression analysis was unable to confirm the effect of 
disease on vomiting rates.  
 
It was anticipated that the treatment used would have a large effect on 
vomiting, as with nausea.  When grouped according to commissioning status, 
cytotoxicity and drug class, there were no statistically significant differences 
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seen between the groups (p>0.1). When grouped according to the number of 
drugs, vomiting increased significantly, the more drugs used. A Spearman’s 
correlation coefficient of 0.184 (p<0.01) suggested a positive correlation, as 
seen with nausea. No data was found in the literature to support this, although 
it is known that dose can affect CINV and so it may follow that the additive 
toxicities of different agents can increase the risk of vomiting (Hesketh, 2008). 
It is known that some agents have an additive effect, for example 
anthracycline/cyclophosphamide combinations are more emetogenic than the 
single agents (Hesketh, Kris, Basch, Bohlke, Barbour, Clark-Snow, Danso, 
Dennis, Dupuis, Dusetzina, Eng, Feyer, Jordan, Noonan, Sparacio, Somerfield 
and Lyman, 2017b).  This could not be confirmed in the regression analysis. As 
expected, vomiting rates were highest in the highly emetogenic chemotherapy 
group. Again, regression analysis could not confirm this, but the differences 
between the groups was significant according Χ2 (p<0.01). 
 
5.5.2.1 Grade of Vomiting 
Ordinal logistic regression analysis revealed no statistically significant 
predictions around the grade of vomiting (p>0.1). As the number of patients 
reporting vomiting was fairly low, it was likely that the sample size was not 
adequate to identify statistically significant links between grade of vomiting and 
the predictors. Unlike nausea, the differences between the age groups of the 
patients who experienced vomiting were statistically significant according to 
Kruskall-Wallis (p<0.01). The youngest group of patients reported the highest 
grades of vomiting. No literature was found that explored the severity of 
vomiting, so comparison was not possible. No other predictor showed a 
statistically significant link with grade of vomiting (p>0.1).  This could be an 
area of interest for future research, as more severe nausea or vomiting may 
have implications for patients and the health economy. A larger sample size 
and data including delayed vomiting would be required to explore this further.  
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5.5.2.2 Vomiting and Admission and Length of Stay 
Only 14 patients who reported vomiting were admitted, meaning that there was 
not sufficient data to perform meaningful analysis, and this was not something 
that was explored in the literature, again making it an area of interest for future 
research.  
 
5.5.3 Fatigue 
Fatigue was the third most reported toxicity. Fatigue is a subjective variable 
and the reporting in this research was in accordance with CTCAE criteria 
(National Cancer Institute, 2010), which was a very crude measure and not 
particularly descriptive. From the literature, it was clear that consensus did not 
exist as to a standardised tool for reporting, assessing or describing fatigue 
(Hauser et al., 2008). As no baseline assessment of fatigue was undertaken, it 
was not possible to definitively say if the fatigue reported was due to 
chemotherapy. It was possible that disease, co-morbidities or other factors 
could have resulted in fatigue.  
 
The rate of fatigue reporting was significantly lower than those seen in the 
literature (Servaes et al., 2008). This was probably explained by the short 
period of time between chemotherapy administration and toxicity assessment. 
All of the trials reviewed assessed fatigue over a much longer period. This 
study only considered first cycle chemotherapy and so it was possible that 
further cycles of chemotherapy had a cumulative effect on fatigue.  
 
The mean age of patients who reported fatigue was slightly lower than the 
whole population and the distribution of age in those patients experiencing 
fatigue looked similar to that of the whole population. No statistical difference 
was found between fatigue rates in the different age groups (p>0.1) and this 
was in agreement with the literature as no studies were found that linked age to 
fatigue.  
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No link was found between performance status and fatigue. Although fatigue 
was linked to comorbidity in the literature (Barnes and Bruera, 2002), no 
studies were found that explicitly looked at performance status as a predictor. 
Hauser et al. linked fatigue with poorer performance status, but this was as an 
outcome rather than a predictor (Hauser et al., 2008).  
 
There was also no statistically significant difference in the fatigue rates 
between treatment intent groups (p>0.1). Much of the literature around fatigue 
focussed on advanced cancer, which would suggest chemotherapy of palliative 
intent was used. Barnes and Bruera stated that treatment is thought to 
contribute to fatigue, but did not go in to detail regarding treatment intent 
(Barnes and Bruera, 2002). There was much data to suggest that advanced 
cancer itself causes fatigue (Cramp and Bryon-Daniel, 2012; Barnes and 
Bruera, 2002; Hauser et al., 2008), but also data from other studies confirming 
that chemotherapy can cause fatigue (Servaes et al., 2008). It could then be 
that there was an additive effect in terms of fatigue, in patients on 
chemotherapy for advanced cancer, however no data was found to support 
this.  
 
The literature elucidated cancer related fatigue as an accepted concept and as 
such it was expected that there would be a difference in fatigue rates between 
the different diseases. Indeed, rates were different between the diseases with 
breast cancer patients having the highest rate of fatigue. The numbers in the 
groups were quite different, meaning that size-effect could not be ruled out, and 
despite χ2 giving p=0.05, regression analysis was unable to show any 
difference between the disease groups. Other variables would automatically be 
introduced when dividing fatigue rates by disease, for example breast cancer 
patients received the highest proportion of adjuvant and neoadjuvant treatment. 
Data was found in the literature linking fatigue with different types of cancer, 
but no studies were seen that compared fatigue rates between different 
diseases. It was difficult to know what was cancer related fatigue and what 
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fatigue was due to chemotherapy. A baseline assessment of fatigue would 
have helped to explain this. The rates of fatigue in this study were significantly 
lower than in the literature, with one study quoting fatigue rates in cancer 
patients of up to 99% (Barnes and Bruera, 2002). This was probably due to the 
fact that this study only focussed on acute toxicity. It was probable that if 
patients had been followed up for longer, higher reporting rates of fatigue would 
have been seen.  
 
From the literature, it was anticipated that the type of treatment would have a 
major impact on the occurrence of fatigue. Little literature was found that 
compared fatigue rates between different treatments. When grouped according 
to cytotoxicity (p<0.01), number of drugs (p<0.01) and commissioning status 
(p<0.01), fatigue rates were statistically significantly different between the 
groups. Regression analysis confirmed that cytotoxic chemotherapy was 
significantly less likely to be associated with fatigue than those on a mixed 
regimen. Those on non-cytotoxic chemotherapy were the least likely to 
experience fatigue. This could have been explained by an additive effect on 
toxicity of using a combination of drugs. It should be noted that the numbers in 
each group were significantly different, so size effect was likely. Also, this 
interacted with the number of drugs variable, as patients in the mixed group 
would be receiving >1 drug. As seen with other toxicities, the higher the 
number of drugs, the more likely fatigue was to be seen. This also could have 
been explained by an additive effect, possibly with different agents inducing 
fatigue via differing mechanisms. The effect of number of drugs on fatigue 
could not be confirmed by the regression analysis. The other factor found to 
predict fatigue was the commissioning status of a drug. Those on cancer drugs 
fund funded drugs experienced a significantly higher rate of fatigue. The size of 
these groups was vastly different and so size-effect was highly likely. The other 
means of grouping the treatments did not yield any statistically significant 
differences.  
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5.5.3.1 Grade of Fatigue  
Grade of fatigue did not appear to be affected by any of the predictors in an 
ordinal logistic regression analysis. No data was found in the literature around 
the severity of fatigue and so no comparisons could be made.  As the number 
of patients reporting fatigue was fairly small, the numbers in each of the various 
groups was also small, making it difficult to draw reliable conclusions. The 
effect of age on the grade of fatigue was unclear. The differences between the 
age groups was statistically significant (p<0.05), but there did not appear to be 
any pattern to the proportions of patients complaining of each grade of fatigue.   
 
It was seen that the higher the performance status, the higher the proportion of 
patients reporting fatigue, with the inverse being true for grade 1 fatigue. This 
agreed with Hauser et al., who suggested that fatigue was associated with 
higher performance status. It was not known if the fatigue resulted in the higher 
performance status, or if the poorer functional state resulted in the fatigue 
(Hauser et al., 2008). It was not possible to identify from this data, if the 
reported fatigue was a result of disease, co-morbidities or cancer treatment and 
again, a baseline assessment of fatigue would have helped to clarify this.  
 
The numbers in the groups when fatigue severity was compared between the 
different treatment intents were too wide to draw any conclusions from. 
Disease and treatment grouped according to cytotoxicity, number of drugs, 
drug class and emetogenicity did not appear to have any effect on the grade of 
fatigue (p>0.1). When grouped according to commissioning status, CDF 
patients had a higher rate of grade 2 fatigue than baseline commissioning 
patients, but this could not be confirmed in the regression analysis. The 
significance of this was unclear, as it was a very broad way of grouping the 
treatments, but may have been of interest considering the controversial nature 
of the CDF (Aggarwal et al., 2017).  
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5.5.3.2 Admission and Length of Stay and Fatigue 
Only 26 admissions were seen in patients complaining of fatigue, which 
accounted for 16.4% of those patients, higher than the admission rate in the 
wider study population. Only 2 patients were admitted due to fatigue or 
weakness. It was possible that fatigue contributed to other reasons for 
admission. As Ryan et al. explained, fatigue is often associated with other 
conditions such as anaemia and cachexia, which could have contributed to 
hospital admission rates (Ryan et al., 2007). Median length of stay was shorter 
than that of the whole population, but the number of patients involved made it 
impossible to undertake any meaningful analysis. There was no data found in 
the literature around fatigue and admission or length of stay.  
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5.6 Economic Effects of Hospitalisation 
Assessing the financial cost of admission from toxicity proved difficult. A 
national tariff was available at the time of writing, covering hospital admission in 
England (NHS Improvement and NHS England, 2017). Each admission 
attracted a different tariff depending on the investigations and interventions 
undertaken in that admission and based on the complexity of the care required. 
This made identifying a cost of admission due to chemotherapy toxicity difficult, 
as each individual case would attract a different tariff. For example, in the 
national tariff workbook, there were 11 possible codes for a sepsis care 
episode and 4 codes for fever of unknown origin. Many chemotherapy patients 
would be admitted with fever and some with neutropenic sepsis, even with this 
specific reason for admission, there was not one clear tariff that would apply, in 
order to assess the economic impact of admission. Without that detail, it was 
still possible to say that admission to hospital was a cost pressure to the health 
economy and the ability to predict and reduce toxicity and subsequent 
admission, would be financially beneficial to the health economy. In order to 
explore this further in this study population, it would be necessary to investigate 
each individual admission and assess how it was coded. This would have to be 
done at patient level and was too time consuming to be undertaken in this 
study, but is an area that further research could focus on.  The lack of available 
literature regarding the economic impact of chemotherapy toxicity and hospital 
admission, suggested that this was an area that was not well understood and 
was not an area that this research was able to add to. Some studies were 
found that looked at the cost of admission in specific diseases, but none looked 
at a whole chemotherapy population (Latremouille-Viau et al., 2017; Irwin et al., 
2016; Paessens et al., 2011). Mean costs of admission were quoted and were 
fairly similar in each study, however none of the data was from UK patients and 
admissions within the NHS.  
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5.7 Implications for Practice 
The findings of this research may have various implications for practice, as well 
as identifying areas for future research as described above. The literature 
showed that toxicity was generally felt to be a negative phenomenon with 
implications for the patient and the healthcare system. As such there are 
potential implications for the patient and the healthcare system: 
 Implications for the patient 
o Knowledge of the likelihood of toxicity occurring or the potential 
severity of toxicity may influence decisions around proceeding 
with chemotherapy treatment. An example may be in adjuvant 
chemotherapy where the potential benefit to survival may be 
relatively small (Neal and Hoskin, 2009)  
o Knowledge of the likelihood of toxicity occurring or the potential 
severity of toxicity may influence choice between different 
treatments when more than one option is available 
o Knowledge of the likelihood of a hospital admission due to toxicity 
may influence treatment choice, for example patients who have 
caring responsibilities may choose not to undertake a treatment 
that is more likely to result in an admission 
o Greater element of control for patients around treatment 
decisions and planning ahead when undergoing treatment 
 
 Implications for the healthcare provider 
o Greater knowledge of the likelihood of toxicity, hospital admission 
and length of stay allows for better planning of services required 
to respond to the needs of patients in terms of : 
 Financial planning 
 Capacity planning 
 Resource planning 
 Education of workforce 
 Forward planning when introducing new treatments or 
evaluating existing treatments 
o At NUH, this will allow the CATT team to develop evidence-based 
interventions to target patients most at risk of toxicity and hospital 
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admission. It may be that certain groups of patients would benefit 
from further telephone calls and supported self-management of 
toxicities. A review of the service could decide where to focus the 
resource so that it provides the best possible service to patients. 
Ongoing data collection will allow for further analysis in the future 
and continual review of the service 
 
Further research would be required to further validate the findings of this study, 
with a multi-centred approach and larger numbers of patients, following 
patients up for longer. This could aim to produce and validate a prediction tool 
for toxicity and subsequent admission, which would provide a robust estimation 
of toxicity and admission risk and further ratify the implications for practice 
mentioned above.  
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5.8 Limitations 
Due to time constraints and difficulty obtaining the data, it was not possible to 
review deaths within 30 days of chemotherapy in this study. Death data is 
collected in a separate system in the trust and cause of death as stated on 
death certificates does not make it clear if a chemotherapy toxicity was 
responsible for the cause of death or if another cause was implicated. As such 
death data was not collected and was omitted from the research. Mortality is an 
important factor in terms of chemotherapy as any drug carries an element of 
risk and the clinician needs to be sure that the risks of chemotherapy are out-
weighed by the potential benefit. Death within 30 days of chemotherapy was 
the interest of the 2008 NCEPOD report, which made various 
recommendations to ensure that decisions to use chemotherapy fully assessed 
the potential risk of its use (Mort et al., 2008). These recommendations have 
been embedded into practice at NUH, with any death within 30 days of 
administration of chemotherapy, warranting discussion at the monthly morbidity 
and mortality meeting. The meeting aims to review practice and identify and 
share any learning points for the future.  
 
5.7.1 Methodology Limitations 
It was acknowledged that the methodology had a number of limitations. Gender 
was not collected as part of the call back service and as such could not be 
included in any data analysis. The possibility of gender being a predictor of 
toxicity or hospital admission could not be included in this research. 
 
As alluded to previously, this study was only able to explore acute 
chemotherapy toxicity within the first 24 hours following the first cycle of 
chemotherapy. The call back service was only able to provide one telephone 
call per patient and as such no data could be collected on any later toxicities 
that may have occurred prior to the next cycle. This was in contrast to all of the 
literature that was reviewed, most of which collected toxicity data for the 
duration of a treatment. In order to draw true comparisons, this study would 
have had to continue to collect toxicity data for the duration of treatments, but 
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this would have been extremely labour intensive for a population of the size 
seen in the study and the time and resource required to do this were not 
available. The time period of the telephone call also meant that for many oral 
regimens, steady state may not have been reached, so the full extent of toxicity 
was unlikely to be seen.  
 
Only the first cycle of toxicity was included in the data. It was possible that 
toxicity may have changed as patients progressed further through 
chemotherapy, with some toxicities occurring as a cumulative effect of 
subsequent cycles of chemotherapy. This was beyond the reach of the data in 
this study, although if a similar methodology was applied prior to subsequent 
cycles of chemotherapy, it would allow for analysis of such effects on toxicity.  
 
Stage of disease was not recorded in the data of this study, meaning that within 
each disease group there were many variations of the same disease. Some 
disease that is localised to a non-visceral area, may have been unlikely to 
produce significant symptoms, whereas metastatic disease affecting a number 
or organs, may have produced significant symptoms and affected functioning, 
thus affecting toxicity and admission rates.  
 
Outcomes of toxicity were recorded as free text by the nurses, however not 
explored in this study. The outcome recorded would have been the outcome at 
the time of the telephone call. This could be a referral to another healthcare 
provider, advice for self-management or hospital admission. This would not 
elucidate the true effect of a toxicity as this effect could be felt well beyond the 
initial 24 hours after chemotherapy.  
 
There were 37 different reasons for admission within 30 days of chemotherapy. 
As such it was very difficult to draw any conclusions, as numbers for each 
admission were so small. It was also impossible to be certain that the 
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admission was due to a chemotherapy toxicity, as many of the symptoms could 
have been due to other causes such as disease.  
 
This study looked at the occurrence and severity of toxicity as well as hospital 
admission and length of stay, but did not extend to the consequences of any of 
these. It was assumed that toxicity was a negative experience for the patient 
and detrimental to their overall wellbeing. Kalsi et al. suggested that toxicity 
was responsible for dose reduction, discontinuation and even death (Kalsi et 
al., 2014). Further research would be warranted in to the effects and outcomes 
of patients experiencing toxicity.  
 
Toxicity can be a subjective outcome and although a nurse-led toxicity 
assessment was performed, the data collected still relied on patients reporting 
the toxicities. Different patients may have rated toxicities differently. The 
CTCAE criteria (National Cancer Institute, 2010) should have minimised the 
patient bias in this, but it could not be completely excluded as a potential factor 
for some variance. What was severe for one patient may have been mild for 
another. A particular example of this would be fatigue. Jenner et al. showed 
that patients had a high rate of reporting toxicity when asked to complete 
questionnaires (Jenner et al., 2010), however this study did not have a 
comparator and no literature was found that compared toxicity rates in patients 
asked to complete structured self reporting of toxicity with standard of care. It is 
likely that different centres have different means of assessing and recording 
toxicity and so comparison could be difficult. Further research would be 
required to further explore this and to elucidate the effect of reporting models 
on toxicity.  
 
The study did not include a baseline assessment of toxicity symptoms, prior to 
the first cycle of chemotherapy. It was therefore possible that some patients 
may have already been experiencing the toxicity symptoms caused by other 
factors such as disease, prior surgery or co-morbidity. It was not possible to 
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conclude from this study that the symptoms experienced were definitely a 
direct result of the chemotherapy treatment.  
 
Haematological and non-patient reported toxicities were not included in the 
research as they were not collected. Haematological toxicity is a common 
consequence of chemotherapy (Chua et al., 2011), but in order to collect data 
on this, a significant investment of resource would have been needed to review 
and record blood count results over a prolonged period of time. Other effects 
such as impairment of renal or liver function or electrolyte disturbances were 
not assessed in this research.  
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6.0 Conclusion 
The research aimed to identify the factors influencing the occurrence and 
severity of acute chemotherapy toxicity along with the likelihood of hospital 
admission, which was partly achieved. It focussed on a whole patient 
population of patients with a solid tumour treated with chemotherapy in a large 
UK teaching hospital trust. In order to do this, a dataset of toxicity assessment 
24 hours following the first cycle of chemotherapy was produced and analysed. 
The methodology had known limitations but was able to address the initial 
research question.  This study was felt to be unique as nothing similar was 
seen in the published literature, although studies looking at similar questions 
were found, none used an identical population.  
 
A heterogeneous population was studied, which had a wide age range and 
range of performance statuses. Chemotherapy of all treatment intents was 
studied and nearly all cancer types were included in the analyses, although 
small numbers in some groups meant that they had to be excluded. A wide 
range of treatments was used and it was necessary to group these by several 
different mechanisms.  
 
Overall incidence of toxicity was found to be 35.6% (530 patients), which was 
comparable to other studies seen in the literature. The incidence of 
hospitalisation due to chemotherapy toxicity within 30 days of the first cycle 
was found to be 13.1% (203 patients). The incidence of death due to 
chemotherapy toxicity could not be established due to difficulties in collecting 
the data.  
 
Factors affecting the occurrence of toxicity were identified. The disease being 
treated was found to influence toxicity, with breast and upper GI cancer 
patients more likely to experience a toxicity than other tumour sites. It was 
acknowledged that there was potential overlap of the predictors and this could 
be especially evident with disease. Age and treatment intent were found not to 
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affect the occurrence of toxicity. Initial findings suggested that performance 
status had an effect on toxicity, this was not proved in logistic regression 
analysis. When treatment was grouped according to the number of drugs used 
in the chemotherapy regimen, regression analysis suggested that the more 
drugs given, the higher the rate of toxicity. It was not possible to prove an effect 
on toxicity of the emetogenicity of a regimen, this was thought to have a 
relationship with toxicity, but was possibly confounded by other variables or 
there was a type I error in the data.  
 
Factors affecting the severity of toxicity were identified using descriptive 
statistics to highlight any possible relationships and ordinal logistic regression 
analysis to assess these relationships further.  Disease was the only factor that 
was found to predict the grade of toxicity with urology, gynaecology and lung 
cancer patients all being associated with higher grades of toxicity. It was 
suspected that age and performance status had an effect on the grade of 
toxicity, although this data was not able to prove this when multivariable 
regression was performed.  
 
The risk of hospitalisation due to chemotherapy toxicity within 30 days of 
chemotherapy was explored using multivariable logistic regression analysis. 
The likelihood of admission was found to be affected by the disease being 
treated, with patients with head and neck, upper GI and lung cancer having a 
higher risk of admission than other tumour sites. The number of drugs given 
also had an effect on the risk of admission with patients on three drugs having 
a higher likelihood of being admitted.  Age and performance status appeared to 
have a relationship with the risk of admission in descriptive statistics and 
univariate regression analysis, but multivariable regression was unable to 
explain these links.  
 
Length of stay appeared to reduce as age increased with a statistically 
significant correlation (p=0.04). Intent of treatment, the number of 
chemotherapy drugs in a regimen and emetogenicity all appeared to have an 
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effect on length of stay. Due to complexity of the data and limitations to the 
methodology, it was not possible to undertake regression analysis to confirm 
the effect of the predictors on length of stay.  
 
Sub-group analyses of breast, colorectal and lung cancer patients, used the 
same regression analysis as in the whole study population and showed that in 
breast cancer patients, the use of 3 drugs increased the risk of toxicity 
occurring and in colorectal cancer patients the use of moderately emetogenic 
chemotherapy increased the incidence of toxicity. Admission rates in breast 
cancer patients was lower than the whole population, similar in the colorectal 
cancer patients and higher in the lung cancer patients Length of stay was 
shortest in the lung cancer patients and similar to the study population in breast 
and colorectal cancer patients.  
 
The 3 commonest toxicities seen were nausea, vomiting and fatigue and these 
were analysed as secondary outcome measures using the same regression 
analysis as in toxicity. The analyses showed that the risk of nausea was 
increased as the number of chemotherapy drugs given increased. The same 
was true for vomiting. The number of drugs also had an effect on fatigue, with 
those on 1 drug being less likely to experience fatigue. Admission rates for 
patients with nausea and fatigue did not differ from those patients who did not 
report these toxicities and the admission rate for vomiting did not show a 
difference that was statistically significant (p>0.1).  
 
The complexity of NHS financial systems meant that it was not possible to 
develop an analysis that could accurately estimate the economic effects of 
toxicity.  
 
Further research is warranted into chemotherapy toxicity, as the effects can be 
detrimental to the patient and a burden on the health economy. Toxicity 
assessment over a longer time period or larger patient group would further add 
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to the body of evidence around this. Hospital admission due to chemotherapy 
toxicity is an under-researched area and would benefit from a large, multi-
centre study to analyse the factors that affect the likelihood of this sequela of 
chemotherapy use.  
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Appendix 1 
Chemotherapy Ring-back Service 
Standard Operating Procedure 
 
1. Obtain the list of patients to call that day from the report produced by 
Chemo care, sent to the Admission avoidance team email 
 
2. Open the patient’s Chemo care record and familiarise yourself with the 
regimen. If necessary, look for the appropriate Macmillan information 
sheets in the relevant folder of the shared drive. 
 
3. Check that chemotherapy was given and a ring back is necessary. If 
needed, the day when a ring back is required for each regimen can be 
found in the “days of ring back” spread sheet in the admissions 
avoidance shared drive. Note that some regimens have two ring backs. 
 
4. Open the correct database from the “Database and clinical info” folder in 
the shared drive. Ensure that the database matches the regime 
prescribed on Chemocare 
 
5. Record the patient’s initials in the “patient details” column of the 
database and complete columns B to H. 
 
6. Obtain the patient’s telephone number from NotIS and place the call. 
 
7. Confirm that you are speaking to the patient. Patients can only be 
discussed with a relative with the consent of the patient. 
 
8. After introducing yourself, ask the patient how they are and how they 
have found the chemotherapy. Use open questions to begin with, then 
move on to specific toxicities. For each toxicity, record the grade and the 
outcome. Ensure you get details of: 
 
a. Any fever 
b. Nausea 
c. Vomiting 
d. Stomatitis 
e. Diarrhoea 
f. Constipation 
g. Lethargy 
h. Anorexia 
i. Dyspnoea 
j. Rash 
k. Neuropathy motor 
l. Neuropathy sensory 
m. Bleeding 
n. Arthralgia 
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o. Bruising 
p. Extravasation 
q. Anything else the patient discloses 
 
9. Offer advice as appropriate on self- care and consider the need for 
further assessment. Ensure that the patient knows how to correctly take 
any supportive care.  
10. Consider arranging a further phone call the next day if there are 
concerns about any symptoms. 
 
11. Record all of the toxicities in the relevant database using the drop down 
boxes. 
 
 
12. Ensure that the database is saved – please note that only one person at 
a time can access each database so please ensure that it is closed 
when finished. 
 
13. Find the patient record on NotIS and using medical office – complete a 
letter to the GP. Ensure that you include any details of toxicities 
experienced and the advice given. Include any other info that you feel 
may be relevant. 
 
 
14. Copy the letter on medical office and paste it into the annotation section 
of the patient’s Chemocare record. 
 
15. Make a note of when you feel a further ringback is required. This may 
vary patient to patient. 
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Appendix 2 
Data items collected as part of the Chemotherapy ring back service 
 Date of call 
 Name, hospital number, date of birth (removed for research purposes) 
 Chemotherapy regimen 
 Cancer diagnosis 
 Intent of chemotherapy 
 Cycle number 
 Day of treatment cycle (eg Day 1, day 8) 
 Performance status at time of chemotherapy administration 
 Toxicity review – the following toxicities are assessed and the grade 
recorded along with any advice given: 
o Nausea/vomiting 
o Stomatitis 
o Diarrhoea past 24 hours 
o Constipation 
o Lethargy 
o Anorexia 
o Dyspnoea 
o Rash 
o Neuropathy – motor 
o Neuropathy – sensory 
o Bleeding 
o Arthralgia/pain 
o Bruising 
o Extravasation 
o Other 
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Appendix 3 
       ……… 
 
APPLICANT’S ETHICS CHECKLIST 
 
This checklist is designed to help you to decide whether or not ethics 
approval is required and, if required, to decide on the appropriate ethics 
review procedure –  
please read Annex 1 on page 5 before you complete this form 
 
 
Please Note: 
 
a) This Checklist should be completed for all research projects involving human 
participation, human biological material or human data. 
 
b) All questions on this checklist should be completed. 
 
c) Contact details (email address) should be given for PI or PS and student (if 
applicable). 
 
d) In the case of Student projects, Supervisors should read and sign this checklist 
(in the correct box – EITHER/OR – not both boxes) BEFORE it is submitted to 
the Ethics Administrator for sign off by the Chair of the Research Ethics Panel. 
 
e) Guidance on the 2 different ethics review procedures that together make up the 
University’s Ethics Review System (i.e. ‘University’ and ‘NHS’) is available on 
the University Ethics website. 
 
f) If your project will involve human tissue/biological fluids you should contact the 
UoB Designated Individual for the HTA licence, Dr Sue Boyce for advice 
(s.g.boyce@bradford.ac.uk or on 01274 235879) 
g) If this Checklist is NOT correctly completed, it will be returned to you 
unauthorised. 
 
_______________________________________________________________
____________ 
 
 
Project Title: Assessing the risk of Chemotherapy toxicity and hospital 
admission due to toxicity 
 
 
Name of Principal Investigator / Principal Supervisor: Dr J Silcock / Dr E 
James 
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Contact Details – email address J.Silcock@bradford.ac.uk  
Eleanor.James@nuh.nhs.uk  
 
Department/School Pharmacy, School of Life Sciences 
 
 
Name of Student (if applicable): Samuel Malton 
 
 
Contact Details – email address Samuel.malton@nuh.nhs.uk 
 
Has the Principal Investigator / Principal Supervisor attended appropriate ethics 
training? 
 Yes ‐ No  
 
Has the student attended appropriate ethics training? Yes  No ‐ 
 
Please give summary of project (max 150 words): 
 
At Nottingham University Hospitals, a new service has been established 
involving a nurse led call back service to all oncology patients receiving 
chemotherapy. Patients receive a call back 24 hours after their first cycle of 
chemotherapy and undergo a full toxicity assessment over the telephone. Data 
is collected around toxicity, which will be used to look at the factors that can be 
used to predict chemotherapy toxicity and the risk of hospital admission from 
toxicity.   
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Q1 
 
Is the proposed project an empirical research project 
involving people?    
 Will the project include primary data collection from human 
participants, their data or their tissue?   
 Will it constitute an ‘investigation undertaken in order to 
gain knowledge and understanding’?   (This includes work 
of educational value designed to improve understanding of 
the research process.)   
 
 
If you answer ‘Yes’ to Q1 ethical approval may be required, move 
to Q2. 
 
If you answer ‘No’ to Q1 then a research ethics review is not 
usually required; please move to question 1a.  
Note:  there may be occasions where a project is not defined as 
research but still raises ethical issues – please submit for review if 
this is the case. 
 
 
Yes 
‐
 
No 
 
 
Yes 
‐
 
No 
 
 
Yes 
‐
 
No 
 
 
Q1a 
 
Is the proposed project an audit or service evaluation 
involving humans? 
 
A more detailed definition of Research, Audit and Service 
Evaluation is available on the University Ethics website.   
 
If you consider that ethical review is not required, please explain 
briefly why not, below: 
 
The only data used in the study will be that that is collected as 
part of the chemotherapy service at Nottingham University 
Hospitals. Data is not being collected solely for the purpose of 
research. It is part of the student’s role to be involved with the 
service and the student would have access to the data as part of 
that role even if research were not being undertaken. 
 
 
 
 
 
 
Yes 
‐
 
No 
 
 
Q2 
 
Will the research project involve the NHS?   
See Research Ethics and Governance in NHS and Social Care page 
of the website 
 
If you answer ‘No’ to Q2 move on to Q3 
 
If you answer ‘Yes’ to Q2 ethical approval will be required by NHS 
Research Ethics Committee (NREC). Please submit your 
 
Yes 
‐
 
No 
 
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approved NREC application with this checklist before 
commencing the work. 
 
 
Q3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q3a 
 
Will the research project involve any of the following in the 
UK: 
 Testing a medicinal product  
 Investigating a medical device 
 Taking samples of human biological material (e.g. blood, 
tissue) 
 Prisoners or others in custodial care (e.g. young offenders) 
as participants 
 Adults with mental incapacity as participants 
 Other vulnerable groups (e.g. vulnerable children) as 
participants 
 
If you answer ‘Yes’ to Q3 ethical approval will usually be required 
through a Research Ethics Panel, Ethical Tissue or NHS 
Research Ethics Committee (REC), or where the project includes 
participants that need approval under the Mental Capacity Act, 
approval will be required by the Social Care REC.  
 
If you wish to source material from Ethical Tissue at the 
University, they can be contacted on 01274 235897 or visit 
www.ethicaltissue.org  
 
See information specific to research in Social Care on the 
University Ethics website 
 
If your work involves a medical device, please state its Class 
according to the Medical Devices Directive (93/42/EEC) (see 
http://www.mhra.gov.uk/Howweregulate/Devices/Classification/ 
for further details). 
 
 
If you answer ‘No’ to Q3 move on to Q4 
 
 
Yes 

 
No 
‐ 
 
Q4 
 
Will the research project involve human participants and/or 
human data (but not accessed through the NHS)?   
 
If you ticked ‘Yes’ please give details of: 
 
1. Interviews, questionnaires, surveys, observations, etc (how 
many, how long will they last);  
2. who the participants are;  
3. whether consent will be sought; 
4. where interviews will take place and  
5. attach all documentation including any proposal, consent 
forms, information sheets, interview guidelines, 
questionnaires/surveys, etc. 
 
 
Yes 

 
No 
‐ 
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Q5 
 
 
 
 
 
 
 
 
 
 
Q5a 
 
Will the research project involve human tissue (but not 
requiring NHS approval – see Q3)? 
 
If you answer ‘Yes’ to Q5 University ethical approval is required 
 
If you require advice on human biological material please contact 
Human Tissue Act (HTA) Designated Individual: Dr Sue Boyce 
[s.g.boyce@bradford.ac.uk] 
on ext 5897 or visit www.ethicaltissue.org 
 
If you answered ‘Yes’ to Q5, is the human material over 100 
years old and archaeological? 
 
If ‘YES’ please refer to the Biological Anthropology Research 
Centre (BARC) guidelines at 
http://www.barc.brad.ac.uk/BARC_human_remains_policy.pdf 
 
 
Yes 

 
No 
‐ 
 
 
 
 
 
 
 
 
 
Yes 

 
No 
 
 
If you answer ‘No’ to Q5 and have answered ‘No’ to Q2, Q3 and Q4 ethical 
approval is not required. 
 
 
 
 
 
 
 
PLEASE COMPLETE and SIGN ONE of the two boxes below  
(in the case of a student project, we do require a Supervisor’s signature in 
whichever box is relevant,  before we can have the checklist signed off by the 
Research Ethics Panel): 
 
 
1. I have discussed this project with my student AND/OR 
2. I confirm that there are no ethical issues requiring further consideration. 
 
(Any subsequent changes to the nature of the project will require that the Panel 
are informed of all changes) 
 
Signed by (Principal Investigator or Principal Supervisor (in case of 
student project)): 
 
Signature: ……………………………………………. ……. Date: 
…………………………. 
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PLEASE PRINT NAME 
………………………………………………………………………… 
 
 
 
OR 
 
 
 
I confirm that there are ethical issues requiring further consideration and will either: 
1.  refer the proposal  to Ethical Tissue,  or,  
2.  fill in and submit a full ethics application to be considered by the appropriate 
Research Ethics Panel. 
 
Name (Principal Investigator/Principal Supervisor): 
 
Signature: …………………………………………………………..     Date: 
……………………………. 
 
PLEASE PRINT NAME 
…………………………………………………………………………………….. 
 
 
 
 
 
 
Annex 1 
 
Ethical Scrutiny by a University Research Ethics Panel is not required if: 
 
 The project is NOT a research project.  There may be occasions where 
a project is not defined as research but still raises ethical issues – 
please submit for review if you think this is the case. 
 
 The research project will only involve unlinked or aggregated human 
data which was collected and which was, at the time, subject to 
relevant research ethics panel approval. 
However, where this is the case the researcher should at least confirm this 
in an email to the Research Support Unit’s Ethics Administrator so that the 
Ethics Administrator has a record and can inform the Chair of the 
appropriate Research Ethics Panel that the researcher plans to go ahead 
without ethics approval. The email should confirm that the research project 
does not require ethics approval because it only involves unlinked or 
aggregated data, which when originally obtained from people was obtained 
in accordance with the protocol as approved at the time by an appropriate 
research ethics panel. The email should also briefly explain how the 
researcher now plans to use the unlinked or aggregated data.  
 
 The research is Public Domain Data: 
 243
 The Economic and Social Research Council’s (ESRC) Research Ethics 
Framework states that ethics approval may not be required for data sets 
that exist in the public domain (e.g. datasets that are available from the 
Office for National Statistics or from the ESRC’s Data Archive) so long as 
the appropriate permissions from individuals have already been obtained 
(i.e. informed consent) and where it is not possible to identify the individuals 
from the information provided.  It must be remembered that public domain 
data is still covered by the laws of copyright.  
 
 The research involves Simple Uncontentious Questionnaires: 
If a research project’s only involvement with human subjects is a simple 
brief questionnaire with uncontroversial content it may not require ethical 
approval.  It is the Principal Investigator or Principal Supervisor’s 
responsibility to decide whether a project comes under this category and 
must indicate this at Q.4 on the checklist and attach the questionnaire 
document for information. 
 
Guidance on supervisor and principal investigator sign off of 
uncontentious research 
 
Audit and service evaluation are usually uncontentious, and guidance on how 
to differentiate between research, audit and service evaluation is given at: 
University Ethics website.  
 
Even where a project is clearly research, as a supervisor or principal 
investigator, you can sign off simple, ethically uncontentious projects as not 
needing further ethical scrutiny.  To do this, you should consider the level of 
risk to participants and researchers, the level of effort required by participants, 
the level of intrusion into participants’ lives and the level of sensitivity of both 
the general subject matter and the information requested of participants. 
Basically, the lower these levels, the more likely the research is to be 
uncontentious and the more confident you should feel about signing off. 
 
The following examples may help.   
 
These studies can almost always be signed off by the supervisor or principal 
investigator: 
 
 Brief questionnaires asking opinions about matters which are clearly not 
sensitive (attitudes to a product, beliefs about the usefulness of a course).   
 Brief interviews about such topic. 
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 Observational studies about everyday behaviour in public places which 
involve no risk to subjects or the researcher. 
 
But the following studies almost always need further scrutiny by a University 
Ethics Panel: 
 
 Long questionnaires (these require considerable potential inconvenience to 
subjects). 
 Long interviews 
 Any questionnaires which ask subjects about intimate behaviours or issue 
likely to cause distress or would in other ways normally be regarded as 
contentious or sensitive (e.g. illegal activities, attitudes to abortion, capital 
punishment, immigration, euthanasia). 
 Any interviews which examine these matters. 
 Observational studies which involve intimate behaviours, behaviours which 
are not normally public or which might normally be considered contentious 
or sensitive (Activities of ethics committees, appointment committees, etc; 
professional consultations). 
 
Naturally, this list is for illustration only, and should not be considered in any 
way exhaustive, permissive or prescriptive.  For example, there are many 
categories of research not mentioned here which would definitely require ethics 
approval (e.g. treatment research).  Rather the list demonstrates the issue of 
proportionality.  Thus, even though the method may be the same for activities 
requiring and not requiring further scrutiny, the content in some way 
distinguishes between the two categories. 
 
At the same time, there is obviously some middle ground.  Are ethics 
committees not public?  Is what is discussed so sensitive that the proposal 
needs further scrutiny?  What about asking people about their views on the 
actions of senior members of staff in their organisation?  Probably, it is in these 
middle ground areas that further advice should be sought from a Panel Chair 
about whether the project can be signed off by the supervisor or principal 
investigator alone.  Given that, in so doing, the supervisor or PI is attesting to 
the ethical probity of the study, it is usually best to err on the side of caution 
where there is uncertainty.  Panel chairs are very happy to advise. 
 
(Dr Martin Brinkworth, Chair, Biomedical, Natural, Physical and Health 
Sciences Research Ethics Panel, m.h.brinkworth@bradford.ac.uk, ext. 3584 
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Dr Clare Beckett,  Chair, Humanities, Social and Health Sciences Research 
Ethics Panel, c.beckett@bradford.ac.uk, ext. 3521) 
 
 
 
Please submit this checklist to: 
 
Ethics Administrator, RKTS,  
F.24 Richmond Building 
in hard copy or by email to  
ethics@bradford.ac.uk  
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Appendix 4 
NHS R&D Form IRAS Version 5.3.0  
Welcome to the Integrated Research Application System  
 
IRAS Project Filter  
 
The integrated dataset required for your project will be created from the 
answers you give to the following questions. The system will generate 
only those questions and sections which (a) apply to your study type and 
(b) are required by the bodies reviewing your study. Please ensure you 
answer all the questions before proceeding with your applications.  
Please complete the questions in order. If you change the response to a 
question, please select ‘Save’ and review all the questions as your 
change may have affected subsequent questions.  
 
Please enter a short title for this project (maximum 70 characters) 
Assessing the risk of Chemotherapy toxicity and hospital admission  
1. Is your project research?  
Yes No  
  
 
2. Select one category from the list below:  
Clinical trial of an investigational medicinal product Clinical 
investigation or other study of a medical device Combined trial of an 
investigational medicinal product and an investigational medical 
device Other clinical trial to study a novel intervention or randomised 
clinical trial to compare interventions in clinical practice Basic science 
study involving procedures with human participants  
Study administering questionnaires/interviews for quantitative analysis, 
or using mixed quantitative/qualitative methodology  
Study involving qualitative methods only  
Study limited to working with human tissue samples (or other human 
biological samples) and data (specific project only)  
 247
Study limited to working with data (specific project only) Research tissue 
bank Research database  
If your work does not fit any of these categories, select the option below:  
Other study  
             
2a. Please answer the following question(s):  
a) Will you be processing identifiable data at any stage of the research 
(including in the identification of participants)?  
Yes No  
   
 
3. In which countries of the UK will the research sites be located?(Tick all 
that apply)  
England Scotland Wales Northern Ireland  
    
3a. In which country of the UK will the lead NHS R&D office be located:  
1 179907/966714/14/52  
NHS R&D Form IRAS Version 5.3.0  
 
England Scotland Wales Northern Ireland This study does not involve 
the NHS  
     
 
4. Which applications do you require?  
IMPORTANT: If your project is taking place in the NHS and is led from 
England select 'IRAS Form'. If your project is led from Northern Ireland, 
Scotland or Wales select 'NHS/HSC Research and Development Offices' 
and/or relevant Research Ethics Committee applications, as appropriate.  
IRAS Form NHS/HSC Research and Development offices Social Care 
Research Ethics Committee Research Ethics Committee Confidentiality 
Advisory Group (CAG) National Offender Management Service (NOMS) 
 248
(Prisons & Probation)  
      
For NHS/HSC R&D Offices in Northern Ireland, Scotland and Wales the CI 
must create NHS/HSC Site Specific Information forms, for each site, in 
addition to the study wide forms, and transfer them to the PIs or local 
collaborators.  
For participating NHS organisations in England different arrangements 
apply for the provision of site specific information. Refer to IRAS Help for 
more information.  
 
It looks like your project is research requiring NHS R&D approval but 
does not require review by a REC within the UK Health Departments 
Research Ethics Service – is that right?  
Yes No  
   
 
4b. Please confirm the reason(s) why the project does not require review 
by a REC within the UK Health Departments Research Ethics Service:  
Projects limited to the use of samples/data samples provided by a 
Research Tissue Bank (RTB) with generic ethical approval from a REC, in 
accordance with the conditions of approval.  
Projects limited to the use of data provided by a Research Database with 
generic ethical approval from a REC, in accordance with the conditions of 
approval.  
Research limited to use of previously collected, non-identifiable 
information Research limited to use of previously collected, non-
identifiable tissue samples within terms of donor consent Research 
limited to use of acellular material  
Research limited to use of the premises or facilities of care organisations 
(no involvement of patients/service users as participants)  
Research limited to involvement of staff as participants (no involvement 
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of patients/service users as participants)  
        
 
5. Will any research sites in this study be NHS organisations?  
Yes No  
   
 
2 179907/966714/14/52  
NHS R&D Form IRAS Version 5.3.0  
5a. Are all the research costs and infrastructure costs (funding for the 
support and facilities needed to carry out research e.g. NHS Support 
costs) for this study provided by a NIHR Biomedical Research Centre, 
NIHR Biomedical Research Unit, NIHR Collaboration for Leadership in 
Health Research and Care (CLAHRC), NIHR Patient Safety Translational 
Research Centre or a Diagnostic Evidence Co-operative in all study 
sites?  
Please see information button for further details.  
Yes No  
   
Please see information button for further details.  
 
5b. Do you wish to make an application for the study to be considered for 
NIHR Clinical Research Network (CRN) Support and inclusion in the NIHR 
Clinical Research Network Portfolio?  
Please see information button for further details.  
Yes No  
   
The NIHR Clinical Research Network provides researchers with the 
practical support they need to make clinical studies happen in the NHS 
e.g. by providing access to the people and facilities needed to carry out 
research “on the ground".  
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If you select yes to this question, you must complete a NIHR Clinical 
Research Network (CRN) Portfolio Application Form (PAF) immediately 
after completing this project filter question and before submitting other 
applications. Failing to complete the PAF ahead of other applications e.g. 
HRA Approval, may mean that you will be unable to access NIHR CRN 
Support for your study.  
 
6. Do you plan to include any participants who are children?  
Yes No  
   
 
7. Do you plan at any stage of the project to undertake intrusive research 
involving adults lacking capacity to consent for themselves?  
Yes No  
   
Answer Yes if you plan to recruit living participants aged 16 or over who 
lack capacity, or to retain them in the study following loss of capacity. 
Intrusive research means any research with the living requiring consent 
in law. This includes use of identifiable tissue samples or personal 
information, except where application is being made to the Confidentiality 
Advisory Group to set aside the common law duty of confidentiality in 
England and Wales. Please consult the guidance notes for further 
information on the legal frameworks for research involving adults lacking 
capacity in the UK.  
 
8. Do you plan to include any participants who are prisoners or young 
offenders in the custody of HM Prison Service or who are offenders 
supervised by the probation service in England or Wales?  
Yes No  
   
 
9. Is the study or any part of it being undertaken as an educational 
project?  
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Yes No  
Please describe briefly the involvement of the student(s): Student is the 
main researcher. The student also works in the NHS trust and has access 
to the data as part of the trust role.  
   
 
9a. Is the project being undertaken in part fulfilment of a PhD or other 
doctorate?  
  
Yes No  
3 179907/966714/14/52  
NHS R&D Form IRAS Version 5.3.0  
 
10. Will this research be financially supported by the United States 
Department of Health and Human Services or any of its divisions, 
agencies or programs?  
Yes No  
   
 
11. Will identifiable patient data be accessed outside the care team 
without prior consent at any stage of the project (including identification 
of potential participants)?  
Yes No  
   
 
4 179907/966714/14/52  
NHS R&D Form IRAS Version 5.3.0  
 
 
Integrated Research Application System Application Form for Study 
limited to working with data (specific project only)  
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NHS/HSC R&D Form (project information)  
 
Please refer to the Submission and Checklist tabs for instructions on 
submitting R&D applications.  
 
The Chief Investigator should complete this form. Guidance on the 
questions is available wherever you see this symbol displayed. We 
recommend reading the guidance first. The complete guidance and a 
glossary are available by selecting Help.  
Please define any terms or acronyms that might not be familar to lay 
reviewers of the application.  
 
 
 
Short title and version number: (maximum 70 characters - this will be 
inserted as header on all forms) Assessing the risk of Chemotherapy 
toxicity and hospital admission  
 
 
PART A: Core study information  
 
 
1. ADMINISTRATIVE DETAILS  
 
 
A1. Full title of the research:  
Assessing the risk of Chemotherapy toxicity and hospital admission due 
to chemotherapy toxicity. Using patient reported toxicity after the first 
cycle of chemotherapy to develop a predictor of toxicity and hospital 
admission.  
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A2-1. Educational projects  
Name and contact details of student(s):  
Student 1  
Address  
Post Code E-mail Telephone Fax  
Title Forename/Initials Surname Mr Samuel Malton  
Nottingham City Hospital Hucknall Road Nottingham NG51PB 
samuel.malton@nuh.nhs.uk 01159691169  
Give details of the educational course or degree for which this research 
is being undertaken:  
Name and level of course/ degree: DPharm  
Name of educational establishment: University of Bradford  
Name and contact details of academic supervisor(s):  
   
Academic supervisor 1  
5 179907/966714/14/52  
NHS R&D Form IRAS Version 5.3.0  
Please state which academic supervisor(s) has responsibility for which 
student(s):  
Please click "Save now" before completing this table. This will ensure 
that all of the student and academic supervisor details are shown 
correctly.  
Student(s) Academic supervisor(s) Student 1 Mr Samuel Malton  
   
Dr Jonathan Silcock  
Address  
Post Code E-mail Telephone Fax  
Title Forename/Initials Surname Dr Jonathan Silcock  
University of Bradford Great Horton Rd Bradford BD71DP 
J.Silcock@bradford.ac.uk  
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A copy of a current CV for the student and the academic supervisor 
(maximum 2 pages of A4) must be submitted with the application.  
  
A2-2. Who will act as Chief Investigator for this study?  
Student Academic supervisor Other  
    
A3-1. Chief Investigator:  
Post  
Qualifications  
Employer Work Address  
Post Code Work E-mail * Personal E-mail Work Telephone * Personal 
Telephone/Mobile Fax  
Title Forename/Initials Surname Dr Jonathan Silcock  
Senior Lecturer in Pharmacy Practice  
MRPharmS FHEA PHD  
MSc University of Bradford Great Horton Rd Bradford  
BD71DP j.silcock@bradford.ac.uk  
01274 236624  
* This information is optional. It will not be placed in the public domain or 
disclosed to any other third party without prior consent. A copy of a 
current CV (maximum 2 pages of A4) for the Chief Investigator must be 
submitted with the application.  
6 179907/966714/14/52  
Appendix 4 
NHS R&D Form IRAS Version 5.3.0  
 
A4. Who is the contact on behalf of the sponsor for all correspondence 
relating to applications for this project?  
This contact will receive copies of all correspondence from REC and 
HRA/R&D reviewers that is sent to the CI.  
 255
Address  
Post Code E-mail Telephone Fax  
Title Forename/Initials Surname Mrs Tamsin Holt  
University of Bradford Great Horton Road Bradford BD71DP 
t.l.holt@bradford.ac.uk 01274 235184  
 
A5-1. Research reference numbers. Please give any relevant references 
for your study: Applicant's/organisation's own reference number, e.g. R & 
D (if  
available):  
Sponsor's/protocol number:  
Protocol Version:  
Protocol Date:  
Funder's reference number:  
Project website:  
Additional reference number(s):  
Registration of research studies is encouraged wherever possible. You 
may be able to register your study through your NHS organisation or a 
register run by a medical research charity, or publish your protocol 
through an open access publisher. If you have registered your study 
please give details in the "Additional reference number(s)" section.  
 
  
Ref.Number Description Reference Number  
  
 
A5-2. Is this application linked to a previous study or another current 
application?  
Yes No  
Please give brief details and reference numbers.  
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2. OVERVIEW OF THE RESEARCH  
 
To provide all the information required by review bodies and research 
information systems, we ask a number of specific questions. This section 
invites you to give an overview using language comprehensible to lay 
reviewers and members of the public. Please read the guidance notes for 
advice on this section.  
 
A6-1. Summary of the study. Please provide a brief summary of the 
research (maximum 300 words) using language easily understood by lay 
reviewers and members of the public. Where the research is reviewed by 
a REC within the UK Health Departments’ Research Ethics Service, this 
summary will be published on the Health Research Authority (HRA) 
website following the ethical review. Please refer to the question specific 
guidance for this question.  
At Nottingham University Hospitals, a new service has been established 
involving a nurse led call back service to all oncology patients receiving 
chemotherapy. Patients receive a call back 24 hours after their first cycle 
of chemotherapy  
7 179907/966714/14/52  
NHS R&D Form IRAS Version 5.3.0  
and undergo a full toxicity assessment over the telephone. Data is 
collected around toxicity, which will be used to look at the factors that 
can be used to predict chemotherapy toxicity and the risk of hospital 
admission from toxicity.  
 
A6-2. Summary of main issues. Please summarise the main ethical, legal, 
or management issues arising from your study and say how you have 
addressed them.  
Not all studies raise significant issues. Some studies may have 
straightforward ethical or other issues that can be identified and 
managed routinely. Others may present significant issues requiring 
further consideration by a REC, R&D office or other review body (as 
appropriate to the issue). Studies that present a minimal risk to 
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participants may raise complex organisational or legal issues. You 
should try to consider all the types of issues that the different reviewers 
may need to consider.  
Few significant issues are raised as data is collected as part of a service 
provided by the NHS trust. Data can be anonymised before manipulation. 
There is the potential that services may be changed as a result of any 
findings of the study. If a toxicity predictor is developed it could be used 
to inform clinicians of the treatment to offer patients. Any predictor 
developed would be thoroughly tested and any recommendations made 
from the research will be well though out and evidence based. If more 
research is required to validate any findings then this will be stated. Any 
changes to services within the trust will follow trust policy and procedure 
and will be reviewed by relevant committees.  
 
3. PURPOSE AND DESIGN OF THE RESEARCH  
 
A7. Select the appropriate methodology description for this research. 
Please tick all that apply:  
Case series/ case note review Case control Cohort 
observation Controlled trial without randomisation Cross-sectional 
study  
Database analysis Epidemiology Feasibility/ pilot study Laboratory 
study Metanalysis Qualitative research Questionnaire, interview or 
observation study Randomised controlled trial  
Other (please specify)  
               
 
A10. What is the principal research question/objective? Please put this in 
language comprehensible to a lay person.  
What risk factors can be used to predict chemotherapy toxicity? What is 
the risk of hospital admission for toxicity with chemotherapy? Can a tool 
be developed to predict this?  
 
A11. What are the secondary research questions/objectives if applicable? 
Please put this in language comprehensible to a lay person.  
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A12. What is the scientific justification for the research? Please put this 
in language comprehensible to a lay person.  
Little evidence is available around overall general chemotherapy toxicity 
and the risk of it. There is also little data available around the risk of 
hospital admission for chemotherapy toxicity, despite admission being a 
common consequence of toxicity. Admission is a negative thing for both 
patient and healthcare provider and it is thought that if this can be 
predicted it can either be managed or avoided. A literature search has 
helped to identify many negative  
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effects of chemotherapy toxicity, meaning that a greater understanding of 
the risk of toxicity, which this research aims to provide, will be very 
valuable. A 2008 UK report looked at deaths within 30 days of receiving 
systemic anti-cancer therapy (SACT). It was noted that 43% of patients 
who had died within 30 days of receiving SACT had experienced a grade 
3 or 4 toxicity according to CTCAE (common terminology criteria for 
adverse events) criteria related to their treatment (Mort, D., Lansdown, M., 
Smith, N., Protopapa, K., & Mason, M. (2008, October 3). For better, for 
worse? Retrieved March 11, 2015, from 
http://www.ncepod.org.uk/2008report3/Downloads/SACT_report.pdf). An 
observational study in a London hospital found that early treatment 
discontinuation was required in 21.3% of elderly patients receiving 
chemotherapy for various cancers due to toxicity(Kalsi, T., Babic-Illman, 
G., Fields, P., Hughes, S., Maisey, N., Ross, P., et al. (2014). The impact of 
low-grade toxicity in older people with cancer undergoing chemotherapy, 
111(12), 2224–2228. http://doi.org/10.1038/bjc.2014.496).  
A 2005 breast cancer trial was forced to close a high dose arm early due 
to toxicity (Brain, E., Levy, C., Serin, D., Roché, H., Spielmann, M., Delva, 
R., et al. (2011). High rate of extra-haematological toxicity compromises 
dose-dense sequential adjuvant chemotherapy for breast cancer. British 
Journal of Cancer, 105(10), 1480–1486. 
http://doi.org/10.1038/bjc.2011.414). High rates of skin toxicity (32.4% rate 
of grade 3 /4 toxicity) were reported in the high dose arm of this 
randomized phase II trials which investigated the sequential approach of 
anthracycline and taxane based adjuvant chemotherapy in patients with 
high risk breast cancer. This study highlights the problematic nature of 
toxicity and highlights the potential effects on trials and potentially 
curative chemotherapy. This research aims to identify the risk factors for 
toxicity so that these can be considered when making prescribing 
 259
decisions.  
 
A13. Please summarise your design and methodology. It should be clear 
exactly what will happen to the research participant, how many times and 
in what order. Please complete this section in language comprehensible 
to the lay person. Do not simply reproduce or refer to the protocol. 
Further guidance is available in the guidance notes.  
A service is now in place at Nottingham University Hospitals whereby all 
oncology patients who receive their first chemotherapy, will receive a 
phone call the following day by a nurse to assess any side effects. 
Toxicity is systematically reviewed and recorded in a pre-defined 
database. Patient factors are recorded such as age, disease, performance 
status and records are made of the chemotherapy given. Once data has 
been collected for a full year as part of the existing service, it will be 
anonymised and used for research purposes. It will be collected by 
nurses at Nottingham University Hospitals (NUH) and patient identifiable 
data will only be available to members of the oncology team at NUH. Any 
data used for research will have patient identifiers removed. Multivariate 
analysis will be performed on the data to look at what factors can be used 
to predict the risk of toxicity. The data will be compared with the hospital 
admissions data and the risk of hospital admission from chemotherapy 
toxicity will be calculated.  
 
4. RISKS AND ETHICAL ISSUES  
 
RESEARCH PARTICIPANTS  
 
A15. What is the sample group or cohort to be studied in this research?  
Select all that apply:  
Blood Cancer Cardiovascular Congenital Disorders Dementias and 
Neurodegenerative Diseases Diabetes Ear Eye Generic Health 
Relevance Infection Inflammatory and Immune System Injuries and 
Accidents Mental Health  
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Metabolic and Endocrine Musculoskeletal Neurological Oral and 
Gastrointestinal Paediatrics  
Renal and Urogenital Reproductive Health and Childbirth 
Respiratory Skin Stroke  
Gender: Lower age limit: 18 Upper age limit:  
Male and female participants Years Years  
          
 
A17-1. Please list the principal inclusion criteria (list the most important, 
max 5000 characters).  
Adult patients (over 18 years old) Patients with a diagnosis of a solid 
tumour cancer Patients who have undergone a first cycle of 
chemotherapy at Nottingham University Hospitals (NUH) as an outpatient 
Patients who were able to have a toxicity assessment performed over the 
telephone  
 
A17-2. Please list the principal exclusion criteria (list the most important, 
max 5000 characters).  
Any paediatric patients Any patient receiving chemotherapy classed as 
an inpatient regimen at NUH Any patient receiving chemotherapy as part 
of a clinical trial Any patient who was not able to have toxicity assessed 
the day after chemotherapy or who could not be contacted  
 
RECRUITMENT AND INFORMED CONSENT  
 
In this section we ask you to describe the recruitment procedures for the 
study. Please give separate details for different study groups where 
appropriate.  
 
A27-1. How will potential participants, records or samples be identified? 
Who will carry this out and what resources will be used?For example, 
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identification may involve a disease register, computerised search of GP 
records, or review of medical records. Indicate whether this will be done 
by the direct healthcare team or by researchers acting under 
arrangements with the responsible care organisation(s).  
Details of all toxicity assessments are recorded in an NUH excel 
spreadsheet. Patients who have undergone the pre- defined treatment the 
day before are identified by automatic report run by the chemotherapy 
electronic prescribing system "Chemocare". All data is recorded and 
processed by the team providing the service.  
 
A27-2. Will the identification of potential participants involve reviewing or 
screening the identifiable personal information of patients, service users 
or any other person?  
Yes No  
Please give details below:  
   
 
A28. Will any participants be recruited by publicity through posters, 
leaflets, adverts or websites?  
10 179907/966714/14/52  
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Yes No  
 
A29. How and by whom will potential participants first be approached?  
Participants will not be approached by the research team but will receive 
a phone call as part of the service offered by NUH. The phone call will be 
from the Chemotherapy action team nurse.  
 
A30-1. Will you obtain informed consent from or on behalf of research 
participants?  
Yes No  
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If you will be obtaining consent from adult participants, please give 
details of who will take consent and how it will be done, with details of 
any steps to provide information (a written information sheet, videos, or 
interactive material). Arrangements for adults unable to consent for 
themselves should be described separately in Part B Section 6, and for 
children in Part B Section 7.  
If you plan to seek informed consent from vulnerable groups, say how 
you will ensure that consent is voluntary and fully informed.  
If you are not obtaining consent, please explain why not.  
Data is collected as part of an NHS chemotherapy service. Any data used 
at the point of research will be anonymised. Only NUH employees directly 
involved in the care of chemotherapy patients will have access to any 
identifiable data.  
   
Please enclose a copy of the information sheet(s) and consent form(s).  
 
CONFIDENTIALITY  
 
In this section, personal data means any data relating to a participant 
who could potentially be identified. It includes pseudonymised data 
capable of being linked to a participant through a unique code number.  
 
Storage and use of personal data during the study  
A36. Will you be undertaking any of the following activities at any stage 
(including in the identification of potential participants)?(Tick as 
appropriate)  
Access to medical records by those outside the direct healthcare team 
Access to social care records by those outside the direct social care 
team Electronic transfer by magnetic or optical media, email or computer 
networks Sharing of personal data with other organisations Export of 
personal data outside the EEA Use of personal addresses, postcodes, 
faxes, emails or telephone numbers Publication of direct quotations from 
respondents Publication of data that might allow identification of 
individuals Use of audio/visual recording devices Storage of personal 
data on any of the following:  
Manual files (includes paper or film) NHS computers Social Care Service 
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computers Home or other personal computers University computers  
                
Private company computers  
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Laptop computers  
Further details:  
The toxicity database will be stored on NHS computers only and the only 
patient identifier will be the NHS number. Members of the Nottingham 
University Hospitals Acute Oncology Team will be the only people to 
have access to this data. It will be extracted into a separate spreadsheet 
for research purposes, at which point it will be anonymised and the NHS 
number removed.  
 
A37. Please describe the physical security arrangements for storage of 
personal data during the study?  
This will be done in accordance will NUH policy around data protection. 
Only NUH staff will be able to access any identifiable data.  
 
A38. How will you ensure the confidentiality of personal data?Please 
provide a general statement of the policy and procedures for ensuring 
confidentiality, e.g. anonymisation or pseudonymisation of data.  
The only identifier used in the database will be the NHS number. Only 
NUH staff who are bound by confidentiality policy will have access to 
identifiable data, to which access is restricted. At the point of data 
manipulation identifiers will be removed, making all data anonymous.  
 
A40. Who will have access to participants' personal data during the 
study? Where access is by individuals outside the direct care team, 
please justify and say whether consent will be sought.  
Only NUH employees directly involved in the care of chemotherapy 
patients.  
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Storage and use of data after the end of the study  
 
A41. Where will the data generated by the study be analysed and by 
whom?  
A combination of on NHS computers and personal laptop only once data 
has any identifiers removed. All data will be analysed by the student who 
is also an employee of NUH and directly involved in the care of 
chemotherapy patients.  
 
A42. Who will have control of and act as the custodian for the data 
generated by the study?  
Post Qualifications Work Address  
Post Code Work Email Work Telephone Fax  
Title Forename/Initials Surname Mr Samuel Malton  
Advanced Pharmacy Practitioner, oncology  
MPharm PGCert PGDip MSc  
Nottingham City Hospital Hucknall Road Nottingham NG51PB 
samuel.malton@nuh.nhs.uk 01159691169  
 
A43. How long will personal data be stored or accessed after the study 
has ended?  
 
Less than 3 months  
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3 – 6 months 6 – 12 months 12 months – 3 years Over 3 years  
If longer than 12 months, please justify:  
The service introduced is likely to be on-going and as such continuous 
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data collection and review will occur for the purposes of service review.  
    
 
A44. For how long will you store research data generated by the study?  
Years: 5 Months: 0  
 
A45. Please give details of the long term arrangements for storage of 
research data after the study has ended.Say where data will be stored, 
who will have access and the arrangements to ensure security.  
Any patient data will be stored on NHS computers with only NUH staff 
able to access, in accordance with NUH policy. Anonymised data will be 
stored for 5 years as indicated above.  
 
INCENTIVES AND PAYMENTS  
 
A46. Will research participants receive any payments, reimbursement of 
expenses or any other benefits or incentives for taking part in this 
research?  
Yes No  
   
 
A47. Will individual researchers receive any personal payment over and 
above normal salary, or any other benefits or incentives, for taking part in 
this research?  
Yes No  
   
 
A48. Does the Chief Investigator or any other investigator/collaborator 
have any direct personal involvement (e.g. financial, share holding, 
personal relationship etc.) in the organisations sponsoring or funding the 
research that may give rise to a possible conflict of interest?  
 266
Yes No  
If yes, please give details including the amount of any monetary payment 
or the basis on which this will be calculated:  
Employee of Nottingham University Hospitals  
   
 
NOTIFICATION OF OTHER PROFESSIONALS  
 
PUBLICATION AND DISSEMINATION  
 
A50. Will the research be registered on a public database?  
Yes No  
Please give details, or justify if not registering the research.  
Unaware of an appropriate public database on which to register research. 
Will be registered at the University of  
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Bradford and Nottingham University Hospitals.  
Registration of research studies is encouraged wherever possible. You 
may be able to register your study through your NHS organisation or a 
register run by a medical research charity, or publish your protocol 
through an open access publisher. If you are aware of a suitable register 
or other method of publication, please give details. If not, you may 
indicate that no suitable register exists. Please ensure that you have 
entered registry reference number(s) in question A5-1.  
 
A51. How do you intend to report and disseminate the results of the 
study?Tick as appropriate:  
Peer reviewed scientific journals Internal report Conference presentation 
Publication on website  
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Other publication  
Submission to regulatory authorities  
Access to raw data and right to publish freely by all investigators in study 
or by Independent Steering Committee on behalf of all investigators  
No plans to report or disseminate the results Other (please specify)  
          
 
A52. If you will be using identifiable personal data, how will you ensure 
that anonymity will be maintained when publishing the results?  
No identifiable data will be published  
 
A53. Will you inform participants of the results?  
Yes No  
Please give details of how you will inform participants or justify if not 
doing so.  
Data is not patient identifiable and patients do not consent to being 
included in the research as mentioned above. This would make it 
impossible to trace patients to be able to inform them of results.  
   
 
5. Scientific and Statistical Review  
 
A54. How has the scientific quality of the research been assessed?Tick 
as appropriate:  
Independent external review Review within a company Review within a 
multi  −centre research group Review within the Chief Investigator's 
institution or host organisation Review within the research team Review  
by educational supervisor Other    
Justify and describe the review process and outcome. If the review has 
been undertaken but not seen by the researcher, give details of the body 
which has undertaken the review: Discussion with several clinicians 
from different disciplines within NUH around the purpose of and reason 
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for research and the chosen methodology.  
Discussion and review with academic supervisor at University of 
Bradford.  
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For all studies except non-doctoral student research, please enclose a 
copy of any available scientific critique reports, together with any related 
correspondence.  
For non-doctoral student research, please enclose a copy of the 
assessment from your educational supervisor/ institution.  
 
A56. How have the statistical aspects of the research been reviewed?Tick 
as appropriate:  
Review by independent statistician commissioned by funder or sponsor 
Other review by independent statistician Review by company 
statistician Review by a statistician within the Chief Investigator’s 
institution  
Review by a statistician within the research team or multi−centre group  
Review by educational supervisor  
Other review by individual with relevant statistical expertise  
No review necessary as only frequencies and associations will be 
assessed – details of statistical input not required  
In all cases please give details below of the individual responsible for 
reviewing the statistical aspects. If advice has been provided in 
confidence, give details of the department and institution concerned.  
        
Department Institution Work Address  
Post Code Telephone Fax Mobile E-mail  
a.j.scally@bradford.ac.uk  
Title Forename/Initials Surname  
Dr Andy School of Life Sciences University of Bradford University of 
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Bradford Great Horton Rd Bradford BD71DP  
Scally  
Please enclose a copy of any available comments or reports from a 
statistician.  
 
A57. What is the primary outcome measure for the study?  
The rate of toxicity form chemotherapy and the rate of hospital admission 
due to toxicity  
 
A58. What are the secondary outcome measures?(if any)  
 
A59. What is the sample size for the research? How many 
participants/samples/data records do you plan to study in total? If there 
is more than one group, please give further details below.  
Total UK sample size: 1500 Total international sample size (including 
UK): Total in European Economic Area:  
Further details:  
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A60. How was the sample size decided upon? If a formal sample size 
calculation was used, indicate how this was done, giving sufficient 
information to justify and reproduce the calculation.  
This is the possible number of patients who may receive a first cycle of 
chemotherapy at NUH within one year. The actual number may be more 
but it is expected that the research may focus on specific tumour sites.  
A61. Will participants be allocated to groups at random?  
Yes No  
   
A62. Please describe the methods of analysis (statistical or other 
appropriate methods, e.g. for qualitative research) by which the data will 
be evaluated to meet the study objectives.  
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The mean and median number of toxicities experienced will be calculated 
along with the mean number of instances of hospital admission. The 
research will aim to produce hazard ratios for specific toxicity and for 
hospital admission.  
6. MANAGEMENT OF THE RESEARCH  
A63. Other key investigators/collaborators. Please include all grant 
co−applicants, protocol co−authors and other key members of the Chief 
Investigator’s team, including non-doctoral student researchers.  
Post Qualifications  
Employer Work Address  
Post Code Telephone Fax Mobile Work Email  
Title Forename/Initials Surname Dr Eleanor James  
Consultant clinical oncologist  
MBCHB FRCR  
Nottingham University Hospitals Nottingham City Hospital Hucknall 
Rd Nottingham  
NG51PB  
eleanor.james@nuh.nhs.uk  
A64. Details of research sponsor(s)  
A64-1. Sponsor  
Lead Sponsor  
Status:  NHS or HSC care organisation Academic  
Pharmaceutical industry Medical device industry Local Authority  
Commercial status: Non- Commercial  
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Other social care provider (including voluntary sector or private 
organisation)  
Other  
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If Other, please specify:  
 
Contact person  
Name of organisation Given name Family name Address  
Town/city Post code  
Country  
Telephone Fax E-mail  
University of Bradford Tamsin Holt University of Bradford, Great 
Horton Rd Bradford  
BD71DP UNITED KINGDOM  
t.l.holt@bradford.ac.uk  
Is the sponsor based outside the UK?  
Yes No  
Under the Research Governance Framework for Health and Social Care, a 
sponsor outside the UK must appoint a legal representative established 
in the UK. Please consult the guidance notes.  
   
 
A65. Has external funding for the research been secured?  
Funding secured from one or more funders External funding application 
to one or more funders in progress No application for external funding 
will be made  
What type of research project is this? Standalone project Project that is 
part of a programme grant Project that is part of a Centre grant Project 
that is part of a fellowship/ personal award/ research training award Other  
Other – please state:  
         
A66. Has responsibility for any specific research activities or procedures 
been delegated to a subcontractor (other than a co-sponsor listed in A64-
1) ? Please give details of subcontractors if applicable.  
Yes No  
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A67. Has this or a similar application been previously rejected by a 
Research Ethics Committee in the UK or another  
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country?  
  
Yes No  
Please provide a copy of the unfavourable opinion letter(s). You should 
explain in your answer to question A6-2 how the reasons for the 
unfavourable opinion have been addressed in this application.  
 
A68-1. Give details of the lead NHS R&D contact for this research:  
Organisation Address  
Post Code Work Email Telephone Fax  
Mobile  
Title Forename/Initials Surname Ms Charlotte Davies  
Nottingham University Hospitals Nottingham Integrated Research 
Centre, C-Floor Queens Medical 
Centre Nottingham NG72UH rdappl@nuh.nhs.uk 01159249924  
Details can be obtained from the NHS R&D Forum website: 
http://www.rdforum.nhs.uk  
  
 
A69-1. How long do you expect the study to last in the UK?  
Plannedstartdate: 01/01/2015 Planned end date: 31/12/2016 Total 
duration:  
Years: 1 Months: 11 Days: 31  
 
A71-1. Is this study?  
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Single centre Multicentre  
   
 
A71-2. Where will the research take place? (Tick as appropriate)  
England Scotland Wales Northern Ireland Other countries in 
European Economic Area  
Total UK sites in study 1  
Does this trial involve countries outside the EU?  
Yes No  
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A72. Which organisations in the UK will host the research?Please 
indicate the type of organisation by ticking the box and give approximate 
numbers if known:  
 
NHS organisations in England NHS organisations in Wales NHS 
organisations in Scotland HSC organisations in Northern Ireland GP 
practices in England  
GP practices in Wales GP practices in Scotland GP practices in 
Northern Ireland  
Joint health and social care agencies (eg community mental health 
teams)  
Local authorities Phase 1 trial units Prison establishments Probation 
areas  
Independent (private or voluntary sector) organisations  
Educational establishments Independent research units Other (give 
details)  
1  
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Total UK sites in study: 1  
 
A73-1. Will potential participants be identified through any organisations 
other than the research sites listed above?  
Yes No  
   
 
A74. What arrangements are in place for monitoring and auditing the 
conduct of the research?  
NUH and University of Bradford policy. Regular review on a monthly 
basis of research project with academic supervisor.  
 
A76. Insurance/ indemnity to meet potential legal liabilities  
 
Note: in this question to NHS indemnity schemes include equivalent 
schemes provided by Health and Social Care (HSC) in Northern Ireland  
  
 
A76-1. What arrangements will be made for insurance and/or indemnity to 
meet the potential legal liability of the sponsor(s) for harm to participants 
arising from the management of the research? Please tick box(es) as 
applicable.  
Note: Where a NHS organisation has agreed to act as sponsor or co-
sponsor, indemnity is provided through NHS schemes. Indicate if this 
applies (there is no need to provide documentary evidence). For all other 
sponsors, please describe the arrangements and provide evidence.  
NHS indemnity scheme will apply (NHS sponsors only) Other insurance 
or indemnity arrangements will apply (give details below)  
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University of Bradford is the research sponsor. Professional indemnity 
and public liability insurance are in place. The certificates can be found at 
the following link: http://www.bradford.ac.uk/finance/financial-
information/in surance/liability-insurance/  
There is no patient participation in this research which is solely based on 
data collected as part of a service and so no potential for patient harm 
arising from research activity.  
Please enclose a copy of relevant documents.  
 
A76-2. What arrangements will be made for insurance and/ or indemnity 
to meet the potential legal liability of the sponsor(s) or employer(s) for 
harm to participants arising from the design of the research? Please tick 
box(es) as applicable.  
Note: Where researchers with substantive NHS employment contracts 
have designed the research, indemnity is provided through NHS 
schemes. Indicate if this applies (there is no need to provide 
documentary evidence). For other protocol authors (e.g. company 
employees, university members), please describe the arrangements and 
provide evidence.  
NHS indemnity scheme will apply (protocol authors with NHS contracts 
only) Other insurance or indemnity arrangements will apply (give details 
below)  
University of Bradford is the research sponsor. Professional indemnity 
and public liability insurance are in place. The certificates can be found at 
the following link: http://www.bradford.ac.uk/finance/financial-
information/in surance/liability-insurance/  
     
Please enclose a copy of relevant documents.  
 
A76-3. What arrangements will be made for insurance and/ or indemnity 
to meet the potential legal liability of investigators/collaborators arising 
from harm to participants in the conduct of the research?  
Note: Where the participants are NHS patients, indemnity is provided 
through the NHS schemes or through professional indemnity. Indicate if 
this applies to the whole study (there is no need to provide documentary 
evidence). Where non-NHS sites are to be included in the research, 
including private practices, please describe the arrangements which will 
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be made at these sites and provide evidence.  
NHS indemnity scheme or professional indemnity will apply (participants 
recruited at NHS sites only) Research includes non-NHS sites (give 
details of insurance/ indemnity arrangements for these sites below)  
University of Bradford is the research sponsor. Professional indemnity 
and public liability insurance are in place. The certificates can be found at 
the following link: http://www.bradford.ac.uk/finance/financial-
information/in surance/liability-insurance/  
     
Please enclose a copy of relevant documents.  
 
A78. Could the research lead to the development of a new 
product/process or the generation of intellectual property?  
Yes No Not sure  
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PART C: Overview of research sites  
 
Please enter details of the host organisations (Local Authority, NHS or 
other) in the UK that will be responsible for the research sites. For NHS 
sites, the host organisation is the Trust or Health Board. Where the 
research site is a primary care site, e.g. GP practice, please insert the 
host organisation (PCT or Health Board) in the Institution row and insert 
the research site (e.g. GP practice) in the Department row.  
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Research site  
Institution name Department name Street address Town/city  
Post Code  
Nottingham University Hospitals Oncology/Pharmacy Hucknall 
Rd Nottingham  
NG51PB  
Investigator/ Collaborator/ Contact  
Title Mr  
First name/ Initials  
Samuel Surname Malton  
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PART D: Declarations  
 
D1. Declaration by Chief Investigator  
1. The information in this form is accurate to the best of my 
knowledge and belief and I take full responsibility for it.   
2. I undertake to abide by the ethical principles underlying the 
Declaration of Helsinki and good practice guidelines on the proper 
conduct of research.   
3. If the research is approved I undertake to adhere to the study 
protocol, the terms of the full application as approved and any 
conditions set out by review bodies in giving approval.   
4. I undertake to notify review bodies of substantial amendments to 
the protocol or the terms of the approved application, and to seek a 
favourable opinion from the main REC before implementing the 
amendment.   
5. I undertake to submit annual progress reports setting out the 
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progress of the research, as required by review bodies.   
6. I am aware of my responsibility to be up to date and comply with 
the requirements of the law and relevant guidelines relating to 
security and confidentiality of patient or other personal data, 
including the need to register when necessary with the appropriate 
Data Protection Officer. I understand that I am not permitted to 
disclose identifiable data to third parties unless the disclosure has 
the consent of the data subject or, in the case of patient data in 
England and Wales, the disclosure is covered by the terms of an 
approval under Section 251 of the NHS Act 2006.   
7. I understand that research records/data may be subject to 
inspection by review bodies for audit purposes if required.   
8. I understand that any personal data in this application will be held 
by review bodies and their operational managers and that this will 
be managed according to the principles established in the Data 
Protection Act 1998.   
9. I understand that the information contained in this application, any 
supporting documentation and all correspondence with review 
bodies or their operational managers relating to the application: 
 Will be held by the REC (where applicable) until at least 3 years 
after the end of the study; and by NHS R&D offices (where the 
research requires NHS management permission) in accordance 
with the NHS Code of Practice on Records Management. May be 
disclosed to the operational managers of review bodies, or the 
appointing authority for the REC (where applicable), in order to 
check that the application has been processed correctly or to 
investigate any complaint.  May be seen by auditors appointed to 
undertake accreditation of RECs (where applicable). Will be 
subject to the provisions of the Freedom of Information Acts and 
may be disclosed in response to requests made under the Acts 
except where statutory exemptions apply. May be sent by email to 
REC members.   
10. I understand that information relating to this research, including 
the contact details on this application, may be held on national 
research information systems, and that this will be managed 
according to the principles established in the Data Protection Act 
1998.   
11. Where the research is reviewed by a REC within the UK Health 
Departments Research Ethics Service, I understand that the 
summary of this study will be published on the website of the 
National Research Ethics Service (NRES), together with the contact 
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point for enquiries named below. Publication will take place no 
earlier than 3 months after issue of the ethics committee’s final 
opinion or the withdrawal of the application.   
Contact point for publication(Not applicable for R&D Forms) NRES 
would like to include a contact point with the published summary of the 
study for those wishing to seek further  
information. We would be grateful if you would indicate one of the contact 
points below.  
      
Chief Investigator  
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Sponsor Study co-ordinator Student Other – please give details None  
Access to application for training purposes (Not applicable for R&D 
Forms) Optional – please tick as appropriate:  
I would be content for members of other RECs to have access to the 
information in the application in confidence  
for training purposes. All personal identifiers and references to sponsors, 
funders and research units would be removed.  
This section was signed electronically by Dr Jonathan Silcock on 
16/05/2016 12:27.  
     
Job Title/Post: Organisation: Email:  
Senior Lecturer in Pharmacy Practice University of Bradford 
j.silcock@bradford.ac.uk  
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D2. Declaration by the sponsor's representative  
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If there is more than one sponsor, this declaration should be signed on 
behalf of the co−sponsors by a representative of the lead sponsor named 
at A64-1.  
I confirm that:  
1. This research proposal has been discussed with the Chief 
Investigator and agreement in principle to sponsor the research is 
in place.   
2. An appropriate process of scientific critique has demonstrated that 
this research proposal is worthwhile and of high scientific quality. 
  
3. Any necessary indemnity or insurance arrangements, as described 
in question A76, will be in place before this research starts. 
Insurance or indemnity policies will be renewed for the duration of 
the study where necessary.   
4. Arrangements will be in place before the study starts for the 
research team to access resources and support to deliver the 
research as proposed.   
5. Arrangements to allocate responsibilities for the management, 
monitoring and reporting of the research will be in place before the 
research starts.   
6. The duties of sponsors set out in the Research Governance 
Framework for Health and Social Care will be undertaken in relation 
to this research.  Please note: The declarations below do not form 
part of the application for approval above. They will not be 
considered by the Research Ethics Committee.   
7. Where the research is reviewed by a REC within the UK Health 
Departments Research Ethics Service, I understand that the 
summary of this study will be published on the website of the 
National Research Ethics Service (NRES), together with the contact 
point for enquiries named in this application. Publication will take 
place no earlier than 3 months after issue of the ethics committee's 
final opinion or the withdrawal of the application.   
8. Specifically, for submissions to the Research Ethics Committees 
(RECs) I declare that any and all clinical trials approved by the HRA 
since 30th September 2013 (as defined on IRAS categories as 
clinical trials of medicines, devices, combination of medicines and 
devices or other clinical trials) have been registered on a publically 
accessible register in compliance with the HRA registration 
requirements for the UK, or that any deferral granted by the HRA 
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1. I have read and approved both the research proposal and this 
application. I am satisfied that the scientific content of the research is 
satisfactory for an educational qualification at this level.  
2. I undertake to fulfil the responsibilities of the supervisor for this study 
as set out in the Research Governance Framework for Health and Social 
Care.  
3. I take responsibility for ensuring that this study is conducted in 
accordance with the ethical principles underlying the Declaration of 
Helsinki and good practice guidelines on the proper conduct of research, 
in conjunction with clinical supervisors as appropriate.  
4. I take responsibility for ensuring that the applicant is up to date and 
complies with the requirements of the law and relevant guidelines 
relating to security and confidentiality of patient and other personal data, 
in conjunction with clinical supervisors as appropriate.  
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16/05/2016 12:27.  
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Appendix 5 
Literature Search Strategy 
 
Medline and Embase were both used as the databases of choice for the literature 
search. Where possible controlled vocabulary, thesaurus or MeSH search terms were 
used, however if these yielded no results it was sometimes necessary to broaden the 
search. 
 
Randomised Controlled trials from well known international journals were the literature 
of choice, however when these brought no results smaller scale studies were sought 
from lesser known journals. Only articles available in English were included. Once 
articles were identified, the bibliographies were inspected in order to identify any other 
useful information.  
 
To begin with, literature around the incidence and prevalence of chemotherapy toxicity 
in general was sought using the following terms:  
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
prevalence 
Chemotherapy / antineoplastic  + toxicity (drug related side effects and reactions) + 
incidence 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
admission (hospitalisation) 
 
The economic effects of chemotherapy toxicity were also of interest as well as the 
impact on the services managing these patients. To look at this the following search 
terms were used: 
 
Chemotherapy / antineoplastic + Costs (Healthcare costs, Drug costs, Costs of illness, 
Hospital Costs) + toxicity (drug related side effects and reactions) 
 
More general searching around chemotherapy and cost yielded more data around the 
economic and also other consequences of toxicity. 
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A search was performed to look at the risk of admission from chemotherapy toxicity 
using the following terms: 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
admission (hospitalisation) 
 
This proved difficult and the search terms were broadened which did not identify any 
relevant data. More general data around hospital admission was sought using: 
 
Admission (hospitalisation) + predictors 
Admission (hospitalisation) + risk factors 
 
The next area to focus the search was around predicting toxicity. The following terms 
were used: 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + risk 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + risk 
factors 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
prediction 
 
The next area of interest was any patient factors that may have been identified as 
playing a role in toxicity. A general search was undertaken using the following: 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
patient factors 
 
The results from this were difficult to process as much literature was identified. Search 
terms were therefore made more specific in order to filter the results: 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
age (age groups/age factors) 
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Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
Karnofsky performance status. 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
ECOG performance status. 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + co-
morbidity 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
social class 
 
The next area to look at was any literature regarding measures to protect from overall 
toxicity. 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
primary prevention 
 
It was then decided to look at the more common individual cancers: 
 
Breast Cancer 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
breast neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
incidence + breast neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
prevalence + breast neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) +  
(hospitalisation) + breast neoplasms 
 
Lung Cancer 
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The following terms were used to assess the literature around toxicity in lung cancer. 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
lung neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
incidence + lung neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
prevalence + lung neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) +  
(hospitalisation) + lung neoplasms 
 
Colorectal Cancer 
The same search strategy was employed for colorectal cancer. 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
colorectal neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
incidence + colorectal neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
prevalence + colorectal neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) +  
(hospitalisation) + colorectal neoplasms 
 
Prostate Cancer 
 
Similar search terms were used for prostate cancer. 
 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
prostate neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
incidence + prostate neoplasms 
Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) + 
prevalence + prostate neoplasms 
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Chemotherapy / antineoplastic + toxicity (drug related side effects and reactions) +  
(hospitalisation) + prostate neoplasms 
 
Literature around individual toxicities was then investigated: 
 
Nausea and Vomiting 
 
Chemotherapy / antineoplastic + nausea + vomiting + prevalence 
Chemotherapy / antineoplastic + nausea + vomiting + incidence 
Chemotherapy / antineoplastic + nausea + vomiting + risk 
Chemotherapy / antineoplastic + nausea + vomiting + admission (hospitalisation) 
 
Diarrhoea 
 
The following terms were used to identify literature around patients with experiencing 
diarrhoea with chemotherapy: 
 
Chemotherapy / antineoplastic + diarrhoea + prevalence 
Chemotherapy / antineoplastic + diarrhoea+ incidence 
Chemotherapy / antineoplastic + diarrhoea + risk 
Chemotherapy / antineoplastic + diarrhoea + admission (hospitalisation) 
 
Skin Reactions 
 
To identify the literature around skin reactions with chemotherapy, the following search 
terms were employed: 
 
Chemotherapy / antineoplastic + drug related side effects and adverse reactions + skin 
+ prevalence 
Chemotherapy / antineoplastic + drug related side effects and adverse reactions + skin 
+ incidence 
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Chemotherapy / antineoplastic + drug related side effects and adverse reactions + skin 
+ risk 
Chemotherapy / antineoplastic + drug related side effects and adverse reactions + skin 
+ admission (hospitalisation) 
 
Fatigue 
Chemotherapy / antineoplastic + drug related side effects and adverse reactions + 
fatigue + prevalence 
Chemotherapy / antineoplastic + drug related side effects and adverse reactions + 
fatigue + incidence 
Chemotherapy / antineoplastic + drug related side effects and adverse reactions + 
fatigue + risk 
Chemotherapy / antineoplastic + drug related side effects and adverse reactions + 
fatigue + admission (hospitalisation) 
The above search did not bring many results, so broader terms were used to search 
around fatigue.  
 
 
